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ABSTRACT 
 
Introduction 
Varicose veins affect one third of adults. Complications of varicose veins can have 
detrimental effects on the patient’s quality of life. Morphological changes including intimal 
hyperplasia, smooth muscle cells hypertrophy or atrophy and irregularities of extracellular 
matrix contents have demarcated varicose from non-varicose veins. Some of the biological 
mechanisms behind these changes have been illustrated by the studies investigating the 
individual expressions of proteins (proteomic) and genes (transcriptomics). The evidence 
from these studies also suggests the role of abnormal cell metabolism in the development of 
varicose veins. However, both transcriptomic and proteomic approaches are not able to fully 
explain the irregularities of cell metabolism. Metabolic profiling of tissue and biological 
fluids using nuclear magnetic resonance (NMR) spectroscopy and mass spectrometry (MS) 
has the ability to elucidate irregular cell metabolic pathways and functions of genes and 
enzymes in disease pathogenesis. Metabolic profiling approaches are also used to identify 
toxicity and therapeutic efficacy of drugs.  
 
Aims 
To identify the metabolic profile of varicose veins as compared to non-varicose veins with an 
aim to promote our understanding of the disease pathogenesis.  
 
Methods 
Ethical approval was obtained from the local ethics committee. Firstly, a preliminary study 
was performed. Varicose veins (n=8) were removed from patients following varicose vein 
surgery. Non-varicose veins were removed from patients following operations where there 
was a removal of vein involved as a part of the procedure. Non-varicose veins tissue retrieved 
included great saphenous vein (n=8) from bypass or amputation. Facial veins (n=5) during the 
carotid endarterectomy were also removed.  Metabolic profile of the intact varicose and non-
varicose veins tissues were measured using 1D magic angle spinning (MAS) 
1
H NMR (600). 
In order to develop the most optimal organic and aqueous extraction method for vein tissues, 
11 grams of varicose vein tissues retrieved from different patients was mixed using mortar 
and pestle and cryogenic impact mill in liquid nitrogen producing a homogenous tissue 
mixture. In total, 70 samples were prepared from this homogenate each having a weight of 
145+/- 5 mg. For extraction of aqueous metabolites, 20 samples were treated with two 
different solvents concentrations: 10 samples with Water: Methanol (1:1), and 10 samples 
with Water: Methanol (3:1). For optimisation of organic metabolites, remaining 50 samples 
were extracted using 5 different organic solvents including dichloromethane, chloroform, 
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isopropanol, hexane and ether. Each group had 10 samples or replicates. All aqueous and 
organic extracts were run on 
1
H NMR (600 MHz). Organic extracts were analyzed on ultra 
performance liquid chromatography mass spectrometry (UPLC-MS). Ex-vivo rat inferior 
vena cava stretch experiment was performed in vascular research laboratory, Harvard Medical 
School, Brigham and Women’s Hospital, US. Inferior vena cava of the male Sprague dowley 
rat (n=5) was divided into 4 segments. Two out of these 4 segments were kept at a basal 
tension of 0.5 gram for 4 and 18 hours and the remaining two were stretched with 2 grams 
weight for 4 and 18 hours in an organ culture bath. Aqueous extracts from rat IVC segments 
were analysed using H
1
 NMR (800 MHz). Organic extracts were analyzed on ultra 
performance liquid chromatography mass spectrometry (UPLC-MS).  
 
Lastly, comprehensive profiling of human varicose veins (n=80) and non-varicose veins 
(n=35) tissue extracts was performed. The most optimal extraction method employed to 
extracts metabolites from human veins tissue was developed as mentioned earlier and the 
same extraction protocol was used to extracts metabolites from human veins tissues. Aqueous 
extracts were run on 
1
H NMR (600 MHz). Organic extracts were analyzed on ultra 
performance liquid chromatography mass spectrometry (UPLC-MS).  
 
Spectra obtained from NMR for all experiments were mathematically modeled and 
statistically analyzed using chemomeric software including MATLAB and SIMCA. 
Metabolites were assigned using human metabolome databases and previous published 
reports. Metabolite identification was confirmed using 2D NMR. UPLC-MS based profiling 
data was analysed using MassLynx version 4.1 and SIMCA. UPLC-MS based metabolites 
were assigned using MS/MS experiment and with support databases including lipodomics and 
human metabolome database (HMDB). Pathway analysis was performed using ingenuity 
database and published reports. Multiple testing corrections using Benjamini Yakatieli 
method was performed to exclude false discovery rate in the data. Pathways analysis was  
performed using ingenuity and KEGG pathways databases. 
  
Results 
Magic angle spinning NMR analysis of intact vein tissues showed the presence of lipid 
metabolites at a higher concentration in the non-varicose vein group whilst creatine, lactate, 
myo-inositol, and glutamate metabolites were more characteristic of the varicose vein group. 
The orthogonal partial least square (OPLS) coefficient plot revealed that the differential 
abundance of creatine, myo-inositol and lactate was highly correlated to varicose vein group. 
Metabolic profiles of facial veins were also different from varicose veins. Abundance of 
lipids was also noticed in facial veins.  
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The most optimal method for human veins tissue extraction was found to be the consecutive 
approach of metabolites extraction via first extraction of organic metabolites with MTBE: 
methanol (3:1) followed by methanol: water (1:1) in terms of reproducibility and sensitivity. 
Metabolic differences in rat IVC segments were observed  between rat IVC segments 
stretch for 18 hrs as compared to non-stretched for 18 hrs. Metabolites including choline, 
valine and triglycerides were found in high concentrations in stretched for 18 hrs group as 
compared to non-stretched for 18 hrs. 
 
Comprehensive metabolic profiling of veins tissue extracts using two metabolomics 
analytical platforms (NMR and UPLC-MS) was determined. Both organic and aqueous 
metabolites were extracted from vein tissues using the most optimal extraction method 
developed above. Multivariate analysis of the NMR data from 80 varicose veins and 35 
non-varicose veins showed glutamate, taurine and myo-inositol metabolites in higher 
concentration in varicose veins wall as compared to non-varicose veins wall. Multivariate 
analysis of the lipid metabolites revealed significantly increased concentrations of 
phosphatidylcholine (PC) and sphingomyelin (SM) in varicose veins as compared to non-
varicose veins. Pathway analysis based on online databases and published reports showed 
association of myo-inositol with intracellular pathways linked to cellular proliferation and 
PC and SM with induction of inflammatory response.  
 
Conclusions and Future Work 
This novel work demonstrates a comprehensive metabolic profile of human varicose veins 
with metabolites including PC, SM, myo-inositol, glutamate and taurine differentially 
associated with varicose veins. This work unravels new cellular pathways which should be 
the focus of future research and may enable us to understand disease pathogenesis in more 
details and identify therapeutic targets. Moreover, this work first time provides a 
comprehensive extraction methodology for human vein tissue metabolites extractions 
comprising of MTBE: methanol (3:1) followed by water: methanol (1:1). This work also 
showed that prolonged stretch of 18 hrs duration changes metabolic profile of rat IVC 
segments.  
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1.1 VARICOSE VEINS 
 
1.1.1 Epidemiology 
Varicose veins are one of the most common manifestations of chronic venous disease (CVD), 
and present as dilated and elongated incompetent superficial veins in the lower limbs (Figure 
1-1). This incompetence arises either due to vein wall damage or valve reflux leading to blood 
stasis and venous hypertension damaging the superficial veins [1]. Clinical manifestation of 
the disorder include aching and pain of the lower limbs, muscle cramps, skin irritation, 
swelling and can result in complications including bleeding, lipodermatosclerosis and 
ulceration [2]. No specific cause for the development of varicose veins has been identified; 
however, various genetic and environmental risk factors have been ascribed to their 
formations. 
 
 
 
 
Figure 1-1. Abnormally dilated and tortuous varicose great saphenous vein. 
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Primary varicose veins have been shown to affect up to one third of the western adult 
population, and is a major cause of morbidity. There is much discrepancy between the 
estimates of prevalence from different epidemiological studies with estimates for the disease 
range from 2% to 56% in men and 1% to 73% in women [3, 4]. This inconsistency between 
reports could be due to bias within the study population, its design and the experimental 
methodology employed, and may be distinct from actual variation in the general population. 
Variations have been noted among men and women in the prevalence of varicose veins. Some 
reports suggest that varicose veins are more common in women than men [5-9] while others 
have shown the opposite [2, 3, 10, 11]. A cross sectional survey in Edinburgh involving a 
total of 1566 patients, showed age adjusted prevalence of trunk varices in men 33.3% versus 
26.2% in women [11]. It has also been reported that there is a significant correlation between 
CVD disease onset and sex, with females showing first symptoms at 30.8 years and male 36.8 
years [9]. Evidence suggests that the prevalence of varicose veins increases with age. In the 
same Edinburgh study, it was reported to increase from 11.5% in 18-24 years old age group to 
55.7% in the 55-64 years age group [11]. Similarly, other studies have also reported a direct 
relation between varicose veins and age [2, 3, 8, 11]. An inverse relationship has been 
observed between CVD severity and the age of disease onset [9]. Epidemiological studies 
have shown inconsistencies in the reporting of population prevalence. Furthermore evidence 
suggests that even among the European population prevalence of varicose veins is variable 
and it is more common in central and northern Europe than southern [12]; however the 
general trend leans towards a higher prevalence in developed countries. 
 
There are several established environmental risk factors associated with varicose veins, and 
these include age, sex, pregnancy [7], raised BMI among women but not in men [11], obesity, 
occupations involving standing for long periods of time and a family history of varicose veins 
[4]. Other risk factors including hypertension, low fibre diet and cigarette smoking have been 
reported but there has been some discord in the literature concerning these, and their validity 
needs to be investigated further [4]. 
 
1.1.2 Familial Association of Varicose Veins 
While the risk factors including age, sex, occupation, prolonged standing, obesity, may 
contribute to varicose veins formation, some individuals exposed to similar risks may not 
develop the disease. Furthermore the environmental risk factors also contain a substantial 
genetic component themselves, a fact that is often overlooked; varicosity could potentially be 
associated with distal mutation in these genetic determinates. While familial groupings of 
disease have been observed, little is known about whether any specific genes may make 
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individuals more susceptible to the development of varicose veins. In one study the disease 
status of the first degree relatives of patients with varicose veins were recalled which 
estimated the additive genetic component of chronic venous disease at 17% [9]. However the 
interpretability of these findings is questionable, due to the imprecision of self-reporting and 
the common nature of the disease. 
 
Epidemiological research has highlighted a trend of familial clustering for varicose vein 
disease. One study conducted in Japan demonstrated that 42% of women with varicose veins 
reported a positive family history as compared to 14% without the disease (1). In another case 
control study in UK, Scott and colleagues reported a positive family history of varicose veins 
in 85% of patients with varicosities, as opposed to 22% in individuals without. The authors 
also reported that patients with varicose veins were 21.5 times more likely to report a positive 
family history as compared to controls (2). 
 
In a population based cohort study involving 4,903 subjects in Finland, subjects were asked to 
complete a questionnaire at recruitment and then after 5 years, regarding the history of 
varicose veins in family members. The study estimated that the prevalence of varicose veins 
in the family changed from an odds ratio of 0.14 to 6 depending on the subjects’ own 
reporting of varicose veins in both the first and second survey. This suggests that reporting of 
a family history of varicose veins may be subject to both recall and observer biases (3). 
There are few studies in which health professionals examined both the subjects and their 
family members to determine the presence of varicose veins. In one such study which looked 
at 134 families in France, it was demonstrated that patients had a 90% risk of developing 
varicose veins when both parents had the condition (4). 
 
1.1.3 Varicose Veins Linked to Genetic Disorders 
Varicose veins have been found to be associated with several congenital disorders, some of 
which have a strong hereditary component. 
 
1.1.3.1 Klippel-Trenaunay Syndrome 
Klippel-Trenaunay Syndrome (KTS) consists of cutaneous capillary malformations (port wine 
stain), varicose veins and hypertrophy of bone and soft tissues. KTS was first described by 
Maurice Klippel and Paul Trenaunay in 1900, and was later reported by Parkes and Weber 
who additionally described arterio-venous fistula – Parkes-Weber syndrome (5). KTS is 
considered a paradominant disorder; heterozygotes are asymptomatic while homozygote 
mutations are lethal. The disorder manifests when a loss of heterozygosity mutation occurs 
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early in embryonic development leading to two distinct cell lines in the individual. No ethnic 
or racial predisposition has been reported (6), but increased parental age and number of 
pregnancies have been considered likely contributing factors (7). A de novo balanced 
translocation involving chromosome 8q22.3 and 14q13 has also been reported (8). Other 
mutations such as chromosome translocation t (5;II) and mutations of the EII3K gene and the 
VG5Q gene on chromosome 5 (coding for the angiogenic factor VG5Q) have also been 
reported in some KTS patients (9). An insult at the sixth week of gestation during the process 
of vascular differentiation and invasion of the limb bud, or failure of embryonic lateral border 
veins to regress at the eighth week of gestation have been postulated to lead to features of 
KTS (10). 
 
Varicose veins are found in 76% to 100% of patients with KTS. An abnormal vein is 
sometimes obvious at birth travelling in lateral aspect of the affected leg, draining via the 
gluteal vein into the profunda femoris or internal iliac system (11). Extensive varicosities can 
be visible on the extremities. Infrequently, varicosities may be present in other organs 
including the bladder, colon and pulmonary veins. Some of these patients demonstrate venous 
hypoplasia including an absence of venous valves or the deep venous system (6). Some of the 
deep venous system anomalies including atresia, agenesis or compression of the deep system 
due to fibrous bands have also been seen in KTS patients. Venous obstruction and 
malformations are seen at popliteal or femoral regions, and rarely at iliac or inferior vena cava 
level (12). 
 
1.1.3.2 Lymphoedema Distichaisis and FOXC2 Mutations 
Lymphoedema distichaisis (LD) syndrome is a form of lymphoedema linked with distichiasis 
(extra eye lashes from meibomian glands). Other associated features of the syndrome include 
varicose veins, congenital heart defects, vertebral anomalies, extradural cysts, ptosis and cleft 
palate (13). The haplo-insufficiency (when one copy of the gene is inactive and the remaining 
functioning copy is unable to produce sufficient gene product to allow a healthy condition) of 
FOXC2 genes from the forkhead family of transcription factors were found responsible for 
LD and were mapped to chromosome locus 16q24.3 (14). 
 
FOXC2 is expressed on mesenchymal cells and is involved in the development of endothelial 
and smooth muscle cells of blood vessels, including venous and lymphatic valve leaflets (15). 
Heterozygous mutations in FOXC2 genes were noted in additional families with LD (14, 16, 
17). Brice et al. examined 74 subjects from 18 families of LD syndrome and six isolated cases 
of LD, where approximately half of LD patients were found to have varicose veins (18). A 
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cohort study involving 2,060 pairs of female twins aged 18-80 years compared the incidence 
of varicose veins and haemorrhoids in relation to a candidate marker D16S520 on 
chromosome 16q24.4 (19). This study showed an association of dizygotic twins with a 
candidate marker D16S520 on chromosome 16q24.4, located in close proximity to a 
functional variant of gene FOXC2. Both phenotyping and genotyping showed that 
concordance was significantly higher within monozygotic twins compared to dizygotic twins, 
suggesting a substantial genetic contribution for varicose veins (19). In another study 
involving 18 participants with the FOXC2 mutation, including 3 without lymphoedema, every 
patient showed reflux in the great saphenous vein in comparison with 12 control subjects, 10 
of whom were family members (P<0.0001). Deep venous reflux was recorded in 14/18 
patients with the FOXC2 mutation. This study suggested that FOXC2 is strongly associated 
with primary venous valve failure in both superficial and deep venous systems (20). 
 
1.1.3.3 Chuvash Polycythaemia 
Chuvash polycythemia (CP) is an autosomal recessive disorder caused by homozygous 
mutation of the von Hippel-Lindau gene (VHL 598>T) on chromosome 3p25. CP results in a 
defective oxygen sensing mechanism and is associated with increased levels of hypoxia-
inducible factor (HIF) -1 despite blood normoxia, leading to increased serum erythropoietin 
and haemoglobin concentrations. Although the disorder was first described in the Chuvash 
population of central Russia (21), similar mutations have also been identified in Europeans, 
African American and Pakistani-Bangaldeshi people. Patients with CP are predisposed to 
vertebral haemangiomas, thrombosis, bleeding and stroke. (22). HIFs are nuclear 
transcriptional factors that regulate genes mediating oxygen homoeostasis (23). A matched 
cohort study showed varicose veins were found in 32 out of 43 VHL homozygote as 
compared to the 2 out of 9 heterozygote and 30 out of 77 unaffected individuals (24). There 
was an increased expression of HIF-regulated genes including vascular endothelial growth 
factor, plasminogen activator inhibitors-1, erythropoietin, glucose transporter GLUT-1, 
transferrin and transferring receptor in patients with varicose veins (22, 24). 
 
1.1.3.4 Other Related Genetic Abnormalities 
Venous insufficiency seen in patients with a family with a history of CADASIL (cerebral 
autosomal dominant arteriopathy with sub-cortical infarcts and leukoencephalopathy) has 
been linked to a novel heterozygous mutation of the Notch3 gene was isolated (25).  
Another Mendelian disorder that has been shown to be associated with varicose vein 
development includes severe congenital neutropenia type 4 (SCN4). SCN4 is caused by a 
mutation in the G6PC3 gene. In addition to varicose veins, individuals with SCN4 also 
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develop leg ulcers. Since SCN4 is a multisystem disease, it is not known whether the 
mutation is directly causing CVD or whether it is a secondary effect (26). 
Chromosomal aberrations have been observed in cell culture lines taken from patients with 
varicose veins. These include structural abnormalities, clonal trisomies of chromosomes 7, 12, 
and 18, and monosomy of chromosome 14 (27). 
 
1.1.4 Pathophysiology of Varicose Veins 
 
1.1.4.1   Lower Limb Physiology/ Anatomy 
The venous system functions as a blood capacitance reservoir and also a channel to return the 
blood to the heart. As veins are exposed to lower pressure, it is logical to expect less 
mechanical stretch and shear stress in veins in comparison to arteries. However, this 
hypothesis does not consider the thinner, less muscular and more compliant nature of the vein 
wall. The peripheral venous system in the lower limbs is divided into superficial and deep 
components. Superficial veins are located outside the musculo-fascial compartments and are 
connected to the deep venous system by perforating veins. Great saphenous vein (GSV) and 
short saphenous veins (SSV) are two major truncal veins in the peripheral venous system. 
From the clinical perspective, the peripheral venous system is important, as failure of this 
system is associated with CVI. The peripheral venous system is supported by bicuspid valves 
and muscle pumps to help pump blood centrally towards the heart, and prevent retrograde 
flow into the legs (termed venous reflux) (28, 29). 
 
1.1.4.2  Role of Venous Hypertension and wall stretch 
Contraction of calf muscle ejects over 40-60% of venous volume with a single contraction 
(30). Competent valves serve to prevent retrograde flow and together reduce the volume of 
blood in leg veins. Failure of the valves or muscle pump leads to increased pooling of blood 
in the legs and high venous pressure exerting a static stretch on the vein wall. The resting 
standing venous pressure in a normal leg is about 80 to 100 mmHg. During calf muscle 
contraction, the venous pressure normally drops to 20 to 30 mmHg followed by venous 
refilling. However, patients with venous reflux demonstrate a less than 50% venous pressure 
drop during calf contraction and a much shorter refilling time (Figure 1-2) (30, 31).  
The overall increased venous pressure as a result of blood stasis may result in vein wall 
dilatation, and the characteristic CVI dermal changes with hyperpigmentation, venous 
eczema, subcutaneous tissue fibrosis and ultimately ulceration (31). It has been long 
considered that pathology of vein valve is responsible for venous reflux. Venous reflux causes 
blood stasis, venous hypertension and vein wall weakness. Venous dilatation separates the 
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valve cusps further and worsens the valvular incompetence triggering a vicious cycle. 
Furthermore, distal valves may also become incompetent secondary to the proximal reflux 
and dilatation leading to a retrograde progression of the disease (Figure 1-2) (32-34).  
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a. 
 
 
 
b.                                         Environmental and Genetic Risk Factors 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-2. a. Effect of calf muscle on the venous pressure. From Coleridge smith, 
1994(31).  b. showing the association of different risk factors and vein wall changes. 
 
Vein Wall Changes 
• Inflammation 
• Dysregulated Smooth muscle cell proliferation/ apoptosis 
• Disruption in ECM content 
Venous hypertension 
Vein wall dilatation 
Valve distortion/ leakage 
Altered shear stress 
Mechanical stretch/ Axial stretch 
 30 
 
The failure of vein wall as a primary event was reinforced by the evidence from studies which 
identified valve deformities including tearing, thinning, thickening, splitting and scarring of 
the saphenous vein valves more frequently in varicose than non-varicose veins retrieved from 
surgery and during angioscopy (35-37). Further changes of valve hypotrophy and widening of 
the valvular annulus, less collagen deposition have been seen in varicose veins as compared to 
non-varicose veins (35, 38-40). Moreover, inflammatory markers have been found infiltrated 
into the valvular sinuses of varicose veins (39). However, recent evidence has shown that 
primary vein wall changes occur first and valve failure is an epiphenomenon of the varicose 
veins disease. The evidence in the favour of this theory has shown incompetent varicosities 
below the competent valves which has not uncommonly found to precede valvular 
incompetence. Similarly, venous dilatation is also frequently seen distal to a competent valve 
rather than proximal which one would expect if valvular dysfunction is the initial event (41-
43). In one study, reflux in the main saphenous trunk or tributaries alone has been detected in 
24% of limbs examined without any junctional incompetencies (44). In another study, new 
sites of reflux on duplex ultrasound have also been reported in patients awaiting varicose 
veins surgery over a median period of 19 months (45). Even, venous reflux could occur in any 
part of the superficial and deep venous system without the necessity of a more proximal 
incompetence in patients with primary CVD (46, 47). These data support the theory that the 
disease has got multifocal origin. Therefore, varicose veins do not always initiate at 
saphenofemoral junction (SFJ) or saphenopopliteal junction (SPJ), and progress in a 
descending or retrograde manner. Anterograde or ascending disease progression is more 
likely to be caused by primary vein wall changes leading to subsequent valvular incompetent 
than vice versa (41, 43). In addition to environmental and genetic risk factors, the 
haemodynamic abnormality causing mechanical stretch and low shear stress, hypoxia is also 
considered a possible trigger factor for primary vein wall changes (41, 48).  
 
1.1.4.3 Morphological Changes in Primary Varicose Vein Wall 
Since, the weakness of the vein wall has been strongly considered the primary event in 
pathogenesis of varicose veins, a large number of studies have been published on exploring 
the pathological changes in the vein wall (32-34). The  morphological changes of varicose 
veins intima include irregular intimal hyperplasia associated with collagen deposits, smooth 
muscle cells (SMCs) infiltration and plaques underneath the endothelial lining (Figure 1-3) 
(33, 49-53). Medial wall changes consist of SMCs proliferation and ECM degradation (49, 
50, 54, 55). The adventitia of varicose veins demonstrates areas of increased SMCs, 
fibroblasts and connective tissues with regions of atrophy and is devoid of vasa vasorum (41, 
54). These morphological changes are sporadic and the actual sequence of their occurrence is 
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not clear. Several studies have proposed altered expressions of genes and their transcriptional 
and protein products in varicose veins as compared to non-varicose veins. The altered 
expression of certain genes and proteins explains some of the pathological wall changes (32, 
33, 56-58).  
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Figure 1-3. A. Haematoxylin (H) and eosinophilic (E) stained normal vein wall showing 
tunica intima (I), media (M) and adventitia (AD). B. Varicose vein wall H &E stained 
showing increased thickness of I and M layers. C. Showing normal LSV with blue 
coloured collagen in between different layers of the vein wall. D. increased collagen 
deposition noticeable within three layers of varicose vein wall. E.  Black coloured elastic 
fibres in normal vein wall. F. loss of black coloured elastic fibres in varicose vein wall. 
All illustrations have been taken from the work of Elsharawy et al. (50)  
 
 
a. Dysregulation proliferation/ apoptosis 
The histological changes seen in SMCs include both areas of hypertrophy and atrophy in the 
tunica media layer. SMCs also migrates into intima and displays a change of phenotype from 
contractile to synthetic type (Figure 1-3)(33, 41, 49-53, 59, 60). The synthetic phenotype is 
characterized by features such as loss of contractile actin cytokeleton of cells, loss of myosin, 
increased vacuolisation and phagocytosis (33, 60, 61) (62). This leads to impaired smooth 
muscle cells contractility. This has been demonstrated in varicose veins where phenylephrine 
induced contraction was absent in severe form of varicose veins (63).  Mediators released by 
endothelium such as platelet derived growth factor (PDGF) and fibroblast growth factor 
(FGF) may contribute to some of the alterations of SMCs in varicose veins (33, 41, 48, 64). 
E 
 
 
F 
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Increased FGF mRNA expression was seen in varicose veins wall suggesting its role in vein 
wall remodelling (65).   
Apoptosis, a type of programmed cell death, is an important physiological process in normal 
development, morphogenesis and tissue regulation (66). Improperly regulated apoptosis leads 
to faulty DNA repair mechanisms and cell cycle disruption and may contribute to 
pathological conditions such as cancer, Alzheimer’s disease and ischaemic heart disease (66). 
Dysregulated apoptosis and dysfunction cell cycle have been demonstrated in varicose veins 
(66-70). The overall number and activity of apoptotic cells is reduced in varicose veins (68, 
69, 71). Studies have shown increased expression of cyclin D1 and reduced expression of bax 
and poly ADP-ribose polymerase (PARP) in varicose compared to non-varicose veins. Cyclin 
D1 is a proto oncogene and is involved in the progression of cell cycle through G1 phase. Bax 
is an inducer of apoptosis and PARP is an enzyme involved in genome surveillance and DNA 
repair (68, 69).  
b. Inflammation in Varicose Vein Wall 
Inflammation plays a key role in the pathogenesis of varicose veins. Endothelial cells play 
active roles in the regulation of vascular inflammation and tone (72). Endothelial cells of 
varicose veins are found to be desquamated and degenerated under electron microscopy (54). 
Such injured endothelial cells release various types of inflammatory mediators (41, 48). These 
inflammatory mediators include vascular cell adhesion molecule-1 (VCAM-1), intercellular 
adhesion molecule-1 (ICAM-1) and von Willebrand factor (vWf) (33, 54). Moreover, 
inflammatory cells such as mast cells, macrophages and monocytes infiltrate the damaged 
varicose veins wall and release proteases which desquamate the ECM (73-75). Increased 
expression of mRNA of monocyte chemotactic protein (MCP-1), interleukin (IL 8) 
macrophage inflammatory protein (MIP-1α and 1β) is detected in varicose veins (76).  
Besides vascular inflammation, endothelium also regulates venous tone through the release of 
various vasoactive substances. Some of them are vasoconstrictors (noradrenaline, endothelin-
(33)1) and others vasodilator (nitric oxide and prostacyclin). The overall imbalance of these 
vasoactive substances causes relaxation of varicose veins wall (32, 33, 77, 78). 
 
c. Extracellular matrix degradation 
Extracellular matrix (ECM) interlinks the cellular components such as endothelium and 
VSMCs and, consists of collagen, proteoglycans, elastin, glycoproteins and fibronectin. It is 
a dynamic structure and maintains the integrity and homoeostasis through its interactions 
with the cellular components (79). Disruption in any of the constituents of ECM leads to the 
weakening and dilatation of the veins. For example, disruption to the elastic fibres, loss of 
type III collagen (contributes to elasticity) and upregulation of type I collagen (contributes 
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to tensile strength) has often been observed in varicose veins (Figure 1-3) (49-51, 55, 80-86) 
(49, 51, 55, 59, 61) (85) (61, 86). Loss of elastin and type III collagen is inversely related to 
the vein diameter measured with ultrasonography (87). Therefore, alteration to the balance 
of the elastin and collagen content is likely to weaken the vein wall and cause dilatation (49-
51). Furthermore, activated leukocytes as a result of damaged vein wall releases high 
amount of superoxide anions and proteases which degrade the ECM (41, 48). 
 
Matrix metalloproteinases (MMPs) are zinc dependant endopeptidases and belong to the 
family of proteases called metzincins. Their function is to cleave most of the constituents of 
ECM (32). Out of 23 MMPs identified in humans to date, 14 are found in vascular tissue (88). 
The regulation of the MMPs is complex and can occur at gene transcriptional and protein 
translational levels. Moreover, MMPs are produced as inactive pro-enzymes (zymogens) and 
are activated by various exogenous and endogenous stimuli (89). Their activity is further 
controlled by plasma proteins such as 2-macroglobulin and their endogenous tissue 
inhibitors (TIMPs) (79, 90, 91).  
 
MMP/TIMP imbalances have been observed in varicose veins (72, 92). Significant increase in 
the concentration of pro-MMP-9 and leukocytes (L-selectin) were observed in blood sampled 
from varicose compared to non-varicose veins after 30 minutes of postural blood stasis 
(standing or sitting with the legs hanging down) (93). As varicose veins are under high 
venous pressure, studies have investigated the effect of vein wall tension on MMP activity in 
in an ex vivo animal model. For example, increased in the magnitude and duration of vein 
wall tension in segments of rat inferior vena cava (IVC) were associated with reduced 
contraction, and over expression of mRNA of MMP-2 and MMP-9 (94). MMP-2 and 9 
belong to the gelatinases group of MMPs which act to digest denatured collagens. MMP-2 
and MMP-9 were also found to induce significant relaxation of rat IVC, proposed to be 
through VSMCs hyperpolarisation and activation of large conductance calcium-dependent 
potassium channels, suggesting that MMPs may play a role in the early stages of venous 
dilation secondary to high venous pressure (95). Using similar model of IVC rings, Lim et al. 
found an increased expressions of mRNA HIF 1 and 2 α in association with mRNA of MMP-
2 and MMP-9 genes expression, highlighting the significance of MMPs and HIF genes 
expression in venous wall remodelling under stretch (96). These observations suggest that 
venous hypertension secondary to blood stasis may elevate the production of MMPs, which 
not only increase ECM degradation, but also cause venous relaxation. Therefore, vein wall 
stretch due to high venous pressure is considered a strong predisposing factor in the 
pathogenesis of varicose veins disease. 
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1.1.4.4  Genes Associated with Varicose Veins  
Given the frequent observation of a positive family history of varicose veins in some studies, 
scientific effort has led to the identification of specific genes that may be linked to venous 
function. One study investigated the heritability of venous function measured by impedance 
plethysmography in 46 twin pairs. After comparing the concordance between monozygotic 
and dizygotic twins using a path modelling approach, the study concluded that the unadjusted 
heritability was 60% (P<0.05) for venous capacity and 90% (P<0.05) for venous compliance. 
After adjustment for age and sex, the heritability was estimated to be 30% for venous capacity 
while venous compliance remained unchanged at 90% (97). This study suggests that venous 
compliance is highly dependent on genetic composition and an individual carrying the 
susceptibility loci will have a higher risk of developing a venous disease.  Altered venous 
tone may functionally affect the vein directly by contributing to venous non-compliance and a 
reduced venous capacity resulting in blood stasis, increased intraluminal pressure and 
increased vein wall tension. This diastolic force has been considered to initiate the cellular 
and extracellular changes seen in varicose veins (94). 
 
Some studies have supported the theory that the primary initiation of varicose vein formation 
occurs in smooth muscle cells (85). Downregulation of desmuslin gene expression has been 
noted in the smooth muscle cells of incompetent varicose veins. The desmuslin gene is 
located at chromosome 15q26.3 and encodes the protein desmuslin, which belongs to 
intermediate filament protein family and is located in the smooth muscle cell cytoplasm (98, 
99). Intermediate filament protein complexes provide strength and integrity to the smooth 
muscle cell wall. Breakdown of smooth muscle cell fibres has been described in incompetent 
vein walls  and it has been stipulated that this separation of muscle fibres may cause loss of 
vascular tone leading to venous dilatation (60). 
 
Studies also suggest that the downregulation of desmuslin in the vein wall may be responsible 
for a smooth muscle cell phenotypic switch from the contractile to synthetic phenotype and 
hence cellular weakness(70, 100). In a recent study, desmuslin gene knockdown in cultured 
human saphenous vein smooth muscle cells by RNA interference led to a reduction in the 
expression of various smooth muscles cell proteins that regulate their phenotype. An increase 
in matrix metalloproteinase (MMP) -2 and collagen activity has also been reported, further 
supporting the proposed role of desmuslin in smooth muscle cell differentiation and structural 
integrity in veins(101). 
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Thrombomodulin (TM), involved in the control of thrombus formation via the regulation of 
thrombin, is thought to be associated with varicose veins. In a case control study involving 
327 patients with a history of venous thromboembolism (deep venous thrombosis [DVT] or 
pulmonary embolism), and 398 control subjects, TM mutation (-1208/-1209 TT deletion) was 
associated with a history of varicose veins(102). However, as this study primarily examined 
the biological risk factors of DVT, further studies are required to ascertain the involvement of 
TM in primary varicose veins. 
 
It is important to note that a number of studies have demonstrated differences between 
varicose and non-varicose veins in the differential expression of numerous other genes 
including structural genes regulating the extracellular matrix (ECM), cytoskeletal proteins and 
myofibroblasts (103). Importantly, it remains unclear if the differential expression of these 
genes is a cause or the effect of varicosities. 
 
1.1.4.5  Differential genes expression profilling of varicose veins 
Gene expression profiling of varicose veins tissue have been studied using complementary 
deoxyribonucleic acid (cDNA) microarray analysis.  In comparison to non-varicose veins, 
an up-regulation of 82 genes of the 3063 cDNA clones was identified in varices. The up-
regulated genes included transforming growth factor β-induced gene (BIGH3), tubulin, 
lumican, actinin, type I collagen, versican, actin and tropomyosin (103). These genes 
regulate ECM and cell cytoskeletal. In another study three cDNAs sequence of LIM4 
reppeat, RP11-57L9, clone RP11-29H13 and Alu repetitive sequence of human tropomycin 
4 messenger ribonucleic acid (mRNA) were found to be over expressed in varicose 
compared to non-varicose veins (104). Tropomyosins are actin-binding proteins found in 
both muscular and non-muscular cells and play a key role in maintaining the structure of 
cell contractile system (104). In another study using transcriptomic technology, elevation of 
expression of vascular endothelial growth factors (VEGF)-121, VEGF-165 and two VEGF 
receptors 1 and 2 (flt-1, KDR) were found in varicose veins as compared to non-varicose 
veins (105). VEGF and its receptors are involved in angiogenesis, vascular permeability and 
cell proliferation. Utilising another ‘Omic’ technology, suppressive subtraction DNA 
hybridization approach, overexpression of genes including collagen III, TIMP I, 
dermatopontin, matrix gIa protein and tenascin were identified in varicose vein group. The 
relative protein translational products to differentially upregulated genes were also elevated. 
The overexpression of matrix gIa protein in varicose vein may contribute to venous wall 
remodelling by affecting proliferation of smooth muscle cells and mineralisation of matrix. 
Overall, this study showed 34 overly expressed genes in varicose veins. The functional 
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classes of transcriptionally regulated genes corresponded to cell metabolism, ECM 
remodelling and cell organization. The differential gene profile of varicose veins associated 
with metabolism suggests a role of dysregulated metabolism and mitochondrial dysfunction 
in varicose veins development (106).  
 
The evidence from studies examining the expression of genes and their transcriptional 
profiles, and protein expression is not yet able to fully elucidate the abnormal cellular 
pathways and dysregulated enzyme functions involved in instigating the abnormal vein wall 
changes. Many cellular pathways and cell processes are simply not reflected in protein or 
genes expression changes and therefore the proteomic and genes expressions data may only 
highlight the potential for pathophysiological effects (107). Moreover, any covert 
involvement of abnormal metabolism, which has been suggested in some studies, is totally 
overlooked by such approaches. 
 
1.1.5  Treatment of Varicose veins and role of pharmacotherapy 
In UK, about 40,000 operations are performed for varicose veins per year (108).  About 60% 
to 70% of patients with varicose veins have incompetent sapheno-femoral junction and a 
reflux in great saphenous vein. Therefore, primary emphasis is on the treatment of the reflux 
in varicose veins management. Treatment of varicose veins dates back to the era of 
Hippocrates. The standard conventional surgical treatment was first described over 100 years 
ago (109). The last decade has seen the advent of endovenous therapies which have been 
evolving rapidly (110). Non-invasive management (e.g. compression and drugs) have also 
been used ether concomitantly or in isolation. Anatomical distribution of venous reflux, 
pathophysiology of the disease, patient’s comorbid conditions, patient’s and surgeon’s 
preference, availability of treatment options, and affordability are the factors which decide 
which treatment options to choose for your patient (110-113). 
 
1.1.5.1  Open Surgery 
Treatment of the reflux with high tie and stripping of Great Saphenous vein (GSV) has been 
considered the Gold Standard treatment of varicose veins and other emerging treatments are 
compared against it. Stripping has been demonstrated to reduce the risk of reoperation by 
two-thirds after 5 years (114). ESCHAR trial demonstrated that combining surgery and 
compression therapy reduced recurrence of venous ulcers compared to compression therapy 
alone (115). Short saphenous vein (SSV) incompetence is treated with ligation of the 
saphenopopliteal junction (SPJ) with or without stripping of the SSV.  Varicosities of the 
tributary veins are usually treated with multiple phlebectomies or avulsions.  
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1.1.5.2  Endovenous Thermal Ablation 
The technique of radiofrequency ablation (RFA) was described in 2000 (116) and Navarro 
described endovenous LASER ablation (EVLA) treatment in 2001(117). Endovenous ablation 
involves inserting and passing a catheter or fibre along the lumen of varicose veins under 
ultrasound guidance. Tumescent, a diluted local anaesthetic (for example diluting 30ml of 2% 
lidocaine and 1:200,000 adrenaline in 500ml of normal saline) is usually infiltrated into the 
surrounding tissues of the varicose veins to be treated. Tumescent infiltration also protects the 
surrounding tissues from injury. Ablation of the varicose veins is then performed either with 
laser or radiofrequency. This can be done under general or local anaesthesia. Overall, RFA is 
safe with success rate equivalent to surgery and sclerotherapy (118, 119). Technical success 
rates with EVLA have been found to be excellent with occlusion rates reported to be around 
97% at 4 years and 87% at 6 years. Therefore, EVLA is considered better than surgery and 
Radiofrequency ablation (RFA) in terms of technical success rate (120). The emerging 
endovenous technologies include thermal ablation, mechanochemical ablation and 
pharmacological occlusion. Currently, the efficacy of these new technologies is being studied 
in some clinical trials. 
 
1.1.5.3 Injection Sclerotherapy 
Injection sclerotherapy involves injecting a sclerosant into the varicosities. Injection 
sclerotherapy can be performed on its own or in combination with open surgery and 
endovenous thermal ablation (121). Sodium tetradecyl and polidocanol are commonly used 
sclerosant (122). Blood in the varicosities is displaced by the foam which then causes 
vasospasms and venous occlusion. Injection sclerotherapy is less invasive, cheaper and can be 
done in out-patients settings. Injection sclerotherapy is associated with risks of recurrence, 
skin pigmentation, visual disturbances, migraine and headache. 
 
1.1.5.4  Compression Therapy 
Compression therapy with bandages or hosiery works by physically occluding the superficial 
veins, and hence preventing blood stasis (123). Compression therapy is safe and effective, 
although non-compliance can be an issue with some patients (123-125). Peripheral arterial 
disease is a relative contraindication to compression therapy. It can be used alone or in 
combination with other treatment modalities such as surgery, endovenous thermal ablation 
and injection sclerotherapy (123, 125). 
 
1.1.5.5  Pharmacological Therapy 
In UK, about 40,000 operations are performed for varicose veins per year (108). Overall 
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open surgery, endovenous thermal ablation and injection sclerotherapy are effective and 
safe, however, recurrence of varicose veins remains still high, and has been estimated to be 
between 20% and 40% (126). It is now strongly considered that neovascularisation is likely 
the most important cause of recurrent disease (127, 128). About 10% of patients with 
varicose veins go on to develop the skin changes of chronic venous insufficiency (CVI) 
including skin ulceration. There are pharmacological agents available for the treatment of 
CVD and CVI. Venoactive drugs such as flavonoids and horse-chestnut extracts have been 
shown to improve symptoms and signs of CVI in randomised controlled trials (129-131). 
Flavonoids such as micronised purified flavonoid fraction (MPFF), containing 90% diosmin 
and 10% hesperidin, may protect vein wall from hypoxia and inhibit the expression of 
adhesion molecules on the endothelium and leukocytes (132, 133). MPFF has been shown 
to improve symptoms of CVI such as oedema and discomfort in randomized controlled 
trials (130, 131). Other anti-inflammatory drugs used to relieve symptoms of CVI include 
Pycnogenol and Mesoglycan. Pycnogenol, containing phenolic compounds extracted 
from the bark of the French maritime plant, has anti-inflammatory properties and inhibits 5-
lipoxygenase and cyclooxygenase-2 gene expression and phospholipase A2 activity (134). 
Mesoglycan inhibits neutrophil adhesion, is a sulphated polysaccharide compound 
consisting of heparan sulphate, dermatan sulphate, heparin and condroitin sulphate (135, 
136).  Horse chestnut seed extract (Aesculuc Hippocastanum L) is a herbel remedy which 
has been used for venous induced leg oedema.  A Cochrane review analysing the results of 
17 randomized trials have compared the horse chestnut seed extracts against placebo (10 
randomised trial), pycnogenol (1 trial), compression stocking (2 trials), and O β 
hydroxyyethyl rutosides (4 trials). In comparisons to placebo treatment, there was a 
significant improvement in leg pain, oedema and pruritus in the group given horse chest nut 
seed extracts.  Horse chestnut seed extracts were found to be comparable in improving leg 
pain and pruritus when compared with pycnogenol or compression stockings or rutosides . 
Horse chestnut seeds extracts were as effective as compression stocking or rutosides but 
were inferior to pycnogenol in relieving leg oedema (137).  
 
There is no consensus among the vascular surgeons on the use of pharmacological agents 
for CVI. This is mainly due to lack of scientific research in the disease pathogenesis. There 
is a need for future research to focus on identifying the disease biomarkers and potential 
pharmacological therapeutic targets. The pharmacological treatment will be beneficial for 
that group of patients who develop recurrent varicose veins refractory to surgical and 
endovenous treatments. It will certainly reduce the cost on the management of dermal 
complications of the disease, currently estimated to be around 600 to 900 million Euro per 
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year in Western European Countries (138).   
 
1.2 METABONOMICS 
Over the last decade changes have been seen in the molecular biology approaches. 
Subsequent to the decoding of human genome, the changes in gene expression have been 
largely explored. This has been performed using DNA Microarray technology or Polymerase 
chain reaction techniques. This systems biology approach is called transcriptomics (139, 140). 
Similarly attention has been focussed on quantifying the translational products of these genes 
and this investigative approach is known as proteomics. Both transcriptomics and proteomics 
methodologies have been very useful in studying pathogenesis of various diseases. However, 
there are some limitations with their use; for example, in transcriptomic method it is difficult 
to link fold change in genes expression to the disease or an end point (140). The final 
downstream products of genome are small molecular weight molecules called metabolites 
which take part in metabolic reactions inside the cells and required for normal growth, cell 
functions and maintenance (Figure 1-4) (141, 142). Metabolites are small and intermediate 
compounds (DK <15,000) in the living cells or fluids produced as a result of enzyme led 
metabolic reactions (143, 144). These include a wide range of compounds including low 
molecular weight polar volatile compounds and classes of  high weight polar glucosides, non-
polar lipids and inorganic compounds (143, 144). Various environmental factors including 
disease, diet and drugs affect cellular metabolism and hence the metabolite pools in the 
extracellular tissues and fluids are affected as a result of this altered metabolism (145). 
Metabonomics measures the dynamic multiparametric metabolic response of living systems 
to pathological stimuli or genetic modifications (146). Although metabolites are the final 
downstream product of genes, however, biochemical changes seen in a disease state or 
noticed under the influence of drugs or other factors does not always occur in the direction of 
downstream pathway (140). These factors can regulate up-stream pathways by directly 
influencing the metabolites and then causing alteration at protein or genes levels afterward 
(140). Therefore, the influence of external or internal factor is more robust at metabolic level 
than at gene level (Figure 1-4) (107). Changes in metabolites reflect more closely the disease 
phenotype than alteration in genes or protein expression. The central role of metabolism in 
disease aetiology has been increasingly acknowledged. This makes metabonomics the optimal 
exploratory platform for discovering biomarkers or understanding disease pathogenesis (107, 
145).  
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Figure 1-4. Influence of disease and other environmental factors on the regulation of 
Genes, mRNA, proteins and metabolites. Illustration has been reproduced with 
modifications (originally published in thesis of Dr Shalhoub which was submitted to 
Imperial College London in 2011. 
 
1.2.1 Metabonomics Analytical Platforms for Metabolic Profiling 
There are various analytical techniques employed to measure metabolites in biological 
samples and evaluate their biological significance. The major analytical platforms include 
nuclear magnetic resonance (NMR) spectrometry and mass spectrometry (MS) coupled with 
chromatography in either gas or liquid phase (140). Spectroscopic profiling generating 
metabolic signature characteristics of a given state itself is important, however, interpretation 
of their significance in relation to a disease or drugs requires use of chemometric and 
bioinformatics methods (145). Spectroscopic analytical platforms when combined with 
chemometric software can facilitate  the elucidation of cellular pathways, provide information 
on gene or enzyme functions and can aid in the determination of the influence, efficacy and 
toxicity of targeting therapeutics (140, 146, 147). 
 
1.2.1.1 Nuclear Magnetic Resonance Spectrometry 
Nuclear magnetic resonance (NMR) spectroscopy is a widely used analytical technique in 
which atomic nuclei such as protons in a biological sample when exposed to radiofrequency 
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pulses of an external magnetic field experience slight differences in magnetic exposure 
depending upon their immediate electronic and chemical environment (Figure 1-5). These 
differences are the basis of the spectral fingerprint containing discrete signals reflecting 
multiple metabolites (148). NMR provides detailed information about the molecular structure, 
dynamics, mobility and concentration of a metabolite.  
 
 
 
 
 
Figure 1-5.  A typical nuclear magnetic resonance spectrometer (600 MHz) and its basic 
internal structure 
 
Nuclei of molecules have a property known as ‘spin’ characterised by a nuclear spin quantum 
number I. Isotopes such as 
1
Hygrogen, 
13
Carbon, and 
31
Phospohorus have a spin quantum 
number I=1/2. Some molecules may have an integral spin quantum number such as I=1 or 2 
and others such as 
16
Oxygen, 
32
Sulphur have no spin (I=0). 
1
Hygrogen, 
13
Carbon, and 
31
Phospohorus are the most commonly encountered molecules in NMR spectroscopy and 
hence concerned spin quantum number is I=1/2. In NMR, any nucleus having a spin other 
than zero can be detected (148) (149). In the presence of an applied external magnetic field 
B0, half a spin nuclei will have two energy states denoted by a quantum number ‘m’; a low 
energy state and a high energy state. Molecules having two or more spins will have higher 
energy levels or states. For the purpose of simplicity, a molecule with half a spin and two 
energy levels can be taken as an example. To detect signals on NMR, radiofrequency pulses 
from the external magnetic field are irradiated on the spinning atomic nuclei in a way that 
forces the nuclei in low energy state to switch to high energy state with their magnetic 
moment in opposite direction to magnetic field. The difference between the energy between 
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the two spin states is very small and is dependent on the size of the applied external magnetic 
field. The transition between the two energy states gives line on NMR spectra. The 
radiofrequency pulses are applied at short intervals and nuclei return to their original state in 
between these intermissions. This phenomenon is called relaxation and depends upon the 
composition of the molecule.  
 
ΔE = γhB0 
        2π 
 
 
h=Plank constant, v= frequency of photon of light, γ= magnetogyric ratio (nuclear 
constant which is different for every nucleus), ΔE= transition energy between the two 
energy states 
 
In NMR, a solution of the sample is placed between the powerful two poles of the 
superconducting magnet (Figure 1-5). Radiofrequency radiation is transmitted via a coil. A 
receiver coil surrounds the sample and detects the oscillating radiofrequency generated as a 
result of the relaxation of nuclei. This is called free induction decay (FID). Emission of 
absorbed radiofrequency is monitored by a coil. The Fourier transformation converts an FID 
signal into its constituent frequencies and magnitudes. Protons spin frequencies are dependent 
on many environmental aspects, one being surrounding electrons, which is called the 
shielding effect. The shielding of a proton affects the frequency of its resonance and so shifts 
it either up or down-field on the parts per million (ppm) scales (see below). The ppm scale 
characterizes the spectral lines from different chemical compounds. The value on the ppm 
scale is essentially the chemical shift of a proton denoted by δ and is dependent on its 
electromagnetic and chemical property. The ppm value of a nucleus represents the difference 
between the applied and experienced magnetic field divided by applied magnetic field. This 
gives a very small numerical number which is usually multiplied by 10
6
 (150). 
 
 
 
Where δ is the chemical shift and fa is the applied resonance frequency of a nucleus and fo is 
the observed frequency of the reference compound added to the sample (usually 3 
trimthylsilyl propionic acid (TSP)) (151). Using a standard reference in the sample such as 
sodium salt of 3 trimthylsilyl propionic acid (TSP), the position of spectral bands or peaks 
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from other molecules are identified. The band area provides information about the relative 
concentration of the substance (140). Absolute concentration can be obtained if the sample 
contains an internal standard of a known substance or concentration of a substance is known 
by an independent means (140). In recent years small intact biological tissue biopsies have 
been analysed using a technique called high resolution NMR magic angle spinning (MAS) 
without any pre-treatment of the tissues. In MAS, the tissue samples are run on NMR 
spectrometer at a high speed at an angle of ϴ 54.70 relative to the magnetic field. This has the 
advantage of using intact tissue, being non-destructive in nature, requiring a small sample 
weight, and less laborious pre-treatment (147). Two dimensional NMR spectroscopy helps in 
structure elucidation of molecules and hence its identification. 
 
1.2.1.2 Mass Spectrometry 
Mass Spectrometry (MS) has been used widely in molecular fingerprinting. It may require 
separation of metabolites from the biological sample by chromatography such as gas 
chromatography (GC) or liquid chromatography (LC) (140). It works on the principle of 
measuring mass to charge ratio to determine the molecule structure and its polarity. MS 
instrument has an ion source, a mass analyser, a detector and a recorder to detect the signal 
(Figure 1-6)(152). The samples can be injected directly or in combination with 
chromatographic techniques such as GC, capillary electrophoresis (CE), high pressure liquid 
chromatography (HPLC) or ultra-high pressure liquid chromatography (UPLC) (152). 
Volatiles compounds are best separated by GC. UPLC-MS allows separation of liquid 
samples (153). CE-MS permits separation of molecules based on their size to charge ratio. 
Recent advances such as ultra-performance liquid chromatography (UPLC) have increased 
the speed and the sensitivity of overall spectroscopic metabolic profiling. Moreover, MS can 
be coupled with NMR which provides a full array of metabolite identification tool. MS is 
sensitive and NMR gives a detailed molecular conformation and has the advantage of 
studying molecular dynamics and compartmentation (140, 142). Together these techniques 
offer a comprehensive metabolic picture of a biological sample, and when combined with 
chemometric software can provide markers of biological significance (140).  
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Figure 1-6. Diagram of Mass spectrometer coupled with a Chromatogram and the basic 
principle of mass spectrometry analyses 
 
1.2.1.3  Multivariate statistical analysis/ Chemometric analysis 
Metabonomic analyses generate spectra which contain a wealth of data. Some of this may be 
noise from the instrument. For the adequate understanding and identification of signals 
responsible for variation between samples, the data are analysed using multivariate statistical 
models including unsupervised Principal Component Analysis (PCA), or supervised Partial 
Least Square (PLS) regression and its variants (154) . Each spectral intensity is given a value 
in the multivariate matrix and each spectrum is considered as an object with a 
multidimensional set of metabolic variables (140).  
 
a. Principal Component Analysis (PCA) 
PCA is a multivariate statistical analytical technique which expresses most of the variance in 
the data set in a few dimensions without any prior knowledge of sample grouping or class. It 
describes any inherent variations in the data set using a smaller number of latent variables 
after linear rearrangement of the observed variables. Principal components (PC) are vectors 
which are used to explain the variation in our observed data. Each PC explains the maximum 
variation that is not covered by the previous PC and is uncorrelated with other PCs (155, 156) 
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but merely display information about the underlying structures within data, revealing trends 
and outliers (155). PCA does not classify the samples of different groupings. This includes 
classes of pathological and metabolic status, and different treatment groups. For that purpose, 
supervised methods are implemented.  
 
b. Partial Least Square regression (PLS) 
Each data set includes independent variables from samples (X matrix) and dependent 
variables for those samples such as response to treatment called Y matrix. The aim of 
employing a statistical model is to explain the variables in the Y matrix or show any 
differences between groups or classes using the X matrix. Due to multicolinearity of NMR 
data, the standard regression models fail to predict the data. Partial least square (PLS) is a 
supervised linear regression method used to relate X matrix to a Y matrix by creating multiple 
components which explain the variations in the data (140, 155, 156). Moreover, it can also, at 
the same time, separate two classes by maximizing X and Y covariance, an approach called 
PLS discriminatory analysis (PLS-DA) (157). PLS model can be used to separate 
uncorrelated variations (orthogonal variations), a method called Orthogonal PLS (O-PLS) 
(158). The influence of time in a data set can be predicted from PLS by using time as a Y 
variable. This approach can be used to model biofluids samples collected over a course of 
time of the progression of a pathological effect (140). Cross validation is required for OPLS 
DA models to minimise any potential over fitting of the model. This involves removing a 
portion of the data prior to modelling and testing the model to see how accurately it can 
predict the removed part. This process is repeated until every variable has been omitted once, 
and then the average percentage of successful attribution is acquired. If the average 
imputation value is above 0.5 (i.e. more than 50% successful prediction) then the model is 
considered fit for data interpretation (154, 156).  
 
c. Structural Assignment 
The final step of metabonomics analysis is the identification of metabolites which relate to 
specific phenotypes. These biomarkers offer a direct link to the underlying biological 
pathways which result in the phenotype under study. Individual metabolite identities can be 
assigned by using data from other in house studies and using other resources such as the 
human metabolome database (159-163). The assignments can be confirmed by 2- 
dimensional (2D) NMR experiments on selected samples, and through the use of the Bruker 
Amix/SBase database. 2D NMR disperses the data into two spectra showing mainly 
correlation between adjacent protons (
1
H-
1
H Correlation Spectroscopy or COSY) or carbon 
atoms 
1
H-
13
C heteronuclear single quantum coherence (HSQC) facilitating elucidation of 
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the structure of each metabolite (147, 161). J–resolved spectra which display the coupling 
patterns and J-coupling values in a second orthogonal dimension can also be used to 
identify metabolites and interpret overlapping signal patterns (164). Another approach is 
Statistical Total Correlation Spectroscopy (STOCSY) which computes the correlation 
between variables in a set of spectra, which allows for the identification of related peaks 
belonging to the same molecule or of different molecules that are correlated for example 
deriving from the same cellular pathway (141). 
 
1.2.2 Applications of Metabonomics 
In order to understand the biological and clinical usefulness of metabonomics, it is necessary 
to know the normal biochemical profiles of biological tissues, fluids or systems. Further to 
identifying the distinct metabolic signature of a healthy or disease state, metabolic profiles 
also report on the effects of drugs and diet.  
 
1.2.2.1 Integration with Transcriptomic Approach 
Metabonomic is complementary to other Omics principles. For example, metabonomics 
approaches can detect the effects of age, sex and menstrual cycle on metabolic profiles of a 
tissue or fluids (140, 142). Moreover, any diurnal variations and interspecies differences on 
the metabolic signatures can also be observed using this approach (165). Transcriptomics data 
can be integrated into metabonomics data in order to study cellular pathways (166). For 
example, changes in genes expression provide information about any transformations in 
enzymatic activity inside the cells. The changed enzyme actions can also be detected by 
analysis of the alteration in the metabolic profile of the same tissue or biofluid (167). 
Metabonomic analysis has improved the suitability of mutant and transgenic animals’ models 
to study human diseases by providing a comparative phenotype between the two (168).  
 
1.2.2.2 Role of Metabonomics in Drug Development and Toxicity 
NMR has also revealed the important symbiotic relationship between mammals and their gut 
microfloral population. The role of gut microbiota in regulating the host metabolic pathways 
has unlocked a new area of understanding certain human diseases and tailoring our 
therapeutic strategies to combat them (169) (170). 
The drug affects each individual differently. These inter individual variation is due to the 
metabolic phenotype of the individuals. The metabolic phenotype is influenced not only by 
the genotype but also by the environmental factors including diet, nutritional status, status of 
gut mirobiota, age, disease and any concomitant use of other drugs (140). 
Pharmacometabonomics involves finding the metabolic make up of individuals and their 
 48 
 
different ability to response to pharmaceutical intervention. This methodology has the 
potential to tailor drug therapy as per individual’s phenotype and hence personalise healthcare 
(171). This methodology not only identifies any side effects of drugs but also provides key 
information regarding their biochemical mechanism for both toxicity and efficacy. Most 
importantly, evaluation of the time course of the effects of toxins such as their onset, 
progression and excretion from the biological systems can be thoroughly studied (172).   
 
1.2.2.3 Role of Metabolic Profiling in Disease Diagnosis and Pathogenesis 
There are numerous clinical uses of NMR based metabolic profiling in disease diagnosis and 
understanding pathogenesis. For example, NMR analysis of serum in cerebrospinal fluid 
(CSF) for Alzheimer disease have aided in diagnosis of Alzheimer disease. Similarly, blood 
metabolite profiles detected by NMR spectroscopy have been employed to study in-born error 
of metabolism in children (173). Identification of biomarkers in CSF has enabled 
differentiation of patients with meningitis from healthy controls (174). Analysis of tissue has 
been applied in diseases such as prostate cancer, renal cell cancer, brain tumours, breast 
cancer, bowel cancer and cardiac tissue has been analysed for muscular dystrophy, 
arrhythmias, and hypertrophy (175-179).  
 
1.2.2.4 Metabonomics and Vascular Diseases 
Metabonomics provides a non-invasive and highly sensitive diagnostic technique for coronary 
artery disease as compared to the gold standard invasive angiography. This was shown in a 
study in which sera of patients with angiographic evidence of triple vessel coronary artery 
disease and normal coronary artery were analysed using 
1
H 600 MHz NMR. The PLS-DA 
scores plot showed separation and clustering between the two groups. The regression 
coeffeicient analysis showed that the most influential metabolites in triple vessel disease 
group were from low and very low density lipoproteins (LDL & VLDL). Patients with normal 
coronary arteries had abundance of high density lipoproteins (HDL) and choline metabolites. 
Using the PLS DA model built using 80% of the samples, the model predicted the class 
membership of the remaining 20% of samples. Moreover, using the metabolic profiles of 
blood serum, the severity of the disease was accurately predicted (180).  
 
Whereas, NMR and UPLC-MS analysis of biofluids delineate a profile from which 
biomarkers may be extracted, spectral imaging techniques are useful in establishing localised 
chemical information. Matrix assisted laser desorption/ ionization imaging mass spectrometry 
(MALDI-IMS) technique uses the mass spectra with spatial information to obtain the 
expression pattern of various lipid species in intact tissue samples. This technique has been 
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used to study varicose veins valves and vein wall samples. Lipid species including 
lyophosphotidylcholine (LPC), phosphotidylcholine (PC) and sphingomyeline were present 
around the damaged valve in varicose veins as compared to non-varicose veins. These lipids 
are associated with inflammation (181). Similarly, the same group, using the Quantitative 
analysis using MS/MS, Oil red O staining and MALDI-IMS analysis has shown an increased 
PC and LPC in media layer of veins in arteriovenous fistula suggesting the role of such lipids 
moieties in the development of inflammatory changes seen in vein under high pressure  (182).  
There is some evidence that providing information regarding specific metabolic changes are 
found in some vascular diseases including varicose veins. However, the evidence is limited, 
particularly in case of varicose veins, where it lacks to provide the full coverage of 
comprehensive metabolic profile of the healthy and disease phenotype, which is essential to 
study the effects of various etiological factors. This raises the need for investigating the 
complete metabolic profiles of varicose veins using robust, stable and reproducible 
metabonomics approaches.  
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1.3 AIMS AND HYPOTHESIS 
 
Hypothesis 
“Varicose veins have distinct metabolic profiles as compared to non-varicose veins.” 
 
This research aims to, 
 
 To identify the metabolic profile of varicose veins and non-varicose veins in intact 
tissue  using magic angle spinning NMR spectroscopy  
 To develop methodology for extraction of aqueous and organic metabolites from 
veins using NMR and UPLC-MS analysis.  
 To employ the optimised extraction methodology developed on a large cohort of 
varicose veins samples and non-varicose veins control of different anatomic origin. 
Extracted aqueous and organic phases will be run on both NMR and MS to 
characterise a comprehensive set of metabolites for vein tissue (both varicose and 
non-varicose)  
 To identify and compare the metabolic profiles of vein tissue exposed to stretch and 
no-stretch to investigate the role of stretch in disease aetiology. 
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2 Analysis of Intact Varicose and 
Non-Varicose Veins Tissue 
Samples using Magic Angle 
Spinning NMR  
 
 52 
 
2.1 INTRODUCTION 
Pathological changes involve all layers of varicose vein wall. The primary pathological events 
in a cellular process for these changes are still unknown, although abnormal cellular 
metabolism has also been considered to influence the vein wall. The application of metabolic 
profiling offers a mechanism for characterising abnormal cellular metabolic pathways 
particularly in relation to the disease phenotype. Magic angle spinning (MAS) NMR is a 
metbonomics approach which measures the metabolites in intact tissue biopsies. The benefit 
of this approach is that it provides a robust non-destructive analysis of small intact biological 
tissue which can then be analysed using other technologies.  A preliminary study using 
varicose veins, non-varicose veins great saphenous veins (GSV) and facial veins was 
performed using this analytical platform with a view to establish differential metabolic 
profiles of varicose veins and its influence in understanding pathogenesis of varicose veins 
disease.  
 
2.2 MATERIALS AND METHODS  
2.2.1 Ethical Approval 
Ethical approval has been obtained for the research from the Riverside Research Ethics 
Committee (RREC 3092). Inclusion of an amendment on the original ethics was requested 
and obtained from the Riverside Research Ethics Committee (RREC 3092) in December 
2010. The research has also been registered to the Imperial College London Research 
Services, and the Imperial College Healthcare NHS Trust Research and Development 
department. All the specimens collected were anonymised according to the rules set out in the 
Human Tissue Bill (2004). Informed consent was obtained from all the patients involved in 
the study. 
 
2.2.2 Patient Selection and Tissue Sampling 
Varicose veins were retrieved from patients who were treated with either high tie or ligation 
of saphenofemoral junction and stripping of great saphenous vein (GSV) with or without 
phlebectomies or had phlebectomies with or without endovenous thermal ablation at Charing 
Cross Hospital and St. Mary’s Hospital, both part of the Imperial College London Healthcare 
NHS Trust. The patients were initially assessed in the outpatient department at their 
respective hospitals for varicose veins to determine whether or not they required surgery or 
endovenous treatment. A full clinical history was taken and clinical examination was 
performed. All the patients were also assessed with duplex ultrasonography performed by 
accredited vascular scientists and/or the vascular surgeons treating them. The anatomy of the 
whole venous system of the affected legs and assessment of the direction of blood flow 
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including the presence of any venous reflux or valvular incompetence was evaluated by 
duplex venous scan. Control veins were obtained from patients undergoing any surgery which 
involved routine removal of non-varicose veins that were later discarded. Varicose veins were 
collected from patients undergoing surgery for lower extremity varicose veins (n=8). Three 
control non-varicose GSV samples were collected from patients undergoing lower limb 
amputation and 5 non-varicose GSV samples from individuals having peripheral arterial 
bypass surgery. Five facial veins were removed from patients who had carotid endarterectomy. 
In order to assess tissue homogeneity within an individual sample and to establish whether the 
metabolic profile is relatively uniform across a length of vein tissue, one vein segment from 
each group (varicose and non-varicose veins control) was divided into three adjacent parts 
and analysed independently. Retrieved GSV varicose samples were also inspected carefully to 
select for analysis only dilated and tortuous vein segments. In total, 10 samples from 8 
varicose veins patients, 10 samples from 8 non-varicose veins control patients, and 5 samples 
of facial veins were analysed.  
 
2.2.2.1 Inclusion Criteria  
 Patients who had surgery for unilateral or bilateral primary varicose veins, with only 
reflux as aetiology, were included in the study.   
 Patients with present and past history of varicose veins were not included in the non-
varicose vein control group, even if the varicosity had been successfully treated. 
Evidence suggests that patients with varicose veins demonstrated systemic alteration 
of extracellular matrix including in the skin and could therefore affect other veins 
even if they were non-varicose (183). 
 
2.2.2.2 Exclusion criteria 
 Patients with recurrent varicosities and therefore had previous varicose vein surgery 
and/or intervention were not included in the study.  
 Varicose and non-varicose veins of the affected limbs of patients with a history of 
deep vein thrombosis (DVT) were excluded from the study although veins from the 
other parts of their body would still be included. Similarly varicose veins patients 
with evidence of superficial thrombophlebitis were excluded from the study.  
 Meanwhile, patients with following diseases/ conditions were excluded from the 
study: 
- Congenital diseases associated with varicose veins including Klippel-Trenaunay 
Syndrome and arterio-venous malformation 
- Patients with secondary varicose veins  
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- Patients with rheumatoid arthritis, connective tissue disorders and vasculitis 
- Patients with cancer 
- Patients with human immunodeficiency virus (HIV)-positive 
- Patients who were taking regular systemic steroids such as glucocorticoids  
- Patients on oestrogen and/or progesterone therapy such as oral contraceptive pills and    
hormone replacement therapy  
 
2.2.3  NMR Spectroscopy of Intact Vein Tissue 
Intact tissue samples were prepared as previously described (147, 160). Each vein sample 
was collected fresh at the time of surgery, snap frozen in liquid nitrogen and stored at -80°C. 
The entire circumference of vein tissue was cut using a sterile scalpel and forceps; any peri-
vascular fat was gently removed. Each sample was weighed (average weight 10.33 +/- 0.8 
milligrams).  
Each sample was placed inside an insert. D20 (15µl) was added to each sample and insert 
was closed with a plug. Each insert containing a sample was placed in a zachronium rotor 
and spun at 5 KHz in high-resolution magic angle spinning (MAS) 600 MHz 
1
H-NMR 
spectroscope (Bruker BioSpin, Rheinstetten, Germany). Standard one-dimensional spectra 
were acquired with suppression of the water signal to adjust the dynamic range to the 
metabolites of interest. The Carr-Purcell-Meiboom-Gill (CPMG) spin-echo pulse sequence 
was also applied as a second measurement to reduce effects of broader resonances from 
high molecular weight compounds such as lipoproteins therefore enabling sharp resonances 
from low molecular weight compounds to be easily identified. For all experiments, a total 
spin-spin relaxation time of 120 ms was chosen (n=300, τ=200 µs). Spectral width of δ 20 
ppm was used with relaxation delay of 2 s and acquisition time of 2.72 s. For each intact 
vein tissue sample, 256 scans were acquired into 64K data points. Each intact vein tissue 
spectrum was phased, calibrated using the chemical shift of the alanine methyl group at 
δ1.48 or the β-glucose (H1) doublet at δ 4.644, and baseline was corrected using TOPSPIN 
2.0a software (Bruker BioSpin, Rheinstetten, Germany).  
 
2.2.4    Chemometric Analysis of NMR Spectra 
Spectra were imported into MATLAB R2009b (Mathworks™, 2009) using in-house software. 
The region containing the water resonance (from δ4.68 to δ5.24) was removed from each 
spectrum. All spectra were subsequently aligned and normalised using probabilistic quotient 
normalisation (184). Data were transferred to SIMCA-P+ 11.5 statistical software 
(UMETRICS™, Sweden). Principal components analysis (PCA) and orthogonal partial least 
square discriminatory (OPLS-DA) analysis were employed using unit variance (UV) scaled 
data and pareto scaled data to identify the presence of inherent similarities in the data and 
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investigate differences between the groups. OPLS is a supervised linear regression approach 
which can model separately the co-varying variation from structured noise (orthogonal 
variation), while simultaneously maximizing the X and Y covariance, i.e. the differences 
between two groups (157).  
 
An in-house mathematical modelling algorithm in MATLAB (Mathworks, 2009) was 
employed to identify the strength of correlation of the influential metabolite peaks with a 
particular class. The colour-coded orthogonal 2 partial least square (O2PLS) regression 
coefficient was employed for the analysis of intact vein tissue samples to identify the strength 
of correlation of a metabolite to a particular tissue type. We performed receiver operating 
characteristic (ROC) curve analysis to examine the diagnostic accuracy of partial least square 
driven class discrimination. An area between 0.9 and 1 under the ROC curve represents a 
strong diagnostic accuracy of the model (185). Individual metabolite identities were assigned 
by using data from other studies examining human tissue metabolic profiles via MAS NMR 
and using the human metabolome database (159-163). The assignments were confirmed by 2- 
dimensional (2D) NMR experiments on selected intact varicose vein and non-varicose vein 
samples, and through the use of the Bruker Amix/SBase database. 2D NMR disperses the data 
into two spectra showing mainly correlation between adjacent protons (
1
H-
1
H Correlation 
Spectroscopy or COSY) or proton and carbon atoms 
1
H-
13
C heteronuclear single quantum 
coherence (HSQC) spectroscopy, facilitating elucidation of the structure of each metabolite 
(147, 161). J-resolved spectra which display the coupling patterns and J-coupling values in a 
second orthogonal dimension were also used to identify metabolites and interpret overlapping 
signal patterns (164). 
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2.2.5 Results 
Due to ethical limitations upon the study design, patients from whom varicose veins tissue 
samples were obtained were younger and had fewer comorbidities as compared with those 
from whom non-varicose veins were collected (Table 1).  
 
 
Table 1.  Demographic details of patients recruited in MAS NMR analysis of varicose 
veins tissue 
 
 
 
 
2.2.5.1 Differences between Varicose and Non-varicose veins Spectra 
1
H NMR spectra from all samples with relevant varicose (n=10) and non-varicose veins 
(n=10) spectra are shown in (Figure 2-1) and facial veins in comparison to non-varicose veins 
are shown in Figure 2-2. Assigned spectra from each group are shown in Figure 2-3 and 
Figure 2-4. Spectral similarities within each group and differences between the two groups of 
veins were evident. There is clearly more intra-segmental versus inter-sample homogeneity. 
The large peaks of triglycerides (unsaturated and saturated) were found in abundance in the 
non-varicose veins group (Figure 2-3). Creatine, myo-inositol, lactate and glutamate were 
found in relatively higher levels in varicose veins tissues (Figure 2-4). These findings were 
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supported by the results of 2D NMR on selected vein tissue (Figure 2-5). Similarly facial vein 
spectra (Figure 2-2) showed continued resonances mainly from lipid peaks with very few 
peaks for other metabolites.  
 
 
 
 
 
 
Figure 2-1: Spectra from 10 non-varicose vein samples and 10 varicose vein samples.  
Similarities of spectral peaks within the varicose veins group representing homogeneity 
within the group. Spectra coloured in blue in each group represent the samples taken 
from the single vein segment of a patient of that group.  
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Figure 2-2. Spectra from non-varicose GSV and facial veins. 
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Figure 2-3: Magic Angle Spinning-
1
H
 
NMR (600 MHz) Carr-Purcell-Meiboom-Gill 
(CPMG) spectrum detailing the metabolic profiles of a non-varicose vein tissue. Whole 
spectrum is displayed in two segments; (a) displays region from δ 0.5 up to δ 4.67 and (b) 
represents the aromatic spectral region. 
 
  
 
 
 
a 
b 
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Figure 2-4. Magic Angle Spinning-
1
H NMR (600 MHz) Carr-Purcell-Meiboom-Gill 
(CPMG) spectrum listing the metabolic profiles of a varicose vein tissue.  Whole 
spectrum is displayed in two segments; (a) displays the spectral region from δ 0.5 to δ 
4.67 and (b) represents the aromatic spectral region.  
 
 
 
 
 
 
 
 
a 
b 
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a. 
 
b. 
 
Figure 2-5. 2D 
1
H-
1
H Correlation Spectroscopy or COSY spectra of varicose vein (a) 
and non-varicose vein (b) showing the correlation of metabolic features with their 
respective peaks on 1D NMR spectra. 
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2.2.5.2 Multivariate Analysis 
Analysis of the PCA scores plot of CPMG spectra of varicose and non-varicose veins GSV 
(Figure 2-6) showed that the variance in the first two components was skewed by 2 outliers. 
These outliers comprised two samples out of a series of three biological replicates from the 
same vein and contained substantially higher concentrations of triglycerides compared to 
other samples. However, after exclusion of these two outlying samples variation was still 
relatively higher in the non-varicose veins group compared to varicose veins samples 
(Figure 2-6). 
 
There was evidence for clustering of a subset of the samples from the varicose veins group 
and so OPLS analysis was used to identify systematic variation relating to disease class. To 
avoid potential bias in OPLS discriminatory analyses, only one out of three replicates from 
the same vein segment in each group was included for the OPLS discriminatory analysis. 
Although the number of samples in this pilot study was small, the OPLS scores plot (Figure 
2-7) clearly highlights the separation of the two groups, with tighter clustering of the 
varicose veins samples compared to non-varicose veins samples. Examination of the 
O2PLS coefficients plot showed that creatine, myo-inositol and lactate were highly 
correlated with the varicose veins group (Figure 2-8). The ROC curve analysis confirmed 
that the diagnostic accuracy of our model was excellent with an area under the curve score 
of 0.92 (Figure 2-9). 
 
Analysis of the PCA score plot of varicose veins, non-varicose GSV and facial veins again 
showed clustering of varicose veins samples (Figure 2-10). Non varicose veins GSV and 
facial veins samples were spread out showing that the metabolic profiles was less 
homogeneous  between the non-varicose GSV and facial veins.  
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Figure 2-6 a and b. Principal components analysis (PCA) scores plot of varicose vein and 
non-varicose veins GSV CPMG spectra, showing variance between samples and the 
direction of the largest variance in the data. Each symbol represents a vein sample with  
    representing non-varicose vein and       represents varicose vein.   The Percentage of 
variation in the NMR data explained by first and second principal components were 
79% and 8%, respectively, in the presence of all replicates (figure a), and 53% and 19%, 
respectively, when two out of three replicates were removed from each group (figure b). 
Varicose vein samples are grouped together in the unsupervised PCA analysis. Intra-
segmental versus inter-sample homogeneity is also noticeable in the non-varicose veins 
group. 
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Figure 2-7. Orthogonal partial least square (OPLS) analysis clearly separates the two 
classes (varicose and non-varicose veins) based on their metabolic profiles detected using 
MAS-
1
H NMR. Probabilistic quotient normalisation and unit variance settings were 
applied for data analysis. R
2
Ycum was 0.788 and Q
2
cum was 0.406 for orthogonal 
component. Q
2
 indicates the fraction of variation predicted by the model for cross 
validation. One non-varicose vein sample is closer to the varicose veins group (spectrum 
5 in figure 1). 
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Figure 2-8. O2PLS co-efficient plot showing 
1
H NMR CPMG spectral data of veins 
acquired using MAS NMR. Spectra have been processed using probabilistic quotient 
normalisation and unit variance scaling.  
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Red peaks represent highly correlated metabolites to the respective group and are responsible 
for the distinction between the two groups, yellow are less correlated metabolites, and blue 
the least correlated. Highly correlated metabolites to the varicose veins group are creatine, 
lactate and myo-inositol. Statistical Total Correlated Spectroscopy (STOCSY) of metabolic 
features at δ3.26 confirms the correlation of myo-inositol peaks. 
 
 
Figure 2-9. Receiver operating characteristic (ROC) curve diagnostic analysis for 
predictive O2PLS model. Area under the curve score of 0.9218 shows excellent 
predictive accuracy of the model. 
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Figure 2-10. PCA analysis of varicose veins, non-varicose veins great saphenous veins 
and facial veins showing clustering of varicose veins samples and dispersion of non-
varicose veins GSV and facial veins samples.  
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2.3 DISCUSSION 
This study showed that the metabolic profiles of varicose veins vary significantly from non-
varicose veins. The main differentiating biomarkers are creatine, myo-inositol and lactate, 
which were higher in varicose veins tissue than non-varicose veins tissue. On the other hand, 
triglycerides were found in higher abundance in non-varicose veins and facial veins. 
 
Creatine is a nitrogenous organic acid originating from the diet, and also synthesized in the 
liver. It is stored in skeletal muscle where it acts as a cellular energy source (Figure 2-11) 
(186). Intracellular ATP transfers its phosphate group to creatine to form phosphocreatine 
(187). Phosphocreatine is found in a concentration ranging between 20-35 mM in skeletal 
muscle cells and 5-10 mM in other excitable tissue including brain and smooth muscle 
(187). In our study, varicose veins samples were observed to be thick walled on inspection. 
Hypertrophied and hyperplastic smooth muscle mass in the varicose veins wall is therefore 
likely to be responsible for the creatine abundance observed in this group. However, 
varicose veins can also have smooth muscle atrophy and be thin walled, therefore inclusion 
of a large sample including both thin and thick walled varicose veins, with metabolite 
extraction for NMR and mass spectrometry analysis is recommended for future studies. 
 
Myo-inositol, in addition to regulating intracellular osmolality in the brain (188), forms a 
structural component of the phosphatidylinositol and phosphatidylinositides, which function 
as second messengers. Phosphatidylinositides are involved in lipid signalling and cell 
signalling via intracellular pathways containing phosphatidylinositol kinases (Figure 2-11) 
(64, 189), protein kinase C and nuclear factor kappa B (NFκB) (190, 191). NFκB signalling 
plays a role in the regulation of adhesion molecules, cytokines, chemokines, growth factors 
and matrix metalloproteinases (MMPs) in vascular cells (192, 193). Varicose veins have 
been found to be associated with upregulation of growth factors, including vascular 
endothelial growth factor, transforming growth factor-β1 and acidic fibroblast growth 
factors (65, 105, 194). Similarly, inflammatory cytokines and adhesion molecules have 
been considered to be involved in vein valve insufficiency (195). Alteration in levels and 
activity of MMPs and their inhibitors have been implicated in the pathogenesis of varicose 
veins (196). 
 
Excess lactate represents increased anaerobic metabolism of pyruvate by the lactate 
dehydrogenase (LDH) enzyme (197), which occurs in a number of states including hypoxia. 
Importantly, hypoxia and increased activation of hypoxia-inducible pathway have been 
recently implicated in the pathogenesis of varicose veins (48, 198). Increased activity of the 
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anaerobic fraction of LDH has also been reported in varicose veins suggesting increased 
anaerobic glycolysis in this context (199). Association of the metabolites lactate and myo-
inositol with such key signalling pathways proposes these pathways for future research. 
 
To the best of my knowledge, this is the first study to characterize the metabolic profile of 
varicose veins by MAS 
1
H NMR spectroscopy. From this study it is apparent that 
metabonomic techniques are suitable for characterising vein pathology. A limitation of our 
study is that the control group did not accurately match with the varicose veins group in 
terms of demographic features, past medical history and medications. Factors such as age, 
medications and past medical history may influence the metabolic profile of vein tissue. 
However, to our knowledge, there has been no demonstration of the effect of age on 
metabolic profile of vein tissue so far. Statins and most of the other cardiovascular 
medications have a short half-life (less than 24 hours) (200) and neither parent statins nor 
their metabolites were detected in the NMR profiles. Although this does not evade the 
possibility that an endogenous metabolic response to chronic use of statins might be 
detected, in light of the nature of the metabolic changes it seems unlikely that statins would 
be responsible for any of the observed differences in metabolic profile between the varicose 
vein and control groups. In this study, each vein segment was washed with deuterium oxide 
before the experiment. It is challenging to obtain non-varicose vein control tissue from age-
matched (often young and otherwise healthy) individuals. Use of inferior epigastric vein 
retrieved at inguinal hernia surgery may facilitate patient matching. However, this will not 
reflect the relevant hemodynamic stresses to which a GSV is exposed. However, presence 
of lipids moieties both in non-varicose veins GSV and facial veins spectra may drive us to 
propose that control group of different origins may share a common metabolic picture 
which is altered by the varicose veins disease. This proposition is not well supported by the 
multivariate PCA analysis as control veins samples are not well clustered as compared to 
varicose veins samples (Figure 2-10). This may be partially due to the small number of 
samples and partially due to other differences within control group samples including their 
anatomical location. This suggests the need to examine control vein tissue from various 
anatomical regions including arm vein during haemodialysis fistula formation, inferior 
epigastric veins from inguinal hernia repairs, and inferior mesenteric vein from bowel 
resections, to document any metabolic differences between the veins from different 
anatomical regions and to assign a metabolic profile of multiple non-varicose vein tissue.  
 
This study utilised 
1
H
 
MAS NMR spectroscopy to rapidly obtain a picture of the metabolic 
profile of vein tissue. Furthermore, metabolites can also be extracted from tissue and 
analysed by conventional NMR spectroscopy. Correlation of metabolic profiles with 
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histopathological analysis, of tissue samples may further advance our understanding of the 
pathophysiology of varicose veins. These approaches will form part of our on-going 
investigative plan, to be applied in larger sample sets, for establishing the differential 
metabolic signature of varicose veins as compared to non-varicose veins. 
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C. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-11. Diagrams A, B and C showing the proposed implications of differentially 
isolated metabolites (creatine, lactate and myo-inositol) in varicose veins on disease 
pathogenesis
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3 Optimisation of Extraction 
Methodology for Vein Tissue 
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3.1 INTRODUCTION 
Analytical approaches including ultra-performance liquid chromatography-mass spectrometry 
(UPLC-MS) and nuclear magnetic resonance (NMR) spectroscopy provide non-targeted 
comprehensive metabolic profiles of biological fluids and tissues (107). With the aid of 
chemomatrics tools, key information relating to the influential metabolites on disease 
pathogenesis and diagnosis are recovered from complex datasets(142). Metabolic profiling of 
biofluids and tissues generates metabolic phenotypes that can be related to specific 
physiological or pathological states (144, 146, 201). Typically polar and non-polar 
metabolites can be extracted from biological tissues for analysis by NMR and UPLC-MS 
(202, 203). The concomitant use of these two analytical platforms (LC-MS and NMR) for 
analysis of extracted metabolites from biological tissue increases coverage of the 
metabolome. To acquire a comprehensive and meaningful coverage of biochemical 
composition, a highly robust, fast  and reproducible method for metabolite extraction from a 
biological tissue is vital (204). Various studies report different protocols for the extraction of 
polar metabolites from tissues for example methanol: water (1:3 or 1:1) or acetonitrile: water 
(1:1) (205, 206).  Mixture of ethanol: phosphate buffer has also been tested to be of adequate 
reproducibility and providing good concentrations of metabolites for UPLC-MS based 
profiling of brain tissue (151).  Methanol: water (80%: 20%) has been used for UPLC-MS 
based metabolite recovery in wide range of human tissue including muscle, adrenal gland, 
colon, lung, pancreas, small intestine, spleen, stomach, prostate, kidney (154). For NMR 
analysis of liver extracts, mixture of methanol: chloroform : water was found to be the best in 
terms of metabolic yield and reproducibility (207).  On the contrary, Masson et al. showed 
that the optimal protocol for metabolic profiling of liver extracts was methanol: water (1:1) 
followed by an organic extraction with dichloromethane: water (3: 1) for UPLC-MS based 
analysis (208). A range of solvents including chloroform(150), dichloromethane (DCM), 
methyl tert-hydro butyl ether (MTBE) (141), hexane and isopropanol (ISP) have been used 
for non-polar metabolites extraction (209) (210, 211).  Bligh and Dyer described a rapid and 
simple method for lipid extraction from biological material using chloroform: methanol in 
1959(209). Since then, chloroform: methanol has been considered as the gold standard 
extraction protocol (150, 152), although chloroform carries health and environmental hazards. 
Dichloromethane (DCM): methanol was found to be comparable to chloroform: methanol in 
terms of efficiency but less toxic(212). Lipid metabolites have been recovered from different 
types of biological fluids and tissues including human blood, (213, 214) faeces, (215) colonic 
tissue (216), mouse brain, and different bacterial strains(210). There are two types of 
approaches used for metabolite extractions when wishing to capture both the polar and non-
polar components, namely, bilayer and consecutive approaches. The bilayer approach 
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involves simultaneous extraction of polar and nonpolar metabolites using a combination of 
water: methanol: chloroform, which results in two layers separated by a protein pellet (207, 
208). The consecutive approach comprises of an aqueous extraction followed by the non-
polar organic extraction or vice versa (205).  Masson et al. and Gier et al. have shown that the 
consecutive approach has the advantage over bilayer approach in terms of reproducibility and 
yields for liver extracts and Caenorhabditis elegans tissue extracts, respectively (206, 208). 
 
Differential metabolites of potential biological significance have been identified in human 
varicose veins tissue using magic angle spinning NMR spectroscopy (2.2.5) (201). This has 
prompted further metabolic profiling studies to comprehensively understand the metabolic 
signature of human blood vessel tissue extracts by both NMR and UPLC-MS. However, the 
extraction method for human blood vessel has not yet been assessed and optimised. This 
study developed and optimised a tissue extraction method using the protocol as shown in 
figure Figure 3-1 and Figure 3-2. This study firstly identified the best solvent system (aqueous 
and organic) and subsequently assessed the influence of the sequence of solvent use on the 
robustness of metabolite recovery for both aqueous and organic phases.  
 
3.2 METHODOLOGY 
 
3.2.1 Preparation of a homogenous tissue sample 
Solvents for extraction including chloroform, acetonitrile, DCM, ISP, hexane and MTBE 
were obtained from Sigma (Gillingham UK) and chilled before use. Methanol and water were 
both UPLC-MS grade from Sigma (Gillingham UK). Formic acid, leucine encephalin salt, 
ammonium formate (HPLC grade) and sodium formate were obtained from Sigma. Vein 
tissues were collected from patients who had surgery for varicose veins, under an ethical 
approval (REC 3092). A total of about 10.5 grams of great saphenous vein tissue was 
collected from 12 patients, with the purpose of preparing a homogenate mixture. Human vein 
tissues were snap frozen in liquid nitrogen and stored at -80 °C. All the frozen tissue was 
combined in a 15 cm mortar (VWR, UK), immersed in liquid nitrogen and mixed using a 
pestle in a class II vacuum hood. The frozen homogenate was then further ground into powder 
using a cryogenic impact mill (freezer mill 6870, SPEX, Stanmore, UK) (217) with a cooling 
step (3 min) and a grinding cycle (2 min, at 10 Hz). A total of 70 aliquots, each weighing 
145+/- 5 mg, were obtained. Each group consisted of 10 aliquots and was treated with a 
solvent system. Therefore, a total of 7 solvents systems were used: 2 for extraction of aqueous 
extracts and 5 for organic extracts (Figure 3-1).  
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3.2.2 Extraction of aqueous and organic tissue extraction 
Figure 3-1and Figure 3-2 highlight the protocol for aqueous and organic tissue extraction.  
 
 
 
 
Figure 3-1. Diagram showing the steps for extraction methodology study-Stage 1  
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Figure 3-2. Diagram showing the steps for extraction methodology study- Stage 2 
 
3.2.2.1 Extraction of aqueous metabolites for stage 1 
Samples were kept on dry ice throughout the protocol. Extraction of aqueous metabolites was 
performed by adding 1.5 ml of pre-chilled water: methanol (3:1) or water: methanol (1:1) in 
each 2 ml microtube (VWR, UK) containing tissue sample (145 +/- 5mg) and 1 mm 
zirconium beads (BioSpec USA). A blank sample only containing beads and solvents was 
also prepared for each group and run in parallel with other tissue samples. Samples were 
subsequently loaded onto a bead beater (Bertin Technologies, Precellys 24) and 4 cycles were 
carried out in order to maximise dissolution of the powder. Each cycle was 40 sec at the speed 
of 6500 Hz, followed by a 5 min cooling on dry ice. Samples were centrifuged (Eppendorf 
5417) at 17949 x g for 20 minutes at 4°C temperature. The extraction step was repeated 4 
times. A total of 1.25 ml of supernatant was obtained from each sample and further divided 
into 5 aliquots with 250 µl each.   
 
For the purpose of improving protein precipitations and prevention of column degradation, 
the methanol concentration was increased from 25% to 75% in methanol: water (1:3) group 
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by adding 750 µl of methanol in each of its aliquot. Similarly the methanol concentration was 
increased from 50% to 75% (in methanol: water (1:1) group by adding 250 µl of methanol to 
each of its aliquot. Aliquots were vortexed for 1 minute, followed by centrifugation at 17949 
x g for 20 minutes at 4°C. The supernatant from each aliquot was transferred into a new 
Eppendorf tube. Samples were dried in a speed vacuum overnight at room temperature and 
then frozen at -40°C.  
3.2.2.2 Extraction of organic metabolites for stage 1 
Extraction of organic metabolites was performed by adding 1.5 ml of 75% organic solvent 
(chloroform, DCM, Hexane, ISP or MTBE): 25% methanol in each sample in a microtube 
with zirconia beads and extraction on a bead beater. ISP was mixed in the hexane and 
methanol solvent preparation to avoid formation of a double layer and to allow mixing the 
two solvents. The final proportion were hexane (65%), ISP (10%) and methanol 25%.  
Likewise, a blank sample was also prepared and run in parallel. The remaining steps of 
running the samples on bead beater and centrifugation were the same as used for the aqueous 
extraction. The content from each beading tube was then transferred into 5 glass vials with 
PTFE seal (Fisher, UK) each containing 200 µl. Samples were dried overnight in a fume hood 
at room temperature and then frozen at -40°C .  
3.2.2.3 Consecutive Extraction methodology employed in the stage 2 
For the second stage of the experiment, another 3 g of the aforementioned human vein tissue 
powder was weighed out and divided into 20 samples with 10 samples in each group. One 
group had the aqueous extraction performed first using the most optimal aqueous solvents 
chosen from the stage 1 (either methanol: water 1:1 or 1:3) followed by organic extraction 
with the optimal organic solvent again selected from stage 1 [(one of DCM, chloroform, ISP, 
hexane, MTBE): methanol (3:1)]. In the other group the sequence of extraction was reversed 
with organic extraction performed first followed by aqueous extraction.  
 
For the group where aqueous extraction was performed first followed by organic extraction, 
the sequence of events included; addition of 1.5 ml of aqueous solvent (either methanol: water 
1:1 or 1:3, selected from 1
st
 stage) to each 2 ml microtube (VWR, UK) containing tissue 
sample and 1 mm zirconium beads (BioSpec USA) followed by bead beating and 
centrifugation (using the same protocol as mentioned in stage 1). A blank sample was also 
prepared for each group and run in parallel with other tissue samples. A total of 5 aliquots 
were obtained from each sample, each containing 250 µl of aqueous supernatant. Aqueous 
samples were dried in a speed vacuum overnight at room temperature and frozen at -40°C. 
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After removal of aqueous extracts, 1.5 mls of organic solvent [(one of DCM, chloroform, ISP, 
hexane, MTBE): methanol (3:1) selected from the first stage] was added in the microtube 
containing tissue and zirconium beads. Microtube containing tissue, organic solvent and 
beads were loaded onto bead beater and this time only 2 cycles of beading were carried out, 
each lasting for 40 sec at speed of 6400 Hz and cooling of samples for 5 minutes in between 
the cycles. This was followed by centrifugation at 17949 x g for 20 minutes at 4°C. 
Approximately 1.2 ml supernatant from each sample was transferred into 5 glass vials, each 
containing 200 µl. Samples were dried in vacuum hood overnight at room temperature and 
then frozen at -40°C. 
 
For the group which had organic metabolites extracted first, 1.5 ml of organic solvent [(one of 
DCM, chloroform, ISP, hexane, MTBE): methanol (3:1) selected from the first stage] was 
added into to each 2 ml microtube (VWR, UK) containing tissue sample and 1 mm zirconium 
beads (BioSpec USA). These were subjected to bead beating and centrifugation (using the 
same protocol as mentioned in stage 1). Approximately 1.2 ml supernatant from each sample 
was transferred into 5 glass vials, each containing 200 µl. Samples were dried in a vacuum 
hood overnight at room temperature and then frozen at -40°C. After removal of organic 
extracts, 1.5 mls of aqueous solvent (either methanol: water 1:1 or 1:3, selected from 1
st
 stage) 
was added in the microtube containing the remaining tissue and beads. Only 2 cycles of 
beading were carried out on each sample this time, each lasting for 40 sec at speed of 6400 Hz 
and cooling of samples for 5 minutes in between the cycles. This was followed by 
centrifugation at 17949 x g for 20 minutes at 4°C. A total of 5 aliquots were obtained from 
each sample, each containing 250 µl of aqueous supernatant. Aqueous samples were dried in 
a speed vacuum overnight at room temperature and frozen at -40°C. 
3.2.3 Preparation and Analysis on NMR 
3.2.3.1 Preparation of aqueous and organic extracts for NMR 
Aqueous extracts were prepared for NMR spectroscopy using the method described by 
Beckonert et al. (202) with some modification. Dried aqueous extracts were suspended in 
deuterated sodium phosphate buffer solution (0.2 M, 0.05% of sodium 3-trimethylsilyl-1-
[2,2,3,3,-
2
H4] propionate (TSP), 70% D2O, pH 7.4) before transferring into NMR tubes. A 
volume of 650 µl of 1.72% TSP containing buffered D2O was added into first aliquot of each 
sample. The aliquots were vortexed for 1 minute, sonicated for 5 minutes and vortexed for 
additional 1 minute. This was followed by centrifugation for 30 sec at 17949 x g for at 4
0
C. 
Contents of the first aliquot of each sample were transferred into the second aliquot of the 
same sample and the whole procedure was repeated except that the centrifugation was 
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performed for 10 minutes at 17949 g at 4°C. The supernatant was transferred into an NMR 
tube with an outer diameter of 5 mm.  
Organic extracts from groups (chloroform: methanol, DCM: methanol, ISP: methanol, 
hexane: ISP: methanol, MTBE: methanol) were suspended in 2:1 chloroform-D with 0.05% 
TMS (Goss Scientific UK). 500µl of chloroform-D with TMS (0.05%) was added into the 
first aliquot (glass vial) of the sample. Aliquot was vortexed for 1 minute and the contents 
were then transferred into the second aliquot of the same sample. Second aliquot was 
vortexed for 1 minute and the supernatant from 2
nd
 aliquot was transferred into NMR tube 
with an outer diameter of 5 mm. 
3.2.3.2 Analysis on NMR 
Aqueous and organic vein extracts were analysed using a 600 MHz NMR spectrometer 
(Bruker BioSpin, Rheinstetten, Germany).  A standard 1D pulse sequence (recycle delay 
(RD)-90
o
-t1-90
o
-tm-90
o
-acquire free induction decay (FID)) was used with water suppression 
applied during RD of 2 s. A Carr Purcell Meiboom Gill sequence (CPMG) pulse sequence 
was used to acquire spectra from aqueous extracts and 512 scans were accumulated into 64 k 
data points. A standard one dimension experiment (Zg30pr) was selected for all organic 
samples and 256 scans were attained on a 32 k data points. The spectral width was 20.00 ppm 
with a RD of 2 sec, acquisition time 1.36 sec, spin-echo delay t=400 µs and total echo time of 
64 ms for all organic and aqueous experiments. Aqueous and organic spectra were phased, 
baseline corrected and calibrated to chemical shift of TSP and TMS at δ 0.00, respectively, 
using TOPSPIN 3.0 software (Bruker BioSpin, Rheinstetten, Germany). Spectra were 
imported into MATLAB R2009b (Mathworks™, 2009) using in-house developed scripts. The 
regions containing the water resonance (from δ 4.68 to δ 5.24) and TSP or TMS (from δ -1 to 
δ 0.2) were removed from all spectra. The resulting spectra were aligned using recursive 
segment-wise peak alignment and normalised using probabilistic quotient normalisation (184).  
 
3.2.4 Analysis of aqueous and Organic extracts on UPLC-MS  
3.2.4.1 Sample preparation  
Dried aqueous extracts were resuspended in 95% acetonitrile: 5% water for UPLC-MS 
hydrophilic interaction liquid chromatography (HILIC) analysis and acetonitrile:  water (1:1) 
for reversed phase (RP) analysis. Samples were vortexed for 1 minute, sonicated for 5 
minutes, vortexed again for 1 minute and then centrifuged at 17949 g at 4°C for 8 minutes. 
Contents were then transferred into LCMS grade total recovery glass vials (Waters, USA). 50 
µl from each sample was added together to make a quality control (QC) sample (218). Dried 
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organic extracts were suspended in ISP (2): acetonitrile: water (1:1). The same routine of 
sample vortexing and sonication was followed as mentioned above for suspension of aqueous 
extracts.  After centrifugation at 17949 g at 4°C for 8 minutes,  contents were then transferred 
into LCMS grade glass vials with inserts (Waters, USA) and 50 µl from each sample was 
added together to make a quality control (QC) sample. 
3.2.4.2 Mass spectrometry coupled with chromatography 
Analysis of aqueous extract was performed on an Acquity UPLC System (Waters 
Technologies). Positive and negative electrospray ionisation (ESI) modes were performed. 
Samples were placed in glass vials which were kept at 4
o
C during the analyses. The 
hydrophilic interaction liquid chromatography (HILIC) chromatography for aqueous extracts 
was carried out using a Waters Acquity BEH HILIC column (1.7 μm, 2.1 × 100 mm, Waters 
Corporation, Milford, U.S.A.) and maintained at 35 C
o
. The composition of the mobile phases 
was: 0.1% (v/v) formic acid and 10 mM ammonium acetate in 95/5% acetonitrile/H2O (A), 
and 0.1% (v/v) formic acid and 10 mM ammonium acetate in 50/50% acetonitrile /H2O (B) at 
a flow rate of 0.4 mL/min. Source temperature was set at 120
 o
C  and desolvation temperature 
at 400
 o
C. Other ESI conditions for aqueous analysis on UPLC-MS included cone gas flow of 
25 L/hr, desolvation gas flow 800 L/hr, capillary voltage 3000V for ESI +ve and 2000V for 
ESI –ve modes, and cone voltage of 25V. The instrument was set to acquire the m/z range of 
50-1000 with scan time of 0.2s and inters can delay of 0.01s.  
 
For reverse phase (RP) analysis, Acquity UPLC System (Waters Technologies) system was 
used. For RP chromatography of aqueous extracts, HSS T3 (2.1x150 mm, 1.8 µm, Waters 
Corporation, Milford, U.S.A.) was used. The composition of mobile phases for RP analysis of 
aqueous extracts included water and 0.1% (v/v) formic acid (A) and 0.1% (v/v) formic acid 
and methanol (B) at a flow rate of 0.4 mL/min. Source settings for RP analysis of aqueous 
extracts included: source temperature of 120
 o
C ,  desolvation temperature at 350
 o
C, cone gas 
flow of 50 L/hr, desolvation gas flow 900 L/hr, capillary voltage 3000V for ESI +ve and 2400 
V for ESI –ve modes, and cone voltage of 30 V. The instrument was set to acquire the m/z 
range of 50-1000 with scan time of 0.2s and inters can delay of 0.01s.  
 
Organic extracts were analysed on an Acquity UPLC system (Waters technology) coupled to 
a Q-Tof Premier mass spectrometer (Waters, Manchester). For chromatography of organic 
extracts, Acquity UPLC column CSH (2.1x150 mm, 1.8 µm, Waters Corporation, Milford, 
U.S.A.) was used. Separation was performed with acetonitrile/water (60:40) with 10 mM 
ammonium formate and 0.1%fromaic acid (A), and isopropanol/acetonitrile (90:10) with 10 
mM ammonium formate and 0.1% formic acid (B). ESI conditions were set with the source 
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temperature 120
o
C, desolvation temperature 400
o
C, cone gas flow 25L/hr, desolvation gas 
flow 800L/hr, capillary voltage 3000 V for ESI+ and 2500V for ESI-, and cone voltage of 30 
V. The instrument was set to acquire over the m/z range 50-1200 in V mode with scan time of 
0.2 s and an inter-scan delay of 0.02 s. Data was collected in centroid mode.  
 
For all UPLC-MS experiments, leucine/enkephalin (200pg/µL, in acetonitrile: water 50:50, 
0.1% formic acid) was used as a lock mass with an analyte-to-reference scan ratio of 4:1. The 
instrument was calibrated before analyses using 0.5mM sodium formate solution. The order 
of injection of samples was randomised. QC samples were run in the beginning of the run (to 
condition the chromatographic column) and periodically after every 3 aqueous samples and 
10 organic samples in stage 1 and after every 3 samples in stage 2 during the experiment to 
assess the analytical ability of the instrument. QC samples were used to monitor the 
performance of UPLC-MS system. Analyses were run in one batch in positive and negative 
mode. Two extraction blanks were injected and two solvent blanks were injected at the end of 
the run to identify any artefacts from the extraction process and solvent systems, respectively. 
 
3.2.5 Chemometrix analysis of NMR and UPLC-MS data 
UPLC-MS data were processed using MassLynx V4.1 software (parameters used for 
assessments of UPLC-MS data are described in Table 13 in Appendix). Three-dimensional 
UPLC-MS data were output into a table of time aligned features with their m/z retention time 
and peak area. Isotope, peaks and fragments and adducts were treated as separate features. 
NMR and UPLC-MS data for each stage were transferred to SIMCA-P+ 12.5 statistical 
software (UMETRICS™, Sweden). Models were constructed using principal component 
analysis (PCA) using pareto scaling. PCA scores plots display the overall variations in the 
dataset based on the minimum number of components and maps the samples based on their 
biochemical similarity or differences to other samples. The PCA scores plot reflects outliers 
and inter-sample variability. The PCA score plot was used to assess the overall effects of the 
different extraction method and solvent systems on the metabolic profiles and to identify any 
runtime or machine variance and analytical performance. Outliers reflecting experimental 
anomalies were identified along with metabolites that were most susceptible under different 
tissue extraction procedure. Reproducibility was checked by measuring the coefficients of 
variations (CVs). Calculation of CVs is a recognised approach to assess the reproducibility. 
CVs were measured for concentrations of each metabolic feature among all replicates of a 
group. The dissemination of these CVs can then be compared between the various groups to 
overview the differences in reproducibility (208, 219). Reproducibility was assessed by 
calculating the percentage of metabolites with their CVs within a certain cut off of their 
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respective mean. A 30% cut-off has been used as a standard to assess reproducibility (220, 
221). This cut off limit has been previously used to assess reproducibility in an untargeted 
UPLC-MS analysis of urinary metabolites (218). For each group, extraction blanks and 
solvents blanks were also analysed for each experiment. In the case of UPLC-MS data, the 
number of features detected in the extraction blank of a specific group was subtracted from 
the combined features of that particular group. In NMR analysis, only those spectral peaks 
that were not present in the respective blank samples were included.  
 
Intensities of each feature among the replicates of different extraction groups analysed on 
UPLC-MS (HILIC, RP and organic features) were measured and features common among the 
groups were determined. This was performed on Excel sheet (Microsoft Excel, USA) using a 
simple calculation. If there were more than 5 replicates from a group had intensities value of 0 
for a specific feature detected at a particular chemical mass and retention time, that particular 
feature was considered different between the two groups. In other words, on comparison of 
two groups, if more than 50% of replicates for each group had detected a specific feature, that 
metabolic feature was considered common amongst the groups.  
 
Metabolites were identified by searching their mass in the online databases including 
METLIN (http://metlin.scripps.edu/metabolites), HMDB http://www.hmdb.ca/), lipid MAPS 
(http://www.lipidmaps.org/tools/) and published literature. Tandem mass spectrometry 
(ms/ms) experiment was also performed for identification of some of the lipid species.  
 
3.2.6 Results 
Human tissues from different anatomical locations including brain, heart and kidney have 
been analysed using metabonomics platforms using a variety of extraction protocols.  Each 
tissue has different structure and biochemical composition and some extraction protocol may 
be more appropriate than other for a particular tissue. Human vein tissue is distributed 
extensively in the body forming a network and functioning as a blood reservoir. Venous tissue 
can show heterogeneity due to the effect of disease or its anatomical location (201). Therefore, 
a rapid, reproducible and sensitive extraction methodology is required. Two different solvents 
systems were compared for extraction of aqueous metabolites and 5 different solvents for 
organic metabolite extraction from human vein tissue homogenate. In the first stage, the 
optimal aqueous and organic solvents were chosen based on reproducibility of spectral 
composition and number of metabolites recovered based on a calculation of features acquired 
from NMR and UPLC-MS analysis. Methanol: water (1:1) and MTBE: methanol (3:1) was 
found to be the best solvents. In the second stage, the order of application of the organic and 
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aqueous solvents was assessed and it was found that non-polar metabolite extraction using 
MTBE: Methanol (3:1) followed by polar metabolite extraction by methanol: water (1:1) gave 
the better recovery and extraction yield.   
 
3.2.6.1 Methanol: water and MTBE give the optimal metabolite recovery from human 
vein tissue 
Reproducibility 
A PCA scores plot of 
1
H NMR spectral data of human vein aqueous extracts (Figure 3-3) 
shows a model driven by two outliers lying outside the 95% confidence eclipse. Both outliers 
belong to the group extracted using methanol: water (1:3). Inspection of individual spectra 
showed that one of the outliers contained higher noise level and the other had generally 
reduced peak intensities and with markedly low intensity for lactate as compared to the other 
samples. These changes noted in outliers samples could be due to an error in sample 
preparation leading to an over diluted sample.  
 
Figure 3-4 shows PCA score plots of aqueous extracts analysed on UPLC-MS (HILIC and RP) 
in ESI +ve and –ve modes. Firstly, the QCs can be seen to be well clustered in all models, 
suggesting a high stability of the instrument during the run. One replicate from methanol: 
water (1:3) group in UPLC MS-RP analysis +ve ESI mode had injection failure with its 
chromatogram similar to the blank sample, which had only air in it (air-blank). This was 
removed from further analysis. 
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                             Outlier sample            
 
Figure 3-3. (a) Principal component analysis score plots shows the variations and trends 
in the data acquired from analysis of aqueous metabolites by NMR in stage 1. Figure b  
shows the variations and trends after removal of the outlier sample. 
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HILIC +ve ESI mode                                           HILIC -ve ESI mode 
 
 
RP +ve ESI mode                                                    RP -ve ESI mode 
 
 
 
Figure 3-4.  Principal component analysis score plots shows the variations and trends in 
the data acquired from analysis of aqueous metabolites from UPLC-MS HILIC and RP 
(both +ve and –ve ESI modes) in stage 1.  
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Figure 3-5 represents the PCA scores plot of samples extracted by 5 different organic solvents. 
NMR analysis of organic extracts (Figure 3-5 a) revealed an overlap between the replicates 
extracted by chloroform: methanol (3:1) and DCM: methanol (3:1), which is in keeping with 
the fact that both solvents have similar formulations. Replicates extracted by MTBE: 
Methanol (3:1) and ISP: methanol (3:1) showed close clustering, whereas hexane: methanol 
extracts were widely spread out.  The PCA scores plots of UPLC-MS +ve and –ve ESI modes 
(Figure 3-5 b and c) show good clustering of QCs, demonstrating satisfactory instrument 
analytical performance. For the UPLC-MS experiment (organic phase), one sample from ISP: 
methanol group showed considerably low intensities chromatogram (both +ve and –ve ESI 
modes) as compared to the rest of the replicates from the same group. While one sample from 
DCM: methanol group failed its injection and hence its chromatogram was similar to blank 
sample. These running errors were due to technical problems during the extraction and 
chromatography, respectively, therefore were removed from further analysis. The pattern of 
distribution of replicates from each group on PCA score plots was similar to that in NMR 
analysis, notably, an overlap between chloroform: methanol (3:1) and DCM: methanol (3:1) 
groups were observed. Replicates from MTBE:  methanol (3:1) was clustered closely to each 
other presenting better reproducibility than the replicates of other groups.  
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Figure 3-5. Principal component analysis scores plots show the variations and trends in 
the data acquired from analysis of non-polar metabolites extracted by 5 different 
solvents systems and run on NMR and LC-MS (both +ve and –ve ESI modes) in stage 1. 
Reproducibility can also be assessed by observing the grouping of replicates for a group.  
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Reproducibility was further tested by CVs. CVs for each group are shown in Table 2. Figure 
3-6 and Figure 3-7 represent the total number of features for all replicates in one class with 
their CVs within the 30% of their mean in the 1
st
 stage of the study. Percentage of NMR peak 
intensities with their CVs within 30% cut off was slightly higher for all replicates of 
methanol: water (1:1) group as compared to replicates of methanol: water (1:3) group (52% vs 
48%). For features acquired from UPLC-MS HILIC and RP data (for both +ve and –ve ESI 
modes), replicates of methanol: water (1:1) group had significantly higher percentage of their 
features with their CVs <30% cut off, for example, 53% of metabolites from methanol: water 
(1:1) as compared to 35% from replicates of methanol: water (1:3) group (Table 2). 
Comparisons of CVs of features acquired from all replicates in one class analysed on NMR 
showed 66% features from replicates of MTBE: methanol group, the highest among organic 
solvents tested in this study, had their CVs < 30% of their mean as compared to 47% for 
DCM: methanol group (Table 2, Figure 3-7). Likewise percentage of features with CVs < 
30% cut off was markedly higher for replicates of MTBE: methanol group as compared to the 
rest of the organic solvents on UPLC-MS +ve & -ve lipid profiling.  
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Table 2.  A table showing % of coefficient of variations (CVs) within the 30% of the 
cut off measured for each group are shown.  
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25% MEOH: 75% water 
50% MEOH: 50% water 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-6. Stage 1- NMR and UPLCMS based aqueous extracts analysis.  Line plots 
comparing the CVs of all features from two aqueous solvents groups. Cut-off limit of 
30% is marked with dotted line.  
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75% DCM: 25% MEOH 
75% Chloroform: 25% MEOH 
75% ISP: 25% MEOH 
65% Hexane: 10% ISP: 25% MEOH 
75% MTBE: 25% MEOH 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-7.  Stage 1- NMR and UPLCMS based organic extracts analysis.  Line plots 
comparing CVs of all features from 5 organic solvents groups. Cut-off limit of 30% is 
marked with dotted line.  
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Features identified 
The main objective of the study was to identify an optimal and robust extraction method for  
human vein tissue which can be used in future studies for global metabolic profiling. It was 
also interesting to know which features were unique to one group. For that purpose, those 
features which were present on the extreme edges of the PCA loadings plots were identified.  
 
Most of the features picked by NMR for aqueous and organic metabolites were common 
between the two groups. On UPLCMS HILIC +ve and –ve ESI modes, both methanol: water 
(1:3) and methanol: water (1:1) had 95% and 91%, of their features common among them, 
respectively. Similarly, >90% of features were shared by two groups on UPLCMS RP +ve 
and –ve ESI modes. At very minimum, 80% of features were common among all 5 solvent 
groups used for extraction of organic metabolites in +ve ESI mode and approximately 90% 
features in -ve ESI mode. MTBE: methanol and chloroform: methanol shared the maximum 
of features (91%). Analysis of the loadings plot generated from PCA score plot for UPLC-MS 
analysis of aqueous and non-polar metabolites again showed that most of the features were 
common between the two groups (the features which were seen in higher concentrations in 
one or the other group were identified, figures included in the Appendix- Figure 9-1, Figure 
9-2 and Table 14). 
 
Table 3 lists the total number of features detected by each group analysed by UPLC-MS (+ve 
and –ve ESIs). Figure 3-8 illustrates comparison of total number of features detected by each 
group in 1
st
 stage of the study. More features were identified in HILIC +ve ESI mode by 
methanol: water (1:1) as compared to methanol: water (1:3) while the reverse is true in 
HILIC-ve mode. In reverse phase UPLC-MS analysis there was no difference between the 
two groups in +ve ESI mode while methanol: water (1:1) had a greater number of features in 
–ve ESI mode. UPLC-MS analysis of organic metabolites extracted by 5 different solvents 
revealed an overall lower number of features for each group in –ve ESI mode than in +ve ESI 
mode. Chloroform: methanol (3:1) provided the highest number of non-polar features both in 
+ve and –ve ESI modes followed by MTBE: methanol (3:1) (Figure 3-8 b). 
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Table 3. Total number of features acquired by each group in 1
st
 stage of the study. 
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a. 
 
 
 
 
 
b. 
 
 
 
 
 
Figure 3-8.  (a) Shows comparison of total number of aqueous features detected on 
UPLC-MS based profiling by the two different extraction solvents in the first stage of 
study. (b) Shows comparison of total number of organic features detected on UPLC-MS 
based profiling by the 5 different extraction solvents in the first stage of study. 
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3.2.6.2 Consecutive extraction with organic followed by aqueous solvent provides better 
metabolite recovery than the reverse order 
Reproducibility 
It has previously been shown that the consecutive approach of extraction of metabolites from 
tissue has the advantage over the bilayer approach (203). Therefore, a consecutive approach 
was used comparing (i) an aqueous extraction followed by organic against, (ii) an organic 
extraction followed by aqueous.  Two mixtures, namely, methanol: water (1:1) and MTBE: 
methanol (3:1), were subsequently chosen to assess the metabolite recovery from human vein 
tissue with a consecutive approach. The PCA scores plot of aqueous extracts analysed by 
NMR shows clear separation between the samples acquired by the two extraction sequence 
(Figure 3-9). For the UPLC-MS-based analysis, QCs samples were observed to be well 
clustered in HILIC –ve, RP +ve and –ve ESIs, however, HILIC +ve ESI showed poor QCs 
grouping at the end of the run (Figure 3-10). Once again two groups were well separated from 
each other with better clustering among replicas of the group in which non-polar metabolites 
were extracted first.  
 
Multivariate analysis of non-polar metabolites from the two protocols is shown in Figure 
3-11. For NMR, samples from two groups have similar pattern of distribution. QCs were 
more clustered for +ve ESI mode as compared to –ve ESI mode UPLC-MS based profiling of 
non-polar metabolites (Figure 3-11 b and c). The distribution and clustering of the samples 
were similar between the groups suggesting comparable reproducibility.  
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Figure 3-9. Principal component analysis score plot showing the variations and trends in 
the data acquired from analysis of aqueous metabolites by NMR in Stage 2. Good 
reproducibility is indicated by the close grouping of replicas from MTBE : MEOH 
followed by MEOH : water group.  
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HILIC +ve ESI mode                                           HILIC -ve ESI mode 
 
  RP +ve ESI mode                                              RP -ve ESI mode 
 
 
Figure 3-10. Principal component analysis score plots show the variations and trends in 
the data acquired from analysis of aqueous metabolites by LC-MS HILIC and RP (both 
+ve and –ve ESI modes) in Stage 2. Good reproducibility is indicated by the close 
grouping of replicas from MTBE : MEOH followed by MEOH : water group.  
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Figure 3-11. Principal component analysis score plots shows the variations and trends in 
the data acquired from analysis of non-polar metabolites by NMR and UPLC-MS (both 
+ve and –ve ESI modes) in Stage 2.  
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Reproducibility was further assessed by measuring the percentage of CVs within 30 % of the 
cut-off limit. On NMR analysis there was no significant difference between the two protocols 
used in stage 2 in terms of reproducibility. Analysis of UPLC-MS data showed that the group, 
which has non-polar metabolites extracted first was observed to have very good 
reproducibility for their polar metabolites. This was evident from high percentage features for 
replicates with their CVs < 30% of their respective mean for that group (for example 34% vs 
16% in HILIC +ve ESI mode) demonstrating high reproducibility (Table 4, Figure 3-12). For 
UPLC-MS based lipid profiling, there was no difference between the two extraction methods 
in terms of reproducibility as manifested from % of features for all replicates for that group 
with CVs within cut off limit. For the NMR-based lipid profiling, % of features with CVs 
values <30% were better from replicates for the group in which aqueous metabolites were 
extracted before organic phase (66% vs 48%) (Table 4 and Figure 3-13). 
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Table 4. Table showing % of CVs from replicates in each group within 30% of their 
mean in the 2
nd
  stage of extraction optimisation process. 
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50% MTBE: 50% MEOH followed by 50% MEOH: 50% MTBE 
50% MEOH: 50% MTBE followed by 50% MTBE: 50% MEOH 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-12.  Stage 2- NMR and UPLCMS based aqueous extracts analysis.  Line plots 
comparing CVs of features from two protocols. Cut-off limit of 30% is marked with 
dotted line.  
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50% MTBE: 50% MEOH followed by 50% MEOH: 50% MTBE 
50% MEOH: 50% MTBE followed by 50% MTBE: 50% MTBE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-13.  Stage 2- NMR and UPLCMS based organic extracts analysis.  Line plots 
comparing CVs of features from two protocols. Cut-off limit of 30% is marked with 
dotted line.  
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Features detected 
Extraction of polar metabolites before organic phase provided a greater number of polar 
features (Table 5) in UPLC-MS based analysis (HILIC –VE, RP +ve and –ve ESI modes). 
However, the difference between the two groups in terms of number of features picked was 
not vast. In contrast, the number of non-polar feature detected was higher for the group 
whereby organic metabolites were extracted before the aqueous phase (Table 5). For UPLC-
MS (HILIC/RP +/- modes) analysis of aqueous extracts, 85% of features were common 
between the two solvent groups used in the stage 2. For organic analysis on UPLC-MS +ve 
ESI and -ve ESI modes, both protocols had 85% and 97.5% features common among them, 
respectively. 
 
Table 5. Table enlisting total number of features acquired by each group in 2nd stage of 
the study. 
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3.2.7 Discussion 
The classical use of metabonomics approaches is for untargeted analyses of a large number of 
analytes. Therefore, when using these approaches to measure a vast range of metabolites in a 
complex mixture, for example untargeted tissue or serum analysis, requires optimized sample 
preparation and protocols. Recent work on intact human vein tissue biopsies using MAS H
1
 
NMR has shown a range of metabolites including alanine, lactate, myo-inositol, glutamate, 
glucose, small amino acids and different species of triglycerides in human veins tissue 
samples (see chapter 2- Analysis of Intact Varicose and Non-Varicose Veins Tissue Samples 
using Magic Angle Spinning NMR). More importantly these metabolites may have a potential 
biomarker value, which may have influence in treatment of varicose veins disease (201). This 
study proposes comprehensive metabolic profiling of human veins tissues using 
complementary metabonomics techniques. This has the advantage of studying poorly 
understood venous disease including varicose veins disease and vein bypass graft disease. 
Extraction of metabolites from tissue is of key significance in tissue analysis using 
metabonomic platforms. The extraction method has to be reproducible, precise and highly 
sensitive, otherwise methodological variation will be reflected in the data acquired and may 
mask disease related effects.  
 
With UPLC-MS based analysis, highly polar compounds cannot be retained due to washing 
off in chromatography while nonpolar compounds can be less soluble in methanol based 
solvents and may not be detected. Therefore a balanced extraction solvent system which can 
pick as much metabolites and improves biomarker discovery is important (141). The work 
from Geier et al and Beltran et al also has shown that it is the solvent which has a greater 
effect on metabolite profiling than the other methodological considerations (206, 222). 
Therefore different solvent systems were studied with respect to their effectiveness to extract 
metabolites. Different solvents were used for extraction. Isopropanol, ether, DCM, MTBE and 
chloroform has been used to extract metabolites from different types of tissues (213, 214) 
(207, 215). Le Belle et al have shown that methanol / chloroform / water extraction is superior 
to percholric acid as a solvent for NMR-based analysis of aqueous extracts from rat brain 
tissue (223). Want et al showed that methanol based extraction methodologies precipitate 
proteins from the serum and hence improve the chromatographic performance of picking the 
signals from metabolites appearing at similar retention time (153, 224). Likewise, Masson et 
al and Geier et al found methanol: water (1:1) and 80% methanol: 20% water to be the most 
efficient for aqueous metabolites extraction for analysis of rat liver and nematodes, 
respectively (206, 225). Both authors also recommended the consecutive approach to 
extraction on the basis of reproducibility. Therefore, methanol-based different solvents were 
chosen for this study.  
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In the first stage of solvent selection, methanol: water (1:1) provided higher reproducibility 
for UPLC-MS based analysis of human vein tissue aqueous extracts with percentage of 
features with the CVs within the standard cut-off of their mean were significantly higher than 
the methanol: water (1:3) group. For NMR analysis the two groups were comparable. On 
comparison of 4 organic solvent systems against the gold standard replicates chloroform: 
methanol (3:1), replicates extracted by MTBE: methanol (3:1) were found to have 22% of 
metabolites with their CVs <30% of their mean as compared to replicates from chloroform: 
water (3:1). The output in relation to number of features observed was better for chloroform: 
methanol (3:1). Therefore, MTBE: methanol (3:1) was selected as the most appropriate and 
reproducible method for human vein tissue profiling. In the second stage of study the 
consecutive approach was used with extraction of polar metabolites first followed by non-
polar and compared with the another group in which the consecutive approach was used with 
extraction of non-polar metabolites first followed by polar metabolites. The percentage of 
features achieving CVs <30% criterion for polar metabolites on UPLC-MS based analysis 
was higher for the group in which non-polar metabolites were extracted using MTBE: 
methanol (3:1) first. For example, 34% of polar metabolites had their CVs within the agreed 
cut off value for MTBE: methanol (3:1) extraction first group as compared to 16% for 
methanol: water (1:1) group. In terms of comparisons of CVs of organic features, NMR was 
in favour of extraction of polar metabolites first using methanol: water (1:1), whilst there was 
no difference between the two groups for UPLC-MS based analysis. However, as 
theoretically expected, more organic features were picked by the group in which organic 
extracts were extracted first by MTBE: methanol (3:1). On balance, for extraction of human 
vein tissue sample across multiplatform, a consecutive approach with extraction of organic 
metabolites using MTBE: methanol (3:1), followed by the extraction of aqueous or polar 
metabolites using methanol: water (1:1) was found to be the optimal protocol for measuring 
samples on multiple analytical platform in terms of reproducibility and comparable in terms 
of metabolic features acquired.  
 
 
 
 
 
 
 
 
QC 
CC 
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4 Mechanical Stretch and Vein 
Metabolic Profiles 
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4.1 INTRODUCTION 
Exposure to an increased hydrostatic pressure in patients with environmental and genetic risk 
factors for the varicose vein disease is considered fundamentally responsible for disease 
development and progression (28, 29, 32). Mechanical stretch exerted by venous hypertension 
may damage the vein wall and valves directly or may cause dilatation of vein walls first 
which then separates the valves apart causing valve incompetency. Incompetent venous 
valves exacerbate the problem further by causing venous reflux and worsening blood stasis 
and venous hypertension. Mechanical stretch has been found to regulate the proliferation, 
apoptosis and migration of vascular cells and reorganisation of extracellular matrix on animal, 
human arterial cells and umbilical vein cells culture models (226, 227). Other studies have 
shown a correlation between high pressure and changes in vein wall by developing 
experimental animal models of venous hypertension. For example, venous hypertension has 
been shown to initiate vein wall changes and valvular damage leading to venous insufficiency 
in a rat model by creating acute venous hypertension through an arteriovenous (AV) fistula 
between the femoral artery and vein (185, 197, 199, 228). Zowlak et al transplanted a rabbit’s 
jugular vein in carotid artery circulation and noticed denuded area of endothelium covered 
with platelets, microthrombi and leukocytes at 1 hr after transplantation and increased smooth 
muscle cells proliferation and vein wall thickening were found at two weeks suggesting high 
pressure may be a cause for such changes (229). Proliferative responses in human veins used 
in coronary artery bypass surgery are also thought to be induced by changes in transmural 
pressure, endothelial damage, local release of growth mediators, low density lipoproteins and 
intrinsic characteristics of vessels (230, 231). Various genes have been considered to be 
affected by pressure induced vein wall changes. For example, our unit has shown in a rat 
inferior vena cava (IVC) explant model that prolonged increases of vein wall tension up-
regulated the expression of hypoxia inducible factors (HIF) -1α and -2α mRNA and proteins, 
and these were associated with increased matrix metalloproteinase (MMPs) expression, 
increased venous relaxation and hence dilatation (232). In the second chapter (2.2.5), it was 
reported that  human varicose veins had an increased concentration of lactate, creatine and 
myo-inositol metabolites in human varicose veins intact samples as compared to non-varicose 
veins control (201). The role of metabolism and vein wall changes has not been explored in 
relation to vein wall stretch and is one of the areas where future research is required to isolate 
the key metabolic pathways and therapeutic targets. To understand the effect of stretch on the 
vein metabolic profile, an ex-vivo rat inferior vena cava vein organ culture model was used 
and vein segments were stretched for 4 and 18 hours durations. In this chapter, I have used 
two analytical platforms; nuclear magnetic resonance spectroscopy and mass spectrometry to 
explore metabolic perturbation in stretched and non-starched rat IVC segments.  
 108 
 
 
4.1.1 Methodology of Applying Stretch to Rat IVC Segments  
Stretching of IVC segments was performed at vascular research laboratory, Brigham and 
Women’s Hospital, Harvard Medical School, Boston, MA, USA. All animal research 
experiments were conducted following the guidelines of the Standing Committee on Animals 
at Harvard Medical School. All the research followed the Ethical Research Guidelines at the 
Brigham and Women's Hospital and Harvard Medical School. Krebs solution contained NaCl 
120 mM, KCl 5.9 mM, NaH2PO4 1.2 mM, dextrose 11.5 mM, CaCl2 2.5 mM, MgCl 2 1.2 mM  
bubbled with 95% O2 5% CO2 at PH 7.4. KCl solution (96 mM) was prepared with same 
equimolar substitution of NaCl with KCl. The α adrenergic agonist phenylephrine (PHE) 10-5 
mM was used to stimulate IVC contraction. Tissue culture medium included minimal 
essential medium supplemented with penicillin streptomycin and amphotericin B (Gibco/ 
Invitrogen Grand Island, NY). Male Sprague-Dawley rats (12 weeks, 250-300 g, Charles 
River Lab, Wilmington, MA, USA) were euthanized by inhalation of CO2. Euthanasia was 
judged by cessation of breathing and heart beats. The abdominal cavity was opened, and the 
inferior vena cava (IVC) was rapidly excised, placed in Krebs solution, and carefully 
dissected and cleaned of adventitial tissue under a dissecting microscope. The IVC was 
portioned into four 3mm wide rings in preparation for isometric contraction experiments. 
 
4.1.1.1 Isometric Contraction 
Each IVC segment was suspended between two tungsten wire hooks, one hook was fixed to a 
glass rod at the bottom of the tissue bath and the other hook was connected to a Grass force 
displacement transducer (FT03, Astro-Med Inc, West Warwick, RI, USA). Vein segments 
were stretched under a pre-determined basal tension (0.5 gram) in a temperature controlled, 
water-jacketed tissue bath, filled with 50 ml Krebs solution continuously bubbled with 95% 
O2 and 5% CO2 at 37°C. The changes in isometric contraction were recorded on a Grass 
polygraph (Model 7D, Astro-Med). IVC segments of rats were subjected to stretch and no 
stretch by applying the weight to the hook. Figure 4-1 shows the apparatus which was used to 
apply the stretch to rat IVC segments. 
 
Contractions were assessed using 96 mM KCl solution on polygraph at the end of each 
experiment for each vein segment. Previous work by Rafetto et al. has demonstrated the 
response of contraction of rat IVC segments to 96 mM KCl membrane depolarisation under 
the influence of different tension (0.0625 gram to maximum of 3 gram) (94). It was noticed 
that tension dependent increase in contraction reached its maximum limit at 0.5 gram of 
tension and then the contractions declined gradually on further increasing the tension. 2 gram 
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tension was reported to be the highest tension causing the maximum stretch without damaging 
the vein wall(94). Therefore 0.5 gram tension was used as the basal tension and 2 gram the 
maximum load. The basal tension of 0.5 gram and maximum tension of 2 gram are also in 
concurrence with the venous pressure observed in lower extremity of humans(96). For 
example, 0.5 gram tension is equivalent to 20.8 mmHg and 2 gram tension is equivalent to 
83.4 mmHg(96). This is calculated with a formula P=F/A where P=pressure in gram/cm
2
 
F=force, A=area (96).  
 
Same protocol for applying stretch and eliciting contractions to rat IVC wall was employed  
as used in previous studies (94, 96). This included stimulation of IVC segments twice with 
96mM KCl and then PHE 10
-5
. Each contraction was followed by a 3 minutes wash in Kreb’s 
solution. The bathing solution was changed to tissue culture medium. The IVC segments were 
then stretched for 4 hrs. After 4 hrs of stretch, contractions were stimulated twice with 96 mM 
KCl followed by PHE 10
-5
 and tissue was bathed with kreb’s solution in between 
contractions. Two IVC segments, stretched to 0.5 gram and 2 gram tension, were then frozen 
in -80°C. The rest two IVC segments were then stretched with basal tension of 0.5 gram and 
prolonged tension of 2 gram for 18 hrs in culture medium.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
Table 6 shows the total number of IVC segments in each group subjected to the either 0.5 
gram basal tension or 2 gram tension for variable amount of time. At 18 hrs time, contractions 
were assessed by stimulation with 96 mM KCl solution and PHE 10
-5
 solutions again before 
storing the samples in -80°C freezer. IVC segments were snap frozen and stored in -80°C 
freezer. The samples were then shipped to Imperial College London via Fedex airway courier 
service. Samples were packed properly in dry ice during the travelling. During the process of 
customs clearance, box carrying samples and dry ice was kept in -20°C. On arrival at Imperial 
College, samples were still found fully immersed in dry ice. Samples were immediately stored 
at -80°C.  
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Figure 4-1. Stretch apparatus used to stretch rat IVC segments in Vascular Research 
Laboratory in Brigham and Women’s Hospital, Boston MA. An IVC segment is shown 
under tension between two hooks attached to 2 g weight with a grass force transducer. 
 
 
 
Water-jacketed tissue 
bath in which IVC 
segment is stretched in 
Kreb’s solution / culture 
medium  
Oxygen circuit providing 
continuous flow of 
oxygen in organ bath  
Outflow circuit for 
replacement of Kreb’s 
solution/ culture 
medium 
Rat IVC segment 
attached to 2 gram of 
tension between 
hooks.  
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Table 6. Table showing numbers of IVC segments in each group subjected to different 
experimental conditions 
Number of IVC segments 
    (Total number of rats=5)               
Tension Applied                     Duration 
5 0.5 gram 4 hours 
5 2 grams 4 hours 
5 0.5 gram 18 hours 
5 2 grams 18 hours 
 
4.1.1.2 Extraction of metabolites from tissues 
Solvents for extraction including dichloromethane (DCM), isopropanol, methanol and water 
were obtained from Sigma (Gillingham UK) and chilled before use. Methanol and water were 
both UHPLC-MS grade. Formic acid, leucine encephalin salt, ammonium formate (HPLC 
grade) and sodium formate were obtained from Sigma. Metabolites were extracted from rat 
IVC segments using Bligh Dyer method of extraction (202, 209). 50% Water: 50% Methanol 
were used for extraction of aqueous metabolites and 75% Dichloromethane: 25% Methanol 
was used for organic metabolites extractions. A bilayer extraction approach was performed. 
The bilayer extraction protocol was adapted from Wu et al.(233). 750 µl of each solvent was 
added in each sample containing zirconium beads. Samples were loaded onto bead beater 
((Bertin Technologies, Precellys 24) and run at 6000 Hz for 30 seconds (2 cycles), followed 
by centrifugation (Eppendorf 5810, US) at relative centrifuge force (RCF) of 17949.49 x g at 
4° C for 20 minutes. Aqueous extracts (supernatant) were removed into eppendorf tubes and 
the remaining organic extracts were put inside the glass vials. Metabolites were extracted 
twice and the whole procedure was repeated again. Eppendorf tubes and glass vials containing 
aqueous and organic extracts were stored in a -80° C freezer. Aqueous extracts were dried in a 
vacuum at 45° C and organic extracts were left at room temperature in a class II hood to dry. 
 
4.1.1.3 Preparation of samples for NMR analysis 
Dried aqueous extracts were suspended in deuterated (D2O) phosphate buffer solution at pH 
7.4 (sodium phosphate buffer, 0.5 mM of sodium 3-trimethylsilyl-1-[2,2,3,3,-
2
H4] propionate 
(TSP))(202).  Deuterated buffer solution (60µl) containing TSP was added into the first out of 
two aliquots for each sample. The aliquots were vortexed for 1 minute, sonicated for 5 
minutes and vortexed again for 1 minute. This was followed by centrifugation for 30 sec at 
10,000 rpm and 4
0
C. Contents of the first aliquot of each sample were transferred into the 
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second aliquot of the same sample and the whole procedure was repeated except that the 
centrifugation was performed for 10 minutes at RCF of 17949.49 x g at 4°C. The supernatant 
was transferred into capillary NMR tube. 
 
Aqueous extracts were analysed using 800 MHz 
1
H-NMR spectrometer (Bruker BioSpin, 
Rheinstetten, Germany). A CPMG pulse sequence RD-90
o
-(t-180
o
-t)n was acquired where 
180
o
 is a radiofrequency pulse, t is the spin echo delay (t =400 µs), n is the number of loops (n 
=160), RD is the relaxation delay (RD =2 sec)(202). 512 scans were acquired into 64 K data 
points with acquisition time of 2 sec and spectrum width of 20. Receiver gain was maintained 
at the same value for all the samples during the experiment. CPMG pulse sequence was 
acquired to diminish the NMR signals of any remaining proteins.  
 
On TOPSPIN 3.0 software (Bruker BioSpin, Rheinstetten, Germany), aqueous spectra were 
phased and calibrated using chemical shift of sodium 3-trimethylsilyl-1-[2,2,3,3,-
2
H4] 
propionate (TSP) at δ 0.00. Base line was corrected manually. Spectra were imported into 
MATLAB R2009b (Mathworks™, 2009) using in-house model built on MATLAB. The 
region containing the water resonance (from δ4.68 to δ5.24) was removed from all spectra. In 
addition, the resonances of TSP (from δ-1 to 0.2 δ) were removed from all spectra. All spectra 
were subsequently aligned and normalised using probabilistic quotient normalisation (184). 
 
4.1.1.4 Preparation of samples for UPLC-MS analysis 
Organic metabolites were re suspended in isopropanol. Following 1 minute of vortexing and 5 
minutes of sonication at 4°C, 150 µl of each sample was put inside the 1.8mm LCMS glass 
vials and the remaining 50 µl of each sample was added together to form the quality control 
(QC) sample. Samples were analysed using an Acquity UPLC System (Waters, Manchester), 
coupled to a Q-Tof Premier mass spectrometer (Waters, Manchester). The instrument was 
operated in both positive (ESI+) and negative (ESI-) electrospray ionization modes. 
Chromatography was carried out at 40°C on a Waters Acquity UPLC CSH column (1.8µm, 
2.1x150mm). Separation was performed with acetonitrile/water (60:40) with 10 mM 
ammonium formate and 0.1% fromic acid (mobile phase A), and isopropanol/acetonitrile 
(90:10) with 10 mM ammonium formate and 0.1% formic acid (mobile phase B). ESI 
conditions were set with the source temperature 120
o
C, desolvation temperature 400
o
C, cone 
gas flow 25L/hr, desolvation gas flow 800L/hr, capillary voltage 3000 V for ESI+ and 2500V 
for ESI-, cone voltage of 30 V for ESI+ and 25 V for ESI-. The instrument was set to acquire 
over the m/z range 50-1200 in V mode with scan time of 0.2 s and an inter-scan delay of 0.02 
s. Data were collected in centroid mode. Leucine/Enkephalin (200pg/µL, in acetonitrile: water 
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50:50, 0.1% formic acid) was used as a lock mass with an analyte-to-reference scan ratio of 
4:1. The instrument was calibrated before analyses using 0.5mM sodium formate solution. 
The order of injection of samples was randomised. QC sample was injected regularly 
throughout the run to monitor the stability of the of the UPLC-MS platform. Samples were 
run using a random sequence and a QC were set to run after every 3 samples. Data was pre-
processed using MasLynx version 4.1 and R version R x 64 2.15.1.  
 
4.1.1.5 Data Processing and statistical analysis  
Processed data were then analysed on the Simca P+12.5 (Umetrics) and MATLAB R2009b 
(Mathworks™, 2009) using in-house model built on MATLAB. The nature of untargeted 
analysis of biological matrices using NMR and LCMS spectroscopy results in a very data rich 
output. The sheer number of variable not only makes the handling of the datasets copious, but 
also encumbers statistical analysis. Considering that each spectral profile of each sample is 
comprised of hundreds of individual variables a multivariate statistical approach is preferred. 
However, if the samples size is less in comparison to the number of variables detected, a 
problem of multi-collinearity may arise leading to problems in analysing the data using 
multivariate approach. I encountered similar problem as a large number of variables were 
identified in the comparatively few of samples analysed. One of the known ways to reduce the 
high dimensionality of the data is to use statistical coupling of variables. Here I employed 
statistical recoupling of variables (SRV), an algorithm developed in house for our NMR data. 
This computational peak picking technique uses a correlation landscape to restore the 
dependency of spectral variables and integrate regions into physically and biologically 
meaningful segments (234). Furthermore, effect of noise on the meaningful segments of the 
spectra is reduced as SRV minimizes the number of variables needed for the perseverance of 
latent variable. Orthogonal partial least square-discriminatory analysis (OPLS-DA) plots were 
acquired for both SRV corrected-NMR data and LCMS data to identify the differential 
variables of potential biological significance between the 4 groups. Furthermore, both for the 
NMR and LCMS data, I also used univariate analysis of variance (2-way ANOVA) for the 
initial whole set of variables to account for the type I error with the presumption that each 
affects the outcome. Benjamini-Yekutieli false discovery rate correction was performed to 
ensure the test statistics correspond to the true null hypotheses(235). Only variables found to 
be significant after correction for the false discovery rate using Benjamini-Yekutieli method 
were considered to be potential biological significant between the different experimental 
groups.  
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4.1.2 Results 
4.1.2.1 Isometric Contraction in Response to 90 mM KCL and PHE10-5 
Isometric contractions in response to 90 mM KCL and PHE10
-5
 in rat IVC segments were 
measured using a polygraph. Compared to the initial basal contraction at 1 hr, there was a 
decline in contraction to 90 mM KCL in all segments except in stretched for 4 hrs IVC 
segment. The fold change difference from baseline contractions was statistically significant in 
rat IVC segment stretched for 18 hrs as compared to basal contraction (Figure 4-2 a). In 
response to PHE10
-5
, there was an increased in contraction at 4 hrs both in stretched and non-
stretched segments. A drop in PHE
10-5
 induced contractions was noticed in both stretched and 
non-stretched segments at 18 hrs. However, statistically significant reduction in contraction to 
PHE
10-5
 was only detected in stretched for 18 hrs vein segments (Figure 4-2 b).  
 
 
 
a 
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Figure 4-2. Fold change in contraction of different stretched and non-stretched rat IVC 
segments in response to 96 mM KCL (a) and Phenylephrine 10-5 (b) at different time 
intervals. 
 
4.1.2.2 Results from analysis of Aqueous Extracts on NMR 
Multivariate OPLS-DA analysis was performed on SRV integrated NMR peaks to identify 
any separation between the groups and differential variables responsible for the separation. 
OPLS models showed differences between samples from veins stretched for 18 hrs group and 
non-stretched for 18 hrs groups, and between non-stretched for 4 hrs and 18 hrs groups 
(Figure 4-3 a and b). The key differential peaks responsible for separation between non-
stretched for 4 hrs and 18 hrs groups were valine, leucine, choline, glucose, glycogen and 
tyrosine (Figure 4-3 a). The differential SRV clustered peaks observed between non-stretched 
and stretched for 18 hrs groups were related to valine and choline metabolites (Figure 4-3 b). 
The low Q
2
 (0.248) values for the OPLS model comparing stretched for 18 hrs against non-
stretched for 18 hrs showed poor predictability of the model. Therefore a univariate analysis 
was performed comparing individual metabolite between the groups. Benjamini-Yakatieli 
multiple testing corrections was applied in order to exclude false positive rate. Table 7 shows 
the list of metabolites found to be significantly different between the groups following 
univariate analysis with Benjamini-Yakatieli multiple testing corrections. There was no 
b 
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significant difference noticed between stretched for 4 hrs and 18 hrs, non-stretched for 4 hrs 
and stretched for 4 hrs, and between stretched for 4 hrs and non-stretched for 18 hrs groups. 
Box plots in Figure 4-4 shows the fold changes in valine and choline metabolites between 
stretched for 18 hrs and non-stretched for 18 hrs groups. 
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Figure 4-3. OPLS-DA plots comparing those groups where a separation was noted due 
to occurrence of highly correlated variables to a particular group.  Each bar represents 
an integrated variable assigned using statistical recoupling of variables (SRV) 
a 
b 
* 
 Non-stretched for 4 hrs 
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algorithms and encodes an underlying biological meaningful NMR spectral signal. Using 
the encryption, highly correlated variables were assigned and confirmed with 2-
dimensional NMR spectroscopy. * Putative assignment either Dimethylglycine/ 
Methylhistidine/ or Anserine.      
 
 
Table 7. Table showing the lists of aqueous metabolites (acquired from SRV corrected 
NMR spectra) found to be differentially present in non-stretched and stretched groups as 
compared to non-stretched groups with corrected p value (Benjamini-Yakatieli correction). 
* Putative assignment either Dimethylglycine/ Methylhistidine/ or Anserine.      
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Figure 4-4. Box plots showing higher concentrations of valine and choline in stretched 
for 18 hrs as compared to non-stretched for 18 hrs rat IVC segments. 
  Corrected  p values using Benjamini-Yakatieli multiple testing corrections. 
 
 
 
 
 
 
Fold Change= 1.9 
Fold Change= 2.8 
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4.1.2.1 UPLC-MS Based Lipid Profiling 
UPLC-MS based Lipid profiling of rat IVC segments were first analysed using a multivariate 
approach. Multivariate OPLS-DA modelling of features detected on +ve ESI mode for each 
group were compared against the others. Q
2
 values were found to be below zero for OPLS-
DA models constructed for comparison of non-stretched for 4 hrs group against each of the 
other groups (non-stretched for 18 hrs, stretched for 4 hrs and stretched for 18 hrs). Such a 
low Q
2
 values suggest poor reliability of the models for identification of any differences 
between the groups under study. Differences were observed between stretched for 18 hrs 
group and non-stretched for 18 hrs group, and between stretched for 4 hrs and non-stretched 
for 18 hrs group (Figure 4-5 a, Figure 4-6 a). Q
2
 values for the models were 0.263 and 0.435, 
respectively. Loadings S plots revealed triglycerides moieties as the differentiating features 
between stretched for 18 hrs and non-stretched for 18 hrs groups (Figure 4-5 b), while 
triglycerides, phosphatidylcholine as the differentiating features between the stretched for 4 
hrs and non- stretched for 18 hrs groups (Figure 4-6 b). Prior to making any assumptions on 
the distribution of differences between the groups, permutation test was performed on PLS-
DA models to identify any false positive rate and type I error. Permutation tests negated the 
PLS-DA models for both groups. Therefore, a univariate approach of data analysis was 
employed. On univariate analysis, intensity of each feature was compared between groups. A 
range of features were found to be significant with a p value less than 0.05. Differences were 
noted between all groups. Benjamini-Yakatieli multiple testing corrections were applied on 
univriate models between the groups in order to exclude any false positive. Only triglycerides 
moieties were found to be significant on multiple testing corrections between stretched for 18 
hrs groups and non-stretched for 18 hrs groups (Table 8). All the other metabolic features 
including TG and PC found significant on univariate analyses of groups were insignificant on 
multiple testing corrections. Figure 4-7 shows the intensities of differential TG between 
individual samples of stretched for 18 hrs and non-stretched for 18 hrs groups.  
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                Non-Stretched for 18 hrs                   Stretched for 18 hrs 
 
 
 
 
 
Figure 4-5. OPLS-DA score plot (a) and Loadings S plot (b) comparing stretched for 18 
hrs and non-stretched for 18 hrs groups. Loadings marked in red in figure b represent 
triglycerides moieties which are present in higher concentrations in stretched for 18 hrs 
group. 
 
a 
b 
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                  Non-Stretched for 18 hrs                   Stretched for 4 hrs        
 
 
 
 
Figure 4-6. OPLS-DA score plot (a) and Loadings S plot (b) UPLC-MS (+ve ESI mode) 
data comparing stretched for 4 hrs and non-stretched for 18 hrs groups. Loadings 
marked in red in figure b represent triglycerides and PC moieties which were present in 
higher concentrations in stretched for 4 hrs group. 
 
 
 
 
a 
b 
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Figure 4-7. Box plots showing the concentrations of triglycerides moieties in stretched 
vein segments for 18 hrs versus non-stretched for 18 hrs. 
  Corrected  p values using Benjamini-Yakatieli multiple testing corrections. 
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Table 8. Triglycerides moieties (UPLC-MS +ve ESI mode data) found to be higher in 
S18 (stretched for 18 hrs) and S4 (Stretched 4 hrs) as compared to N18 (non-streched 
for 18 hrs group).   
TG Triglycerides, SM Sphingomyelin, PC Phosphocholine,  
 
Metabolite Name TG (18:1/18:1/18:2) TG(16:0/17:2/22:1)  TG(16/0:18:2/22:5) 
Mol Formula as 
Detected  
C57H104O6N+ 
[M+NH4]+ 
C58H107O6+ 
[M+H]+ 
C59H104O6N+  
[M+NH4]+ 
Retention time 
(min) 
15.4364 15.1954 15.08 
m/z 
(found) 
900.8038 899.7938 922.79 
m/z 
(theor) 
900.802 899.806 922.786 
Groups 
Compared 
N18 vs S18   N18 vs S18 N18 vs S18   
Concentration Higher in S18 Higher in S18 Higher in S18 
∆ppm -1 14 -4 
p-value 
(corrected) 
0.0308 0.0308 0.034 
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Metabolite 
 Name 
SM  
(18:1/24:1) 
PC  
(18:3/20:2) 
PC  
(18:4/17:1) 
PC  
(18:1/20:3) 
Mol Formula 
as Detected  
C47H94N2O+6P+ 
[M+H]+ 
C46H83NO8P+ 
[M+H]+ 
C43H80N2O8P
+ 
[M+NH4]+ 
C46H85NO8P+ 
[M+H]+ 
Retention time 
(min) 
12.615 5.9392 5.8262 7.7056 
m/z 
(found) 
813.6883 808.5902 783.5761 810.6028 
m/z 
(theor) 
812.6771 808.5856 783.5652 810.6013 
Groups 
Compared 
N18 vs S4   N18 vs S4   N18 vs S4   N18 vs S4   
Concentration Higher in S4 Higher in S4 Higher in S4 Higher in S4 
∆ppm -4 -6 -14 -2 
 p-value 
(Not corrected) 
Corrected p 
values were > 
0.05 (not 
significant) 
0.0048 0.010 0.016 0.021 
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For –ve ESI mode, each group was compared against the other using multivariate OPLS-DA. 
Separation was only observed between stretched for 4 hrs and non-stretched for 18 hrs groups 
with a model yielding a Q
2
 value of 0.50. However, permutation test demonstrated that the 
model was invalid. A univariate approach with multiple testing corrections was therefore 
implemented for group comparisons. Multiple testing corrections for false discovery rate 
revealed no significant difference between stretched for 4 hrs and non-stretched for 18 hrs 
groups.  
 
For both NMR and UPLC-MS data, 4 hrs group (non-stretch and stretch) was compared 
against 18 hrs group (stretch and non-stretch) to observe if there was a time effect on the 
metabolic profile. There was no significant difference seen between 4 hrs group and 18 hrs 
group analyses using PLS-DA method. Similarly, effect of stretch alone regardless of time 
was tested by comparing non-stretch (4 hrs and 18 hrs groups) and stretch (4 hrs and 18 hrs 
groups) and again no significant difference was detected using   PLS-DA analysis.  
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4.1.3 Discussion 
This study aims to characterise the comprehensive metabolic profile of aqueous and organic 
extracts of rat inferior vena cava kept in ex-vivo organ bath for 4 hrs. The metabolic picture 
in rat IVC was dominated by leucine, valine, tyrosine, choline, glucose, glycogen and non-
polar compounds. The effect of short (4 hours) and prolonged (18 hours) stretch on the rat 
IVC segments was also measured. The conclusive findings from this study were depletion of 
leucine, valine, tyrosine, choline and glucose metabolites over the course of 18 hrs, 
exclusively in non-stretched IVC segments, and preservation of these metabolites 
particularly valine and choline in vein segments stretched for 18 hrs. Furthermore, TG 
species were present in higher concentration in stretched for 18 hrs group as compared to 
non-stretched for 18 hrs group.  
 
1
H NMR (800 MHz) analysis of aqueous extracts of rat IVC segments provided us a large 
number of variables. Using SRV algorithms, neighbouring peaks in the spectra were 
integrated and element of noise was shortened. Multivariate OPLS modelling and a top 
down univariate approach were used to test the differences of selected features with multiple 
testing corrections. Comparisons of the groups for their aqueous metabolites revealed an 
interesting picture with loss of some important metabolites over the time. Valine, leucine, 
choline, tyrosine, glucose and glycerol were lost over 18 hrs period as observed in non-
stretched segments at 18 hrs as compared to the 4 hr time point. This suggests that there 
could be diurnal variation present in the samples that encapsulates normal metabolic 
activity. However, time effect over metabolic activity was conserved under the effect of 
stretch as can be seen in stretched for 18 hrs segments whereby valine and choline were 
preserved under the effect of stretch. This suggests that under the influence of stretch, 
biochemical processes within the cells are directed towards the ‘stretch stimuli’ and supress 
the influence of time effect on cell metabolic activity. It is possible that the stress caused by 
the diastolic pressure causes a signalling cascade that alters normal cellular biological 
activity, halting some processes that would normally occur. Analyses of UPLC-MS based 
non-polar metabolites did not display similar pattern of metabolic perturbation as observed 
in polar metabolites tested on 
1
H NMR. The only significant difference was observed 
between stretched for 18 hrs and non-stretched for 18 groups and this was due to presence of 
higher concentration of TG moieties in vein segments stretched for 18 hrs.  
 
Choline is a part of cell membrane and is a precursor molecule to the two common 
phospholipids in the cell membranes; phosphotidylcholine (PC) and sphingomyelin (SM). It 
is also the precursor molecule for the neurotransmitter acetylcholine involved in muscle 
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control (236). The main functions of choline consist of cell membrane integrity, signalling 
for cell membrane and the synthesis of neurotransmitter acetylcholine (236). The presence 
of increased choline in stretched 18 hrs group as compared to non-stretched 18 hrs may be 
due to an increased metabolism of cell membrane phospholipids under the influence of 
stretch releasing choline metabolite, an important constituent of its structural integrity. 
Increased concentrations of branched chain amino acids valine again suggest increased 
breakdown of muscle protein in the stretched 18 hrs group. Branched chain amino acids are 
released from breakdown of muscle proteins in high energy state and are involved in 
gluconeogenesis. Keeping in context the aetiology of varicose veins, whereby vein wall is 
exposed to venous hypertension for long duration, this study suggest that changes in 
metabolic profile commence within 18 hours of stretch.  It can be postulated from this study 
that under the influence of stretch choline may be released from cell membrane and valine 
and leucine from muscle breakdown to provide energy to cells under stress. Analysis of vein 
tissue under prolonged stretch of days or weeks may reveal the complete course of 
metabolic changes in vein tissue.  
 
Lipid profiling was performed by UPLC-MS of rat IVC segments. Significant difference was 
observed between stretched for 18 hrs group and non-stretched for 18 hrs group. Triglycerides 
were the differential metabolites responsible for the separation between these two groups. 
Triglycerides are the major constituents of very low density lipoproteins (VLDL) and 
chylomicrons. Triglycerides play a key role in metabolism by releasing fatty acids in high 
metabolic states. Inflammation plays a vital role in the development of atherosclerotic arterial 
disease (237). It has been shown that triglycerides rich VLDL and chylomicrons induces 
vascular cell adhesion molecule-1 (VCAM-1) expression on the vessel wall (238). Increased 
expression of VCAM-1 and inter cellular adhesion molecule expression has been reported in 
varicose veins wall (33, 54). Desquamated endothelial cells with infiltration of monocytes and 
macrophages have also been observed in varicose veins wall (54). Furthermore increased 
transcriptomic activity of monocyte chemotactic factor has been reported in varicose vein 
incompetent wall (73-75). This evidence strongly suggests the role of inflammatory process in 
development or progression of varicose vein pathogenesis. Exposure to high pressure is an 
aetiological factor for aneurysmal arterial disease and atherosclerotic arterial disease (239). 
Varicose veins are also subjected to chronic venous hypertension (32). High intraluminal 
pressure exerts both mechanical stretch in circumferential and axial directions and also 
generates shear stress (227, 239). The stretch model I used in this study exercises 
circumferential stretch which simulates hemodynamic disturbances generated in chronic 
venous hypertension (95, 239). Considering rat IVC stretch model simulating varicose veins 
intraluminal environment, it may not be too early to propose that prolonged stretch of 18 hrs 
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duration increases concentrations of TG moieties may be responsible for eliciting the 
inflammatory process in varicose veins and should be the focus for future research.  
The study does have some limitations. One of the main limitations is the reduced number of 
sample size which has undoubtedly affected the multivariate approach for data analysis. 
Metabonomics untargeted profiling generate a wealth of variables or metabolic features 
including noise. Data pre-processing using established approaches helps in reducing the noise 
(157, 234). Multivariate analysis including PCA and OPLS-DA are accurate and robust ways 
of analysing such a large scale data to identify biological meaning out of it (157). However, 
when the sample size is low as compared to the number of feature observed as is the case in 
this study, multivariate approach may not be able to provide significant differences with 
legitimacy. Univariate approach with multiple testing corrections is a safe alternative in these 
situations especially when dealing with laboratory animal studies whereby the inter sample 
heterogeneity will be low. Another limitation which should be addressed in planning future 
studies examining metabolic perturbation of rat IVC segments in response to stretch is 
inclusion of a group sampled at zero hours before applying any stretch. Zero hours group 
should include rat IVC segments harvested fresh from the rat and must be immediately snap 
frozen and stored at -80
0
C. Metabolic profile of these freshly frozen rat IVC segments will 
provide the baseline metabolic activity and metabolic profiles of all other groups including 
stretch or non-stretch groups for 4 and 18 hrs should be compared against zero hr groups. I 
did not include such a group in my study because I used a standard protocol which has been 
previously tested for other biological studies such as transcriptomic or protein expression 
studies. However, changes in metabolites have been observed under the effect of time and 
hence future studies should incorporate a time factor while planning such types of 
experiments.   
 
This novel study has investigated the early metabolic changes occurring in an ex-vivo tissue 
culture stretch model. For mapping the comprehensive metabolic fluctuations under stretch 
stimuli, future studies should measure metabolic response to 2 gram stretch for more than 18 
hrs duration applied to a large sample size. The real value in such a study would be to 
ascertain significant metabolic differences via a multivariate approach which can correspond 
to a sustained mechanical stretch applied for different time intervals. This may enable us to 
chart primary metabolic events occurring in reaction to timed stretch stimuli and associate 
these metabolic differences to morphological changes noticed in diseases where continuing 
mechanical stretch is an aetiological factor.  
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5 Comprehensive Metabolic 
Profiling of Human Varicose and 
Non-Varicose Veins Using 1H 
NMR and UPLC-MS  
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5.1 INTRODUCTION 
Since the notion of personalized human medicine has been around, the focus of biological 
research has been on finding healthy and disease phenotypes. Genetics is evidently not the 
sole factor contributing to disease development. Environmental factors also play a substantial 
role. In primary varicose veins disease perspective, age, sex, occupation, pregnancy and 
obesity predispose certain people to develop the disease.  Therefore, determination of varicose 
veins phenotype is important as it would reflect the changes caused by the both environmental 
and genetic factors. As a part of disease phenotype, morphological or physical appearance of 
varicose veins is well established. Underlying morphological changes in vein wall dilatation 
include intimal hyperplasia, disruption of smooth muscle cells and extracellular matrix (29). 
However, the changes in biochemical composition core to this physical appearance are still 
not known. Understanding the contribution of abnormal biochemical changes in the varicose 
vein phenotype may help in determining the abnormal cellular pathways, enzymatic activity, 
and any underlying genetic alteration. Metabonmic analytical platforms are established and 
reproducible tools to identify metabolic and chemical component of healthy and disease 
phenotypes (146, 171). Metabolic profiles of human intact varicose veins were found to be 
different from the non-varicose vein tissue when analysed using MAS-H
1
 NMR spectroscopy. 
Lactate, myo-inositol and creatine were found to be the differential biomarkers responsible for 
the differences between the two groups (Chapter-2 Analysis of Intact Varicose and Non-
Varicose Veins Tissue Samples using Magic Angle Spinning NMR) (201). Triglycerides 
moieties were observed in non-varicose veins spectra (Figure 2-3) on MAS-H
1
 NMR 
spectroscopy of intact vein tissue. Interestingly varicose veins samples were well clustered 
together using OPLS-DA (Figure 2-7) with lactate, myo-inositol and creatine metabolites as 
the differential features responsible for their clustering (Figure 2-8). This preliminary study 
strongly proposed that disease varicose veins share a common metabolic phenotype “varicose 
vein metabolic phenotype” as compared to non-varicose veins. Non-varicose veins group 
including facial veins (n=5) and non-varicose-GSV (n=8) were used as the control group in 
MAS-H
1
 NMR study of intact vein tissue (Chapter 2). Non-varicose veins were noticed to be 
spread out in OPLS-DA analysis (Figure 10 and 11). This dispersion within the non-varicose 
veins group can be considered to be due to presence of other variables including age, sex, past 
medical history and medications or due to their different anatomical locations. To further 
investigate this variations a large sample size and the effect of other variables (age, sex, past 
medical history and medications) is required to be taken into account while performing 
multivariate modelling. Examining non-varicose veins of different anatomical locations may 
highlight “what is called a healthy vein metabolic phenotype” and may elucidate further the 
significance of biomarkers identified in varicose vein wall. Intact tissue analysis using MAS-
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H
1
 NMR is a robust technique of metabolic profiling and provides information about 
metabolic composition of intact tissue, metabolite mobility and potentially 
compartmentalization of metabolites in fixed tissue or cellular compartments (147, 240). 
However, to attain a more global and comprehensive metabolic picture, analysis of extracted 
metabolites from tissue is required using multiple analytical platforms such as NMR and 
UPLC-MS. UPLC-MS has the advantage of illuminating the detailed chemical composition 
of lipid metabolites. This chapter investigates the comprehensive metabolic picture of 
varicose veins in comparison to non-varicose veins of different anatomical locations with an 
aim to design a comprehensive map of varicose vein metabolic profile and identify the 
significant of important biomarkers.  
 
5.2 METHODOLOGY 
Ethical approval was obtained for the research from the Riverside Research Ethics Committee 
(RREC 3092). Inclusion of an amendment on the original ethics was requested and obtained 
from the Riverside Research Ethics Committee (RREC 3092) in December 2010. The 
research has also been registered to the Imperial College London Research Services, and the 
Imperial College Healthcare NHS Trust Research and Development department. All the 
specimens collected were anonymised according to the rules set out in the Human Tissue Bill 
(2004). Informed consent was obtained from all the patients involved in the study. 
 
5.2.1 Samples collection 
Varicose veins were retrieved from patients who were treated with either high tie or ligation 
of saphenofemoral junction and stripping of great saphenous vein (GSV) with or without 
phlebectomies or had phlebectomies with or without endovenous thermal ablation at Charing 
Cross Hospital and St. Mary’s Hospital, both part of the Imperial College London Healthcare 
NHS Trust. Initial assessment of the patient was performed in outpatient department. A full 
clinical history was taken and clinical examination was performed. Duplex ultrasound scan of 
peripheral venous system was performed for all varicose veins patients by accredited vascular 
scientists. Presence of venous reflux and valvular incompetence was assessed. Control veins 
were obtained from patients undergoing any surgery which involved routine removal of non-
varicose veins that were later discarded. Patients who had surgery for unilateral or bilateral 
primary varicose veins, with only reflux as aetiology, were included in the study.  Patients 
with present and past history of varicose veins were not included in the non-varicose vein 
control group, even if the varicosity had been successfully treated. Patients with recurrent 
varicosities and therefore had previous varicose vein surgery and/or intervention were 
included in this study.  
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Varicose and non-varicose veins of the affected limbs of patients with a history of deep vein 
thrombosis (DVT) were excluded from the study although veins from the other parts of their 
body would still be included. Similarly varicose veins patients with evidence of superficial 
thrombophlebitis were excluded from the study. Meanwhile, patients with congenital diseases 
associated with varicose veins including Klippel-Trenaunay Syndrome and arterio-venous 
malformation, patients with secondary varicose veins, and human immunodeficiency virus 
(HIV) infection were not included in the study. 
 
In total, 80 varicose veins and 35 non-varicose veins samples were included in the study. 
Tissue and demographic details of the veins samples are mentioned in the Table 9 and Table 
10, respectively. Samples were cut and prepared on dry ice in the class II vacuum hood at 
Biomolecular Medicine in Imperial College London. The gross appearance of the vein 
segment used was also noted. Samples were cut circumferentially and an average of 140+/- 5 
mg weight sample was used. However, some non-varicose veins were of small weight 
especially inferior epigastric veins retrieved from hernia surgery and facial veins retrieved 
from carotid endarterecomy which were very thin and small segment was only possibly be 
retrievable due to ethical limitations. The effect of different sample weight was compensated 
by respectively suspending the metabolites in different concentrations of solvents during their 
extractions process. For example, if the weight of sample is 75 mg, instead of addition of 1.5 
mls of solvents 0.75 mls were added in the bead beating tube. 
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Table 9. Showing the details of human vein tissue and varicose veins disease status 
analysed in the study.  
 (SD=standard deviation, CEAP= Clinical Aetiology Anatomical Pathophysiology) 
 
 Non-varicose veins 
n=35 
Varicose veins 
n= 80 
Type of vein 
tissue 
Cephalic= 3  
Long saphenous= 15  
Inferior epigastric/ mesenteric= 8 
Facial= 9 
Truncal= 44 
Varicosities= 36 
Age 62 (SD 14.7) 45 (SD 12.0) 
Sex Female= 6 
Male= 29 
Female= 40 
Male= 40 
CEAP - CEAP 2= 4  
CEAP 3= 66 
CEAP 4= 9 
CEAP 5= 1 
Recurrent varicose 
veins 
- 9 
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Table 10. Showing the demographic details of patients (IHD=ischemic heart disease, 
HTN=hypertension, PVD=peripheral arterial disease). 
 
 Varicose veins 
(n=80) 
Non Varicose 
Veins (n=35) 
 p-value 
Age 18-82 (Mean 
45.16) 
32-85 ( mean 
62.7) 
< 0.0001 
HTN 14 21 < 0.0001 
Diabetes 
mellitus 
2 9 0.002 
PVD 8 12 0.02 
IHD 2 12 0.001 
Stroke 2 6 0.03 
Cancer 0 1 0.3 
Connective 
tissue disorders 
0 0 - 
Aspirin 12 18 0.0002 
Simvastatin 12 20 < 0.0001 
Lisinopril 5 17 < 0.0001 
Amlodipine 5 6 0.18 
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5.2.2 Extraction of metabolites 
We identified the most optimal and reproducible method for extraction of aqueous and non-
polar metabolites form vein tissues (Chapter 3-Optimisation of Extraction Methodology for 
Vein Tissue). Consecutive approach using extraction of first non-polar metabolites from 
tissues with 75% MTBE: 25% methanol followed by the extraction of polar metabolites using 
50% water: 50% methanol was found to be the optimum in terms of reproducibility and 
comparable in terms of metabolic yield when compared to the gold standard extraction 
solvent (75% chloroform: 25% methanol followed by 50% water: 50% methanol).  The same 
consecutive extraction as identified in chapter 3 was used, first with 75% MTBE: 25% 
methanol for non-polar metabolites followed by 50% water: 50% methanol for polar 
metabolites. 1.5 mls of 75% MTBE: 25% methanol was added in each 2ml microtube (VWR, 
UK) containing tissue sample and 1mm zirconium beads (BioSpec USA). Two extraction 
blanks samples were also prepared for each group and run parallel with other tissue samples. 
Samples were frozen on dry ice and loaded onto a bead beater (Bertin Technologies, Precellys 
24). 4 cycles were run on the bead beater. Each cycle was at 6500 Hz speed and lasted for 40 
seconds. Cycles were separated by cooling on dry ice. Samples were Centrifuged (Eppendorf 
5810, US) RCF of 17949.49 x g rpm for 20 minutes at 4°C temperature. Content from each 
beading tube was then transferred into 5 glass vials with PTFE seal (Fisher, UK) each 
containing 200 µl. Glass vials containing non-polar metabolites were dried overnight in a 
fume hood at room temperature and then stored in -80°C freezer. 1.5 mls of 50% water: 50% 
methanol was added in each 2ml microtube containing the sample which was then run on 
bead beater for 2 cycles at 6500 Hz speed each lasting 40 seconds. This was followed by 
Centrifuged (Eppendorf 5810, US) RCF of 17949.49 x g for 20 minutes at 4°C temperature. 
The supernatant from each aliquot was transferred into a new appendorf tube. Appendorf 
tubes with aqueous metabolites dried in a speed vacuum overnight at room temperature and 
then stored in -80°C freezer.  
 
5.2.3 Preparation of aqueous extracts for NMR 
Two aliquots holding dried aqueous extracts were prepared for NMR spectroscopy using the 
method described by Beckonert et al (202) with some modification. Dried aqueous extracts 
were suspended in deuterated phosphate buffer solution at pH 7.4 (0.2M NaH2PO4, Na2HPO4, 
0.05% of sodium 3-trimethylsilyl-1-[2,2,3,3,-
2
H4] propionate (TSP), D2O) before transferring 
into NMR tubes. 650µl of 1.72% of TSP containing buffered D20 was added into first out of 
five aliquots of each sample. The aliquots were vortexed for 1 minute, sonicated for 5 minutes 
and vortexed again for 1 minute. This was followed by centrifugation for 30 sec at RCF of 
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17949.49 x g and 4
0
C. Contents of the first aliquot of each sample were transferred into the 
second aliquot of the same sample and the whole procedure was repeated except that the 
centrifugation was performed for 10 minutes at RCF of 17949.49 x g at 4
0
C. The supernatant 
was transferred into an NMR tube.  
 
5.2.4 Analysis on NMR 
Aqueous vein extracts were spun at 600 MHz 
1
H-NMR spectroscope (Bruker BioSpin, 
Rheinstetten, Germany).  Standard 1D pulse sequence (recycle delay (RD)-90
o
-t1-90
o
-tm-90
o
-
acquire FID) with water suppression applied during RD of 2 s. A total of 512 scans were 
acquired into 64K data points. Spectrum width was δ 20.00 with relaxation delay of 2 sec, 
acquisition time 1.36 sec, spin-echo delay t=400µs and total echo time of 64 ms for all 
aqueous experiments. On TOPSPIN 3.0 software (Bruker BioSpin, Rheinstetten, Germany), 
aqueous spectra were phased and calibrated using chemical shift of sodium 3-trimethylsilyl-1-
[2,2,3,3,-
2
H4] propionate (TSP) at δ 0.00. The base line was also corrected manually. Spectra 
were imported into MATLAB R2009b (Mathworks™, 2009) using in-house model built on 
MATLAB. The region containing the water resonance (from δ4.68 to δ5.24) was removed 
from all spectra. In addition, the resonance of TSP (from δ-1 to 0.2 δ) was removed from all 
spectra. All spectra were subsequently aligned and normalised using probabilistic quotient 
normalisation (184).  
 
5.2.5 Preparation of samples for LC-MS analysis 
Dried organic metabolites were re suspended in isopropanol. Following 1 minutes of vortex 
and 5 minutes of sornication at 4°C, 200 µl of each sample was put inside the 1.8mm LCMS 
glass vials and the remaining 50 µl of each sample was added together to form the quality 
control (QC) sample. Samples were analysed using an Acquity UPLC System (Waters, 
Manchester), coupled to a Q-Tof Premier mass spectrometer (Waters, Manchester). The 
instrument was operated in both positive (ESI+) and negative (ESI-) electrospray ionization 
modes. Chromatography was carried out at 40°C on a Waters Acquity UPLC HSS T3 column 
(1.8µm, 2.1x100mm). Separation was performed with acetonitrile/water (60:40) with 10 mM 
ammonium formate and 0.1% fromaic acid (A), and isopropanol/acetonitrile (90:10) with 10 
mM ammonium formate and 0.1% formic acid (B). ESI conditions were set with the source 
temperature 120
o
C, desolvation temperature 400
o
C, cone gas flow 25L/hr, desolvation gas 
flow 800L/hr, capillary voltage 3000 V for ESI+ and 2500V for ESI-, cone voltage of 30 V 
for ESI+ and 25 V for ESI-. The instrument was set to acquire over the m/z range 50-1200 in 
V mode with scan time of 0.2 s and an inter-scan delay of 0.02 s. Data were collected in 
centroid mode. Leucine/Enkephalin (200pg/µL, in acetonitrile: water 50:50, 0.1% formic 
acid) was used as a lock mass with an analyte-to-reference scan ratio of 4:1. The instrument 
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was calibrated before analyses using 0.5mM sodium formate solution. The order of injection 
of samples was randomised. QC sample was injected regularly throughout the run to monitor 
the stability of the of the UPLC-MS platform. Samples were run using a random sequence and 
a QC was set to run after every 10 samples. Data were pre-processed using MasLynx version 
4.1. Three dimensional LC-MS data was processed and aligned into a table of time aligned 
features with their retention time and m/z intensity. Isotops, peaks and fragments and adducts 
were treated as a separate feature 
 
5.2.6 Multivariate statistical analysis 
SIMCA-P+ 12.5 statistical software (UMETRICS™, Sweden) and MATLAB R2009b 
(Mathworks™, 2009) using in-house model built on MATLAB were used to analyse the data 
acquired from NMR and LCMS. Both PCA and OPLS-DA analysis were performed. Validity 
of OPLS models were assessed by performing 1000 permutations. Moreover, univariate 
analysis of variance (2-way ANOVA) was performed for the initial whole set of variables to 
identify the individual effect of variable on the outcome. Benjamini-Yekutieli multiple testing 
corrections for false discovery rate were performed to ensure the test statistics correspond to 
the true null hypotheses (235). Only those metabolites were considered significant which 
were found to be differential on validated multivariate OPLS-DA model and were also 
reported to be significant by univariate analysis following Benjamini-Yekutieli multiple 
testing corrections.  
 
5.3 RESULTS 
5.3.1 Multivariate analysis of 1H NMR spectroscopic based profiling of vein tissue  
OPLS-DA model for aqueous extracts from 
1
H NMR comparing the varicose veins and non-
varicose veins group revealed clear differences between the diseased and control groups. Q
2 
Y 
value was 0.202 and R
2
Y was 0.379 for the model and the model was cross validated using 
permutation testing. NMR peaks corresponding to myo-inositol, taurine and glutamic acid  
(glutamate) metabolites were found to be highly correlated to clustered varicose veins spectra 
(Figure 5-1). Benjamini-Yakatieli multiple testing corrections was applied in order to exclude 
false positive rate. Differential metabolites were found to be highly significant on multiple 
testing corrections. Figure 5-1 showed comparison of clustered spectra of varicose veins and 
non-varicose veins.  
 
 
 
 
Varicose veins 
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Glutamate 
Varicose veins 
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Varicose veins 
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c. 
 
d. 
 
d. 
 
 
 
 
Figure 5-1. OPLS models (for aqueous metabolites analysed on 
1
H NMR) showing the 
differences between the varicose vein and non-varicose veins groups. a. Shows the 
overall differences between the two groups and the peaks that are consistently higher in 
relative concentrations in the varicose veins group.  b., c, d, highlight the taurine, 
glutamate and myo-inositol peaks.  
 
 
 
 
Non-varicose veins 
Varicose veins 
Varicose veins 
Non-varicose veins 
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In order to elucidate the relation of integrated peaks pertaining to a particular molecule, 
Statistical Total Correlated Spectroscopy (STOCSY) of peaks at certain chemical shifts was 
performed (157, 161). At δ3.269, STOCSY revealed correlation of taurine peaks with the 
neighbouring triplet of taurine at δ3.40 (Figure 5-2a). STOCSY at chemical shift of δ4.07 
confirms the correlation of all the peaks relating to myo-inositol (Figure 5-2b).  At δ3.269, 
taurine peaks and myo-inositol peaks can overlap. STOCSY performed for δ3.269 reveals the 
two molecules. Figure 5-2c shows the association of all the peaks relating to glutamate 
molecule.  
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a. 
 
 
 
 
 
b. 
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c. 
 
 
 
 
 
Figure 5-2. STOCSY showing correlation of peaks related to different metabolites. 
Figure a. shows correlation of taurine peaks with the neighbouring triplet of taurine. 
Figure  b. STOCSY at chemical shift of δ4.07 confirms the correlation of all the peaks 
relating to myo-inositol.  Figure c. shows the association of all the peaks relating to 
glutamate molecule.  
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Figure 5-3. Box plots comparing concentrations of differential aqueous metabolites 
between varicose and non-varicose veins.       
     Corrercted p-value using benjamini Yakutieli multiple testing corrections. 
 
 p <0.0001 
 
 
P <0.0001 
p <0.0001 
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5.3.2 Multivariate analysis of UPLC-MS based lipid profiling 
Multivariate analysis of non-polar extracts analysed on UPLC-MS in +ESI mode is shown in 
Figure 5-4and Figure 5-5. PCA score plot showed the sample distribution based on the 
variations observed in the data set with very good clustering of QCs samples (Figure 5-4). 
This confirms instrument stability during the LC-MS experiment. The OPLS-DA model 
showed separation between the disease and control groups (Figure 5-5 a). A Q
2
 value of 0.334 
suggested good prediction ability of the model. Cross validation was done by permutations 
testing. Permutation test confirmed that the model not only predicted the training set well but 
also predict the class (Y) of the samples. Permutation test is performed by changing the order 
of the Y observations randomly and keeping the X-matrix intact. Figure 5-5 b. shows the S-
loadings plot for the OPLS-DA model and is used to identify the significant differences 
between the two groups. Loadings at two extreme ends of S-plot represent the features 
(metabolites or noise) responsible for the separation between the samples of two groups. 
Analysis of non-polar metabolites acquired from UPLC-MS showed increased concentration 
of phosphatidylcholine (PC) and sphingomyeline (SM) signals in varicose veins group and 
triglycerides in non-varicose veins group (Figure 5-5). Relative concentrations of differential 
features in each group identified via multivariate OPLS-DA model are shown in Figure 5-6. 
Details of these features including their chemical formula, retension time, mass detected (both 
theoretical and observed), chemical shift value, fold change and p values are described in 
Table 11. Assignments of the features were established with the help of online databases 
including METLIN (http://metlin.scripps.edu/metabolites), HMDB http://www.hmdb.ca/) and 
lipid MAPS (http://www.lipidmaps.org/tools/). Tandem mass spectrometry (ms/ms) 
experiments were also performed for confirmation of identity of some of the lipid species. 
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                                                                     PCA 
 
 
Figure 5-4.  PCA score plot of data acquired from UPLC-MS +ve ESI mode showing the 
overall variation in the samples and instrument stability (good clustering of QCs 
samples).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
QCs Varicose Veins Non-Varicose Veins 
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 a.                                                      OPLS-DA 
 
 
 
b. 
 
Figure 5-5. Multivariate OPLS –DA score plots for UPLC-MS based lipid profiling (+ve 
ESI mode). a. comparing the varicose veins and non-varicose veins samples. Robustness 
of the OPLS-DA model was confirmed by 1000 permutations testing. b. showing the S 
loadings plot for the OPLS-DA model. Metabolites at the outer most edges of the S plot 
are present in higher concentration in one or other group.  
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Figure 5-6. Plots representing concentrations of differentially abundant metabolites 
identified from OPLS-DA model for UPLC-MS +ve ESI data in each sample.  
TG Triglyceride, PC Phosphatidylcholine, SM Sphingomyeline, PE Phosphorylethanolamine,  
     Corrected p-values using Benjamini-Yakutieli multiple testing corrections. 
 
 p <0.0001 
 p <0.0001 
p <0.0001 
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Table 11. Showing the details of differential features identified between varicose and 
non-varicose veins groups on UP-LCMS +ESI mode analysis.  
TG Triglyceride, PC Phosphatidylcholine, SM Sphingomyeline, PE Phosphorylethanolamine,  
     Corrected p-values using Benjamini-Yakutieli multiple testing corrections. 
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Multivariate analysis of non-polar extracts analysed on UPLC-MS in -ESI mode is shown in 
Figure 5-7. Similar to +ve ESI mode, PCA score plot also showed a very good clustering of 
QC samples for -ve ESI mode (Figure 5-7 a). This confirms instrument stability during the 
UPLC-MS experiment. OPLS-DA model showed separation between the two groups (Figure 
5-7 b). A Q
2
 value of 0.305 for the model (cross validated by permutation test) suggested a 
good prediction ability of the model. Loadings S plot in Figure 5-7 c for the OPLS-DA model 
displays the features responsible for the separation between the samples of two groups. These 
differential metabolites identified included inosine and uridine which were present in higher 
concentration in the varicose veins groups (Figure 5-8).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Varicose Veins Non-Varicose Veins QCs 
a 
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Figure 5-7. Multivariate modelling of UPLC-MS -ve ESI mode based analysis of 
varicose vein and non-varicose veins. (a) Shows the PC score plot demonstrating the 
overall distribution of samples including QCs. Clustering of QCs shows less instrument 
induced variations and stable experiment conditions. (b) Shows the OPLS-DA 
comparing varicose and non-varicose veins samples. Separation between the groups is 
clear (Model’s validity was confirmed by performing 1000 permutations test). (c) Shows 
the Loadings S plot revealing the differential metabolites responsible for the difference 
between the groups.  
b 
c 
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Figure 5-8. Box Plots representing concentrations of differentially abundant metabolites 
in varicose and non-varicose veins groups detected from analysis of non-polar 
metabolites on UPLC-MS -ve ESI mode.  
     Corrected p-values using Benjamini-Yakutieli multiple testing corrections 
 
 
 
p <0.0001 
p <0.0001 
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5.3.3 Effect of other variables on differential metabolites 
Demographic features including age, sex, past medical history have been described in details 
for both groups in Table 10. Patients who have their varicose veins retrieved and used in the 
study were younger and have less comorbid conditions. A multivariate partial least square 
(PLS) regression modelling approach was used to identify any influence of these confounding 
variables on non-polar metabolic profile obtained by analysis of vein tissue extracts on 
UPLC-MS. For each variable (for example age, sex, diabetes etc) a PLS model was 
constructed whereby the y matrix (observations) was replaced with the variable under 
investigation instead of the sample class. Q
2
 and R
2
 values and p values for each model were 
calculated. Table 12 represents the influence of patient’s demographic variables on the 
metabolic profiles (for non-polar metabolites). A low Q
2
 value and p value higher than 0.05 
demonstrate that there was no association of that particular variable with any specific 
metabolic feature and distribution of a specific variable (such as age, sex, diabetes etc) was 
unable to impact any group differences related to disease status (varicose versus non-
varicose). As shown in the table, none of the variables including age, sex, hypertension, 
diabetes mellitus, cancer, history of peripheral vascular disease and medications such as 
aspirin, simvastatin and lisinopril were able to elucidate any metabolic differences. A weak 
correlation was noticed with previous history of stroke with a p value of 0.057.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 157 
 
Table 12. Shows the association of patients demographic variables with non-polar 
metabolic profile acquired from analysis of veins tissue extracts on UP-LCMS +ve ESI 
mode.  
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5.3.4 Pathway Analysis and Discussions 
5.3.4.1 Main Findings 
In this study, 80 varicose veins and 35 non-varicose veins samples were subjected to a 
rigorous extraction process. Both aquoeus (polar) and lipid (non-polar) metabolites were 
extracted from the vein tissues. Polar extracts were analsyed using 
1
H NMR and non-polar on 
UPLC-MS platform. Following mathematical modelling of the data, multivariate statistical 
analysis were performed. Multivariate modelling for polar metabolites identified glutamate, 
myo-inositol and taurine metabolites present in higher concentrations in varicose veins. For 
non-polar metabolites, phosphatidylcholine and sphingomyelin were found in greater 
concentrations in varicose veins. Variations in age, sex and differences in past medical history 
and medications including aspirin, simvastatin and lisinopril had no correlation with any 
metabolic perturbations noticed between the groups.  
 
Glutamate is the key metabolite in cellular mechanism. It serves as the substrate for 
compounds which are involved in glycolysis, gluconeogenesis and tricarboxylic acid cycle. 
Glutamate is also involved in removal of excess nitrogen. A key role of glutamate is in the 
excitation of mammalian nervous system in neural cells. After its release from presynaptic 
nerve terminal into synaptic cleft, glutamate acts on two receptors; post synaptic glutamate 
receptor and metabotropic glutamate receptor on glial cells. By activation of former it causes 
fast excitatory synaptic transmission. By activation of the later, glutamate causes activation of 
2
nd
 messenger systems by coupling of G protein receptor. Through activation of 2
nd
 messenger 
system, growth factor production is activated. Under physiological conditions excess 
glutamate is put back into the presynaptic terminal. In diseases such as Parkinson’s disease 
this process is hindered leading to excess accumulation of glutamate in the synaptic cleft 
which causes increased flux of Ca+ ions into the cells and damages the mitochondria. 
Mitochondrial damage causes upregulation of transcription factors for apoptic genes and leads 
to cell death. Another important function of glutamate is its role in production of glutathione 
and free radicals. Glutathione plays important role in antioxidant defence and cell 
proliferation and apoptosis and cytokine production. Glutamate is also involved in the 
production of a neurotransmitter gamma amino butyric acid (GABA). 
 
Taurine, a sulphur containing amino acid, is an essential amino acid. Taurine is present in 
brain, heart, breast, gallbladder, and kidney and has important role in health and disease. It 
serves as a neurotransmitter in brain, stabilizer of cell membrane and facilitates in the 
transport of ions such as sodium, potassium and magnesium. Taurine can be synthesized in 
the body from cysteine (Figure 5-9). It is the second most important inhibitory 
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neurotransmitter after GABA. Taurine has been considered to protect against diabetes and 
atherosclerosis. Taurine is also involved in intracellular osmoregulation and bile acid 
formation. Hyperhomocysteinemia can increase the risk of coronary atherosclerosis. Studies 
suggest that taurine can inhibit homocystein levels in the either by inhibiting its own pathway 
or other intracellular protective effects. The protective intracellular effects of taurine include 
conjugation with ursiodeoxycholic acid and inhibition of endoplasmic reticulum stress- 
induced apoptosis, prevention of mitochondrial superoxide and inhibition of homocystein 
induced stress of endoplasmic reticulum on vascular smooth muscle by restoring the 
expression and excretion of extracellular superoxide dismutase.  
 
 
Figure 5-9. Diagram showing mechanism of formation of taurine. Illustration is taken 
from Wesseling et al. with some modifications.  
 
Myo-inositol is a carbocyclic polyol which is a structural component of a number of second 
messengers such as inositol phosphates, phosphatidylinositol and phosphatidylinositol 
phosphate lipids. Myo-inositol is synthesized by glucose 6 phosphate. Figure 5-10 is a 
simplistic flow chart showing the metabolism of myo-inostol and production of different 
phosphatidylinositol phosphates. These phosphatidylinositol phosphates are involved in Akt 
signalling pathways, membrane trafficking and regulate apoptosis.  
 
Sphingomyelin (SM) is a type of sphingolipids found in cell membrane, mainly in membrane 
myelin sheath that surrounds some nerve cell axons. It consists of phosphorylcholine and a 
ceramide. Sphingomyelin is involved in signal transduction. Usually abundantly present on in 
extoplasmic side of plasma membrane, also have been reported to be present in inner leaflet 
of cell membrane.  Phosphatidylcholine (PC) is a glycerophospholipid. Phospholipids are the 
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key component of the lipid bilayer. It is also involved in metabolism and cell signalling. PC is 
synthesized by choline (Figure 5-11). It can also be synthesized from conversion of 
phosphoserine to phosphoethanolamine. SM is sythnesized by the transfer of 
phosphorylcholine from PC to a ceramide. This reaction is catalysed by SM synthase (Figure 
5-11).  
 
 
 
Figure 5-10. Metabolism of Myo-inositol and formation of different phosphatidylinositol 
phosphate lipids. 
 
 
Figure 5-11. A flow chart showing synthesis of PC and SM. ATP; adenosine 
triphosphate, CTP; cytidine triphosphate. 
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5.3.4.2 Pathway Analysis 
Using the ingenuity pathway analysis software (http://www.ingenuity.com/products/ipa) 
biological function of differential metabolites was illustrated. Figure 5-12 shows the direct or 
indirect links between the differentially abundant metabolites and different cellular pathways 
and molecules. Differential metabolites were found to be directly or indirectly associated with 
cellular processes such as mitochondrial dysfunction, endothelin 1 signalling, regulation of 
apoptosis and growth, and inflammation. Exploring the pathways linked to differential 
metabolites in details using the published reports on databases (pub med and medline), a 
proposed mechanism of disease pathogenesis was built (Figure 5-13). This is discussed in the 
following paragraphs. 
 
 
 
 
 
Figure 5-12. Direct and indirect association of glutamate, taurine, myo-inositol, 
sphingomyelin and phosphatidylcholine with each other and the other cellular processes. 
Molecules highlighted in red box were metabolites observed in higher concentrations in 
varicose veins tissue. Using ingenuity cellular pathway analysis direct (unbroken black 
lines) and indirect (broken black lines) links with other biological molecules were 
ascertained. Blue lines indicate the biological functions linked to these molecules. 
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Figure 5-13. Diagram illustrating the proposed pathways associated with the differential 
metabolites (observed in varicose veins) for future investigation. Potential cellular 
pathways for further exploration includes activation of PKC pathways which is 
associated with cell survival and proliferation; mitochondrial excess of GSH which 
results in reduced apoptosis by blocking ROC and breakdown products of 
phospholipids which play an important role in inducing inflammation.
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Mitochondria are membrane bound intracellular organelle. Mitochondria are the main energy 
source to the cell and are also involved in cellular signalling, differentiation growth and 
apoptosis (241). Glutathione (GSH) also known as gamma L glutamuyl L cysteinyl glycine is 
synthesised from glutamate and cysteine. Glutathione regulates disulphide molecule bonds of 
proteins and involved in the removal of oxidants and electrophiles (242). Mitochondria are a 
site of oxygen consumption and is the prime source of reactive oxygen species (ROS) most of 
them coming from mitochondrial respiratory chain. Moreover the higher concentrations of 
ROS (> 5 fold higher than cytosol) can damage the mitochondrial matrix therefore 
mitochondria require continuous reduction of these oxygen free radicals (243). For this 
mitochondria mainly rely on GSH. GSH is synthesized and located in the cytosol and is 
transferred across the mitochondrial membrane via membrane carriers dicarboxyate and 2 
oxoglutarate (244). Under the normal physiological state, GSH is able to cope with the 
oxidative stress. Mitochondria play a significant role in intrinsic pathway for apoptosis (245). 
Apoptosis or programmed cell death involves cell membrane blebbing, shrinkage of cell, 
fragmentation of nucleus material in cell and chromatin or DNA fragmentation (241).  In the 
presence of GSH depletion ROS such as hydrogen peroxide or lipid hdroperoxide causes 
release of cytochrome c from mitochondria which trigger the effector caspases. This leads to 
increased apoptosis. However, increased GSH can stop this process by reducing the ROS and 
hence can cause inhibition of apoptosis (240). Exposure of cells to certain stimuli including 
hypoxia, the balance between production of GSH and ROS is disrupted which affects 
mitochondrial functions. Hypoxia up-regulates HIF-I α, a transcription factor, which upsurges 
genes involved in angiogenesis, proliferation and glycolysis (246). Normal GSH levels in 
mitochondria stabilizes hypoxia induced HIF I α and causes NFκB activation resulting in cell 
survival and proliferation (247, 248).  On the other hand in the presence of over generation of 
mitochondrial ROS or depletion of GSH, NFκB inhibition takes place leading to increased 
apoptosis (241). This may have an implication in diseases where by increased cellular 
proliferation is a morphological pattern of the disease such as varicose veins diseases. It has 
also been reported that varicose veins are exposed to hypoxia (249) and HIF-I α is up-
regulated in varicose veins (250). This study found increased concentrations of glutamate in 
varicose veins. Keeping in mind the role of GSH and ROS in mitochondrial induced 
apoptosis, a potential pathway for varicose veins disease pathogenesis can be proposed for 
exploration for future studies (Figure 5-13). A probable explanation of higher level of 
glutamate in varicose veins may be its role in generating more GSH which neutralizes the 
ROS and hence may be responsible for increased cellular proliferation.  
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Vascular endothelial growth factors (VEGF) is a growth factor which is responsible for 
angiogenesis, vascular permeability, endothelial cell proliferation and migration, and 
adhesions of leukocytes to endothelium (251) (252). Other growth factors including tumour 
growth factor (TGF), platelet derived growth factors (PDGF), endothelial cell growth factor 
(EGF) and fibroblast growth factor (FGF) also induces cell proliferation and angiogenesis 
(253). Hypoxia causes increased expression of HIF-1 α which leads to the up regulation of 
VEGF mRNA in inflammatory cells including macrophages (254, 255). Hypoxia induced 
transcriptional activity of VEGF is regulated by cytokines and growth factors such as 
interleukin 6 (IL 6), tumour necrosis factor (TNF α), TGF, and PDGF (255, 256). Endothelin 
1 increases VEGF secretion in smooth muscle cells (257). After release from inflammatory 
cells VEGF is attached to its endothelial or vascular smooth muscle cells surface receptors 
(Figure 5-13). These include VEGFR1 (Flt-1 receptor), VEGFR 2 (KDR receptor), VEGFR 3 
(Flt 4 receptor) (258-260). These receptors have 7 extracellular domain and an intracellular 
domain with tyrosine kinase activity (261). Activation of tyrosine kinase involves receptor 
auto-phosphorylation and intracellular signal transduction (262). Signal is transduced with 
phospholipase C enzyme catalysing phosphatidylinositol 4 5 bisphosphate to inositol 1 4 5 
triphosphate and diacylglycerol (DAG). Protein kinase C (PKC) activation and ca++ release 
from endoplasmic reticulum then leads to cell proliferation (258). Endothelin (ET) 1 
stimulates vascular smooth muscle cells proliferation, migration, contraction and extracellular 
matrix synthesis(263) (264, 265). Moreover ET-1 is also involved in activation of platelet 
derived growth factors and transforming growth factors (266, 267).  Endothelin 1 has been 
implicated in vein graft disease and its failure (268). ET 1 works on ET a and ET b receptors, 
both have been reported in tunica media and intima of porcine saphenous vein graft model 
and  human saphenous veins in regions of increased proliferative activity (269) (270, 271). ET 
1 attachment to its receptors on vascular smooth muscle membrane leads to coupling of 
pertussis insensitive Galph aq/11 and causes activation of phospholipase C (PLC) (272). 
Activation of PLC triggers phosphatidylinositol phosphate second messenger cascade 
resulting in PKC activation (Figure 5-13) (273). Eventual downstream pathways related to 
PKC activation results in VSMC proliferation and migration.  
 
Intact vein tissue analysis using MAS 
1
H NMR revealed increased concentration of myo-
inositol metabolite in varicose veins (see chapter 2). Myo-inositol is found to be the 
differential metabolite again in analysis of vein tissue metabolic extracts further emphasising 
the importance of myo-inositol as a metabolites of significant biological potential. Myo-
inositol is the precursor molecule for second messenger phosphatidylinositol and 
phosphatidylinositol phosphate. These second messengers are catalysed by P13 kinases and 
results in release of calcium from ER and activation of PKC as mentioned in the above 
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paragraph. The important role of inositol phosphate and P13 kinase signalling is summarized 
in Figure 5-13 and should be the target for future studies in understanding disease 
pathogenesis. Hollingworth et al reported an increased transcription of VEGF and VEGF 
receptors (KDR and flt 1) in varicose veins wall as compared to non-varicose veins wall 
(105). Increased expressions of FGF mRNA and FGF receptors and ERK ½ have also been 
found to be up-regulated in varicose veins wall as compared to non-varicose veins wall. This 
suggests the role of FGF and MAPK in varicose veins wall. FGF regulates ECM remodelling 
(65). Up-regulation of growth factors and their receptors in varicose veins wall further back 
the putative pathway shown in Figure 5-13. Dysregulated apoptosis and dysfunction cell cycle 
have been demonstrated in varicose veins (66-70). The overall number and activity of 
apoptotic cells is reduced in varicose veins (68, 69, 71). Studies have shown increased 
expression of cyclin D1 and reduced expression of bax and poly ADP-ribose polymerase 
(PARP) in varicose compared to non-varicose veins. Cyclin D1 is a proto oncogene and is 
involved in the progression of cell cycle through G1 phase. Bax is an inducer of apoptosis and 
PARP is an enzyme involved in genome surveillance and DNA repair (68, 69).  
Phosphatidylcholine and SM moieties have previously been observed in varicose veins. The 
work was performed by Tanaka et al. lysophosphocholine (1-acyl-16:0), sphingomyelin 
(d18:1/16:0) and Phosphocholine (1-acyl 34:1) around the incompetent varicose vein valves 
using a technique employed in mass spectrometry called MALDI (matrix assisted laser 
desorption ionization) imaging (181). Same group, using MALDI imaging technique, also 
reported comparatively higher localisation of triglyceride (TG) in in adventitia layer of 
varicose veins, and PC and LPC in intima and media layer of varicose veins as compared to 
non-varicose veins (274). Imaging mass spectrometry provides a spatial information about the 
distribution of molecules in tissues (275). Lysophosphocholine LPC) is associated with 
inflammation. It is chemotactic for macrophages. Inflammation has been considered playing a 
key role in varicose veins development (276). MMPs damages the endothelium and damaged 
endothelium allows leucocyte to infiltrate the vein wall and triggers inflammtion (32, 277). It 
has been suggested that accumulation of pro-inflammatory lipid molecules around the 
valvular region may be responsible for inflammation and valvular incompetence. 
Phosphatidylcholine (PC) is a substrate for phospholipase A (PLA) 2. PLA 2 causes 
hydrolysis of PC into free fatty acids such as arachiodonic acid (AA) and LPC. AA is a 
precursor molecule for prostaglandins and leukotriene, both responsible for chronic 
inflammation (181). SM is a precursor of sphigolipids such as ceramids which play an 
important role in inflammation and cellular apoptosis (181) (278) (279) (280, 281).  
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Varicose veins have increased concentration of PC and SM and non-varicose veins have 
higher levels of TG and ceramide. As ceramide was present in significantly low concentration 
in varicose veins as compared to non-varicose veins, it may propose low apoptotic activity in 
varicose veins (Figure 5-13). Pathway analysis linked the differential metabolites of 
glutamate, taurine, myo-inositol, sphingomylein, and phosphatidylcholine to some of the key 
pathways inside the cells. The role of these pathways should be the focus for further 
validation in future studies. This study did not separate the varicose veins patients on the basis 
of their CEAP (Clinical Etiology Anatomy Physiology) severity score. This was due to the 
fact that study was intended to investigate any metabolic differences between varicose veins 
and non-varicose veins without any particular focus to the disease severity. 86% of patients 
included in this study had CEAP grade of 3 and 12% of patients had CEAP grade of 4. Due to 
very small number of CEAP patients in each of CEAP 4, 1 and 5/6 class, a sub-group analysis 
based on CEAP class will not be of any scientific value in the current cohort. However, future 
study should compare the CEAP class of different patients to investigate if there is any 
particular metabolic association with a certain CEAP grade.  
 
Taurine plays a role in cell osmoregulation and membrane stabilisation. Taurine is also a 
building block of protein metabolism. Taurine has been observed in colon cancer cells where 
there is an increased cell growth and protein turn over (282). Taurine has also been found in 
other tumours such as gliomas, squamous cell cancer, and prostate cancer (283). Presence of 
higher concentrations of taurine in varicose veins tissue suggests an increased in cellular 
proliferation and protein turnover in varicose veins.  
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6 Final Discussion and Limitations 
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6.1 FINAL DISCUSSION 
Management of diseases are increasingly dependent on our understanding of molecular 
changes at cellular levels. These molecular changes provide information about underlying 
physiological processes, genetic modifications and metabolic alterations under the influence 
of a particular disease. Metabolic perturbations displayed by metabolites provide important 
biomarkers of disease diagnosis, prognosis and may have a potential role in influencing 
treatment (284). Metabolic changes in cells or tissue may reflect local effect of disease or 
environmental stimuli or genetic modifications. However, changes in biological fluids can be 
due to both local and systemic effect of these stimuli (146). Recently evidence from both 
animals and human studies suggest that disease, genetic and environmental factors influence 
the metabolism over variable time frame and mapping these changes over time may help in 
identifying disease biomarkers and therapeutic targets (284). Moreover, metabolic 
phenotyping also named as metabotyping has a potential role in disease risk stratification at a 
large population scale and also in managing individual patients (personalised medicine) (284-
286). There are numerous cell types in human body with each type having a unique function, 
underlying gene expression, protein and metabolic expression (284). Extracellular channels 
including blood and lymphatic may carry some of the metabolic information from the tissues. 
Isolating the disease involving a particular tissue related metabolites requires use of a large 
sample cohort and multivariate approach to data analysis.  
 
Due to differences in physiological status any effect of disease on the snap shot of metabolic 
activity in tissue is not straightforward. Obtaining tissue urine or blood samples over a series 
of time or under different stages of the disease can provide a longitudinal pattern of metabolic 
activity which can help in identifying disease biomarkers, and therapeutic targets. This 
however generates a large amount of data which is difficult to interpret unless a multivariate 
approaches are used. Information retrieved from such a top down system biology approach 
can be used to build hypothesis and ideas which can be tested in bottom up approach for 
validation. This can enable scientist and clinicians to understand disease pathogenesis (284) 
(287, 288). There are numerous studies supporting the practicality of metabonomics in 
studying metabolic phenotype of diseases. For example, Biochemical information from serum 
of patients with type 2 diabetes mellitus (DM) showed an increased concentration of alanine 
and branched amino acids which correlates with the metabolic disturbances in DM such as 
decreased amino acids gluconeogenesis and increased ketogenesis (289). More recent studies 
on DM have further explored the disease mechanism both for type 1 and 2 DM with 
modulation of N methylnicotinamide in type 2 and dysregulation of lipids and amino acids 
metabolism in type 1 DM (290) (291). Even metabolites of disease prediction have been 
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identified in diabetic patients (292). Identification of biomarkers in diseases including cancers 
has been always a major focus for scientific community. Evaluation of serum and urine of 
cancer patient for uncovering metabolic disturbances has been able to provide important 
biomarkers of prognosis. For example, altered pattern of ceramides and lyophospholipids, 
increased ketones, low alanine, valine, and low density lipoproteins have been detected in 
plasma of patients with ovarian cancer (293) (294). In a prospective observational study 
involving 44 patients with confirmed colorectal cancer, metabolic profile of intact tumour 
tissue was compared to the non-cancerous tissue using 
1
H MAS NMR spectroscopy. Higher 
concentrations of lactate, taurine and isoglutamine and decreased level of lipids / triglycerides 
were found in cancer mucosa as compared to normal mucosa. Even metabolic differences 
between colon and rectal cancers were observed and a unique metabolic signature for colon 
cancer at different TNM stage was observed. These alterations in level of metabolites in 
colorectal cancers in different stages of disease progression (TNM Staging) suggest the role 
of metabolic phenotype in disease prognosis and possible therapeutic targets (282).  Increased 
level of glucose, proline, lysine, phenylalanine, and n-acetylcystein in serum has been 
observed in patients with breast cancer who developed micrometastasis as compared to those 
who did not (295). Disease specific metabolic perturbation has also been observed in benign 
diseases including asthma and chronic obstructive pulmonary disease (296, 297). Urinary 
concentration of tricarboxylic acid cycle intermediates alpha ketoglutarate, succinate, 
fumarate and cis aconitrate were found to be different between patients with stable and 
unstable asthma (296, 297). The evidence presented clearly demonstrates a differential 
metabolic phenotype of different diseases. This differential phenotype is not only localised to 
cellular level but also transmitted to other compartments such as urine and blood. The 
differential metabolic phenotype can elucidate disease pathogenesis, and identify biomarker 
of disease prognosis and new therapeutic targets.  
 
Varicose veins are a multifactorial disease which is influenced by environmental factors such 
as occupation, obesity, pregnancy and carries a strong familial predisposition. Environmental 
stimuli in patient with familial predisposition exposes vein wall to high pressure and hypoxia 
both trigger the molecular changes in the vein wall leading to vein wall relaxation and 
dilatation. The main hypothesis of this work was to identify the differential metabolic 
phenotype of varicose veins and its utility in understanding the disease pathogenesis. 
Moreover, as discussed earlier, the metabolic phenotype is influenced by the environmental 
factors. In case of varicose veins disease, the most significant consequence of environmental 
factors (long standing, obesity, pregnancy) is orthostatic blood stasis and venous 
hypertension. Venous hypertension is known to generate mechanical stretch and shear stress 
on the vein wall. In order to comprehend the complete metabolic fluctuations in the varicose 
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vein wall in context of the influence of its known environmental factors, an ex-vivo rat IVC 
vein wall stretch model was used and metabolic fluctuations of rat IVC both at short and 
prolonged stretch were measured. It was postulated that stretch will induce metabolic changes 
in rat IVC segments.  
 
In order to prove or refute the first hypothesis experiments were designed with a view to 
utilising a multiple metabonomic platforms so that a comprehensive metabolic picture can be 
ascertained. 
1
H MAS-NMR spectroscopy was first used to analyse intact varicose and non-
varicose vein tissue samples. In the first chapter using 
1
H MAS-NMR spectroscopy analysis 
of the intact vein tissue was performed. 
1
H MAS-NMR spectroscopy is a non-destructive 
approach which is also quick and requires minimal tissue preparation. Creatine, lactate and 
myo-inositol metabolites were found in higher concentrations in varicose veins wall as 
compared to no-varicose veins control. Creatine reflects the hypertrophic nature of dilated 
varicose veins wall and lactate is associated with anaerobic metabolism under the effect of 
hypoxia (a stimuli probably generated as a result of blood stasis-which itself affected by 
multiple disease specific environmental factors as mentioned above). Myo-inositol being a 
structural component of second messengers plays a role in cell signalling and ca++ signalling. 
Higher level of TG was seen in non-varicose veins tissue.  
 
Intact tissue analysis is one way of metabolites measurements. Metabolites are also extracted 
from tissue using different extraction protocols designed for different tissue types. Extracted 
metabolites are then analysed on UPLC-MS and NMR to detect their structure and 
concentration. However, there was no extraction protocol existed for vein tissue. Therefore, 
an extraction protocol for human vein tissue was developed (chapter 3). This involved first 
identification of optimal extraction solvents for isolation of both aqueous and organic (lipid) 
metabolites from tissue, followed by identification of the most optimal extraction protocols 
based on their reproducibility and sensitivity. The extraction protocol developed for human 
vein tissue was equally sensitive and reproducible for both NMR and UPLC-MS based 
profiling. Subsequently, the most reproducible and sensitive protocol was used to extract 
metabolites from human vein tissue (discussed in chapter 5). UPLC-MS and 
1
H NMR based 
profiling of 80 human varicose veins against 35 non-varicose veins confirmed some of the 
metabolic changes observed in intact tissue MAS 
1
H NMR study explained in the 2
nd
 chapter. 
Myo-inositol, glutamate, taurine, PC and SM were found in higher concentrations in varicose 
veins tissue extracts and TG were found in higher level in non-varicose veins tissue extracts. 
Creatine and lactate metabolites which were noted in MAS 
1
H NMR study was also observed 
in both varicose veins and non-varicose veins tissue extracts but statistically they were not 
significantly different between the groups. Similarly, glutamate was observed in higher 
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quantity in tissue extracts of varicose veins samples, however in intact tissue analysis using 
MAS 
1
H NMR glutamate though was observed in varicose veins intact tissue as shown in 
Figure 2-4, but statistically glutamate was not the differential metabolite between the groups. 
The statistical significant may not have been observed simply due to less number of samples 
in MAS 
1
H NMR study (chapter 2) as compared to analysis of vein tissue extracts  (chapter 
5).  
 
Pathway analysis using different well established online tools an association was noticed 
between the possible environmental factors including hypoxia and stretch through activation 
of hypoxia inducible factors and growth factors and differential metabolites observed (Figure 
5-12, Figure 5-13). Growth factors through activation of its cell surface receptors trigger an 
activation cascade which involves PIP (derived from myo-inositol) and eventually causes 
ca++ release from endoplasmic reticulum which leads to activation of PKC. Increased growth 
activity as a result of PKC pathway may explain increased smooth muscle cells proliferation 
and change in their phenotype from contractile to proliferative phase. It is well known that 
proliferative phenotype affect vein wall contraction and leads to vein wall relaxation and 
weakness. Keeping in context environmental factors behind the varicose veins disease and 
previously known histological and molecular changes in varicose veins wall, differential 
metabolic picture identified in varicose veins wall in this work has demonstrated plausible 
cellular pathways which may be involved in disease development. Targeted pathways analysis 
should be the focus for future research not just for validity but also to identify any potential 
therapeutic drug targets. Development of drug therapy in venous disease may help in halting 
the disease progression. Moreover, disease prevention in genetically prone cases that are 
exposed to disease specific environmental factors is another front where drug therapy may 
have a role to play.  
 
Varicose veins are classified according to CEAP classification into different grades (298). In 
simple terms, CEAP 1 and 2 are asymptomatic varicose veins, CEAP 3 incorporates 
symptomatic varicose veins with oedema, CEAP 4 involves skin changes of pigmentation. C5 
and C6 represent more severe form of varicose veins; C5 characterizes healed ulcers and C6 
denotes active venous ulceration. In this study a large number of varicose veins belong to 
CEAP 3. This study did not intend to specifically investigate the disease related biomarkers. 
However, due to significant metabonomics utility in identifying disease specific biomarkers, 
future studies should incorporate serum and urine analysis, in addition to tissue, of patients 
with varying CEAP grades. Identification of varicose veins tissue specific differential 
metabolites in serum and urine and their association with different CEAP grades will have a 
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significant biomarker potential. This may aid clinicians to follow the disease progression and 
tailor therapy accordingly.  
 
Mechanical stretch generated by venous hypertension affect the vein wall and is likely 
induced by environmental stimuli. Effect of mechanical stretch on the Rat IVC segments 
metabolism was measured to explore whether stretch changes metabolic profile (chapter 4). 
KCL and phenylephrine induced contraction were significantly reduced in rat IVC segment 
stretched over 18 hrs demonstrating vein wall relaxation under stretch. This was a 
physiological assessment of the vein wall response to stretch stimuli and have been previously 
reported as well (232). 
1
H NMR and UPLC-MS based analysis of aqueous tissue and organic 
extracts from rat IVC segments, respectively, showed preservation of choline and valine 
metabolites over 18 hrs under the effect of prolonged stretch and increased levels of TG under 
the effect of prolonged stretch of 18 hrs. Valine is a branched chain amino acids and its 
preservation in stretched segments suggest that there is an increased protein breakdown under 
the effect of stretch. Choline a component of cell membrane is also precursor of PC. Though 
choline was not significantly present in varicose veins tissue extracts as shown in chapter 5, 
PC was found to be a differential metabolite in varicose veins tissue extracts. Increased level 
of choline, a cell membrane constituent and precursor of PC, over 18 hrs stretch may suggest 
that increased cell membrane breakdown start over 18 hrs time in response to stretch stimuli. 
It can be postulated here that if the stretch can be applied to the vein wall for longer than 18 
hrs period, choline may eventually lead to synthesis of PC. This argument can be supported 
by the fact that varicose veins are exposed to mechanical forces generated by venous 
hypertension for considerably longer than 18 hrs period and PC is a differential metabolic 
phenotype of varicose vein wall tissue. The most plausible explanation for the presence of 
increased choline in non-stretch segment at 4 hrs (under basal tension) could be that the 
immediate response of tissue in an ex-vivo environment may destabilize cell membrane 
constituents leading to release of increased choline. Leaving the tissue under the same basal 
tension (no-stretch) for longer period of time without adding any extra stretch may cause the 
veins tissue to adapt and maintain cell membrane stability. Therefore, release of cell 
membrane constituents is slowed down. Addition of extra tension and stretch on the vein wall 
put strain on the cell membrane further consequently disrupting its constituents. Similar 
explanation can be proposed for increased levels of valine in stretched for 18 hrs segments 
and non-stretched for 4 hrs segments as compared to non-stretched for 18 hrs segments. 
Increased levels of TG in rat IVC segments over prolonged stretch for 18 hrs suggest the 
initiation of inflammatory processes led by increased TG levels over 18 hrs stretch. Metabolic 
profiling of human varicose veins tissue showed TG as a differential metabolite in non-
varicose veins and PC and SM as differential metabolites in varicose veins tissue extracts. 
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Though stretch is a common stimuli among both (rat IVC segment and human varicose 
veins), the duration of stretch is significantly variable. Mapping metabolic fluctuations in a 
longitudinal fashion in rat IVC segments may disclose sequential metabolic changes and may 
uncover unrequited questions. Moreover the TG species found in human non-varicose veins 
wall were different from what were observed in rat IVC segment exposed to prolonged 
starched 18 hrs.  
 
In conclusion this novel work has first time extensively investigated the metabolic changes in 
human varicose veins as compared to non-varicose veins. This work has proven the 
hypothesis that metabolic profiles of human varicose veins are different from non-varicose 
veins tissues. Furthermore differential metabolites found in varicose veins wall are associated 
with some very important intracellular pathways of cellular proliferation and inflammation. 
These pathways should be the focus of future research in comprehending disease pathogenesis 
and identifying drug targets. Furthermore, this work has also shown first time that prolonged 
mechanical stretch of 18 hrs duration alters the rat IVC segments metabolic profiles as 
compared to non-stretched IVC segments.  
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6.2 LIMITATION 
The main limitation of my work is the non-varicose veins control group. The control group 
did not accurately match with the varicose veins group in terms of demographic features, past 
medical history and the medications. Factors such as age, medications and past medical 
history may influence the metabolic profile of vein tissue. However, to my knowledge, there 
has been no demonstration of the effect of age on metabolic profile of vein tissue so far. 
Statins and most other cardiovascular medications have a short half-life (less than 24 hours) 
(200) and neither parent drugs nor their metabolites were detected in our NMR or LCMS 
based profiling. Although this does not exclude the possibility that an endogenous metabolic 
response to chronic use of medications or chronic health diseases such as hypertension or 
diabetes might be detected.  In light of the nature of the metabolic changes it seems unlikely 
that this could be the effect of chronic health diseases or medications.  
 
Ideal control would be non-varicose great saphenous vein from age matched patients who are 
also comparable in their co-morbidities to varicose veins patients.  This work compared GSV 
from patients who had lower limb bypass operations or had amputations against varicose 
veins. Patients with peripheral vascular disease have lower limb ischemia and hence GSV 
from these patients may also be exposed to ischemia and are known to have pathological 
changes.  Also  veins  from other anatomical locations as, facial veins, inferior epigastric 
veins,  and cephalic veins were used. However, this does not reflect the relevant 
hemodynamic stresses to which a GSV is exposed.  On OPLS-DA plots (Figure 5-1 and 
Figure 5-2) the facial veins, inferior epigastric veins samples were more close to non-varicose 
GSV and well separated from varicose GSV which clearly shows that clustering of samples is 
due to a disease related metabolic profiles and not under the influence of anatomical location 
or ischemia. Moreover, the presence of lipids moieties both in non-varicose veins GSV and 
facial veins may drive us to propose that control group of different origins may share a 
common metabolic picture which is altered by the varicose veins disease.  
We used a multivariate partial least square (PLS) regression modelling approach to identify 
any influence of these confounding variables on non-polar metabolic profile obtained by 
analysis of vein tissue extracts on UPLC-MS. For each variable (for example age, sex, 
diabetes etc) a PLS model was constructed whereby the y matrix (observations) was replaced 
with the variable under investigation instead of the sample class. Table 12 represents the 
influence of patient’s demographic variables on the metabolic profiles (for non-polar 
metabolites). There was no association of a particular variable with any specific metabolic 
feature and distribution of a specific variable (such as age, sex, diabetes etc) was unable to 
impact any group differences related to disease status (varicose versus non-varicose).  
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It is very challenging owing to ethical reasons to obtain non-varicose vein control tissue from 
age-matched (often young and otherwise healthy) individuals. One way to reduce the 
confounding variable such as exposure to ischemia is to take GSV from patients who had 
cardiac bypass surgery where GSV are used as a conduit. In this situation GSV may not be 
subjected to ischemia if patients do not have any associated PVD but patients with cardiac 
disease may still be on medications such as aspirin, statin and β blocker. However again it is 
well documented that vein harvested at the time of cardiac surgery is not “normal”.  Future 
studies need take into account these limitations at planning stage and every efforts should be 
made to retrieve control as closest as possible to varicose veins. This is of key importance for 
validation of pathways suggested in this work.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 176 
 
7 FUTURE PLANS 
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7.1 TARGET PATHWAY ANALYSIS 
This work opened many ideas for future research. Target analysis of pathways associated with 
the differential metabolites should be the main focus for future research. Figure 5-13 
represents a detailed overview of the possible pathways for further examining.  
1. Sequential targeting analysis starting at activation of VEGF receptors, 
phosphorylation of phospholipase c upto activation of activated kinase and protein 
kinase c in varicose veins.  
2. Another pathway for putative significant is endothelin 1 pathway, from activation of 
ET receptors to PKC. Role of glutathione in diminishing reactive oxygen species and 
up-regulation of NFκB is also proposed from the observation that glutamate was 
present in significantly concentration in varicose veins.  
3. Future studies should also investigate intrinsic pathway of apoptosis in varicose veins 
as our work propose that this pathway may be down-regulated in varicose veins.  
4. Our previous work has shown up-regulation of HIF-1 α in varicose veins. Role of 
hypoxia in context of differential metabolic picture can be further clarified by 
exposing the non-varicose veins and varicose veins cells to hypoxia and normoxia in 
an organ culture model. Hypoxia and normoxic vein tissue should be then analysed 
by metabonomic platforms to assess metabolic perturbation. 
 
Laboratory techniques required to measure molecules in each pathway include polymerase 
chain reaction for assessing the transcriptomic activity, western blotting for determining 
protein and enzymatic expressions and immunohistochemistry methods for certain cytokines 
and proteins expression. The ultimate objective of pathway analysis should be to highlight 
putative targets for drug development. 
 
7.2 EXPLORING THE ROLE AS POTENTIAL BIOMARKERS 
FOR DISEASE PROGNOSIS  
Another prospect which can be drawn from this work is a potential ability of differential 
metabolites as biomarkers for disease prediction and prognosis. Metabonomic platforms have 
proven their ability to identify biomarkers for diseases including colon cancer and 
hypertension. 
It is suggested that metabolic profiling may provide a unique metabolic phenotype for each 
individual influenced by environmental stimuli, disease, drug and genetic modifications. 
Distinctive metabolic phenotype for each patient can be taken into consideration while 
offering different treatment modalities. Identification and comparisons of the differential 
metabolites in serum and urine of patients with varicose veins disease as compared to non-
 178 
 
varicose veins disease healthy control should be the focus of future studies. Elucidating an 
association of differential biomarkers with a specific CEAP grade may provide biomarker for 
disease progression. Moreover, potential biomarkers may help in predicting patients who will 
develop disease in the future and targeted preventive therapy can be offered at early stage.  
 
7.3 METABOLIC PROFILING OF ENDOTHELIAL AND 
VASCULAR SMOOTH MUSCLE CELLS 
Another potential focus for future research is to identify the origins of differential metabolites 
which may help in understanding role of different cells in disease development. Identification 
of metabolic profiles of endothelial and vascular smooth muscle cells culture models should 
be first assessed. Moreover, metabolic changes under the effect of pressure and stretch on cell 
culture should be measured. 
 
7.4 EFFECT OF PROLONGED STRETCH ON RAT IVC 
Chapter 4 studies the effect of 4 and 18 hrs stretch on metabolic fingerprint of rat IVC tissue. 
Differences and trends were noted. In order to identify a more clear explanation of the role of 
stretch on rat IVC segments, future studies should focus on measuring the metabolic 
alterations occurring in response to a sustained mechanical stretch applied for different time 
intervals (more than 24 hrs intervals). This may enable us to chart primary metabolic events 
occurring in reaction to timed stretch stimuli and associate these metabolic differences to 
morphological changes noticed in diseases where continuing mechanical stretch is an 
aetiological factor.  
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9.1  DETAILED PROTOCOL USED IN EXTRACTION METHODOLOGY STUDY 
 
9.1.1 Extraction methodology for aqueous metabolites using 75% water: 25% 
methanol 
1. 1.5 ml of 75% water: 25% methanol (3:1) (methanol HPLC gradient grade, Fisher; water 
LC-MS grade, Fluka) was added in each tissue sample (weight of each sample 140 mg (+/- 5 
mg)) in a bead beating tube 
2. A bead beating tube containing 1mm zirconium beads and solvent but no tissue (blank 
sample) was also prepared and run parallel with other tissue samples 
3. Samples were frozen on dry ice and loaded onto a bead beater (Bertin Technologies, 
Precellys 24) 
4. 4 cycles were run on the bead beater. Each cycle was at 6500 Hz speed and lasted for 40 
seconds. Cycles were separated by cooling on dry ice 
5. Samples were Centrifuged (Eppendorf 5810, us) RCF of 17949.49 x g for 20 minutes at 
4°C temperature 
6. 5 appendorf tubes aliquots were made from each sample (beading tube), each containing 
250 microlitre of supernatant  
7. Then the methanol concentration was increased from 25% to 75% by adding 750 
microlitre of methanol in each eppendorf tube to precipitate protein molecules. This 
concentration was calculated using the following formula, 
 
C1 X V1= C2 X V2 
75% x 250= 25% x v2 
V2= 75 %x 250/ 25% 
V2=750 microlitre 
8. Appendorf tubes were vortexed for 1 minute, followed by centrifugation at 13,000 rpm 
for 20 minutes at 4°C. 
9.  The supernatant from each aliquot was transferred into a new appendorf tube.  
10. Pool sample was made by taking 200 microlitre from each aliquots. 
11. Samples were dried in a speed vacuum overnight at room temperature and then stored in 
-40°C freezer 
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9.1.2 Extraction methodology for aqueous metabolites using 50% water: 50% 
methanol 
1. 1.5 ml of 50% water: 50% methanol (3:1) (methanol HPLC gradient grade, Fisher; water 
LC-MS grade, Fluka) was added in each tissue sample (weight of each sample 140 mg (+/- 5 
mg)) in a bead beating tube 
2. A bead beating tube containing 1mm zirconium beads and solvent but no tissue (blank 
sample) was also prepared and run parallel with other tissue samples 
3. Samples were frozen on dry ice and loaded onto a bead beater (Bertin Technologies, 
Precellys 24) 
4. 4 cycles were run on the bead beater. Each cycle was at 6500 Hz speed and lasted for 40 
seconds. Cycles were separated by cooling on dry ice 
5. Samples were Centrifuged (Eppendorf 5810, US) RCF of 17949.49 x g for 20 minutes at 
4°C temperature 
6. 5 appendorf tubes aliquots were made from each sample (beading tube), each containing 
250 microlitre of supernatant  
7. The methanol concentration was increased from 50% to 75% by adding 250 microlitre of 
methanol in each eppendorf tube to precipitate protein molecules. This concentration was 
calculated using the following formula, 
 
C1 X V1= C2 X V2 
50% x 250= 50% x v2 
V2= 75 %x 250/ 50% 
V2=250 microlitre 
8. Appendorf tubes were vortexed for 1 minute, followed by centrifugation at 13,000 rpm 
for 20 minutes at 4°C. 
9. The supernatant from each aliquot was transferred into a new appendorf tube.  
10. Pool sample was made by taking 100 microlitre from each aliquots. 
11. Samples were dried in a speed vacuum overnight at room temperature and then stored in 
-40°C freezer 
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9.1.3 Extraction methodology for organic metabolites using 5 different organic   
solvents including Chloroform, Methyl Tetrabutyl Ether (MTBE), Hexane, 
Dichloromethane (DCM), and Isopropanol 
1. 1.5 mls of organic solvent: methanol (3:1) (methanol HPLC gradient grade, Fisher;) was 
added in each tissue sample (weight 140 mg +/- 5 mg) in a bead beating tube 
2. A bead beating tube containing 1mm zirconium beads and solvent but no tissue (blank 
sample) was also prepared and run parallel with other tissue samples 
 3.  Sample were frozen on dry ice and loaded onto a bead beater (Bertin Technologies, 
Precellys 24) 
4.  Four cycles were run on the bead beater. Each cycle was at 6500 Hz speed and lasted for 
40 seconds. Cycles were separated by cooling on dry ice 
5.  This was followed by Centrifugation (Eppendorf 5810, US) RCF of 17949.49 x g for 20 
minutes at 4C ° temperature.  
6. Content from each beading tube was then transferred into 5 glass vials, each containing 
200 microlitre.  
7.     A pool samples was prepared by taking 200 microlitre from each sample. 
8.    Samples were dried overnight in a fume hood and then stored in -40°C freezer. 
 
This was the standard procedure for extraction of organic metabolites. However, there were 
certain additional steps pertinent to some organic solvents, for example, 
Dichloromethane: Methanol (3:1) and Chloroform: Methanol (3:1):   All steps related to 
handling of DCM and were performed in safety fume hood.  
Hexane: Methanol (3:1): Due to oily suspension of the hexane, isopropanol was mixed in the   
hexane and methanol (3:1) solvent preparation. The actual concentration was Hexane 
65%:Isoproponol10%: Methanol 25%.   
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Table 13. Table showing the different parameters used in MassLynx V4.1 software for 
analysis of data acquired from different experiments.  
 
 
 
    For each experiment, different noise level was determined and then multiplied with 40 in 
order to set up a minimum intensity threshold to be labelled as a feature.
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9.2 SUPPLEMENTARY DATA FOR EXTRACTION METHODOLOGY STUDY-
CHAPTER 3 
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Figure 9-1. Showing PCA score and loadings plots for aqueous metabolites analysis on 
UPLC-MS. Most features are shared between the two groups. Labelled features which 
are on the periphery of loading plots are higher in one or the other group. 
RP -VE 
RP -VE 
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Figure 9-2. Showing PCA score and loadings plot for non-polar metabolites analysis on 
UPLC-MS. Most features are shared between the two groups. Labelled features which 
are on the periphery of loading plots are higher in one or the other group. 
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Table 14 (a,b,c,d,e,f) showing the details of metabolites which were observed in 
periphery of loading plots (as labelled in Figure 9-1and Figure 9-2).  
 
 
 
 
 
 
 
 
TG Triglyceride, PC Phosphatidylcholine, SM Sphingomyeline, PE Phosphorylethanolamine, 
MG Monoacylglycerol, PI Phosphoinositol 
 
 
a. UPLCMS-HILIC +ve mode 
 
Met Name Mol Formula  
as Detected  
Retention 
time 
(min) 
m/z 
(found) 
m/z 
(theor) 
∆ppm CV%  
PC(32:1) C40H79NO8P+ 
[M+H]+ 
4.70 732.5558 732.5543 
 
-2 A=26%,  
B=6%,  
QC=5% 
PC(38:4) C46H85NO8P+ 
[M+H]+ 
4.61 810.5834 810.6013 22 A=12%,  
B=3%,  
QC=5% 
Hypoxanthine C5H5N4O+ 
[M+H]+ 
2.329 137.0449 137.0463 10 A=19%,  
B=5%,  
QC=4% 
LysoPC C24H51NO7P+ 
[M+H]+ 
5.44 496.3416 496.3403 -3 A=32%, 
B=12%,  
QC=8% 
 
   
 
 
 
 
 
 
A= 25% methanol: 75% water B= 50% methanol: 50% water 
C= 75% DCM: 25% methanol D= 75% chloroform: 25% methanol 
G= 75% Isopropanol: 25% methanol 
F= 65% hexane: 10% ISP: 25% methanol E= 75% ether: 25% methanol 
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b. UPLCMS-HILIC -ve mode 
Met Name Mol Formula as 
Detected  
Retention 
time 
(min) 
m/z 
(found) 
m/z 
(theor) 
∆ppm CV%  
PE (0-38:5) C43H77NO7P- 
[M-H]- 
 
4.40 750.5429 750.5438 1 A=61%  
B=14%  
QC=6% 
PE (0-36:5) C41H73NO7P- 
[M-H]- 
4.08 722.5117 722.5125 1 A=25%  
B=17%  
QC=5% 
PE (0-38:6) C43H75NO7P- 
[M-H]- 
4.03 748.5268 748.5281 -2 A=28%  
B=17%  
QC=3% 
Inosine C10H11N4O5- 
[M-H]- 
3.01 267.0702 267.0729 10 A=14%  
B=10%  
QC=3% 
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c. UPLCMS-RP  +ve mode 
Met Name Mol Formula as 
Detected  
Retention 
time 
(min) 
m/z 
(found) 
m/z 
(theor) 
∆ppm CV%  
MG (18:0) C21H41O3+ 
[M+H-H2O]+ 
13.83 341.3054 341.3056 
0 
A=47% 
B=15% 
QC=13% 
MG (16:0) C19H37O3+ 
[M+H-H2O] 
12.957 313.2776 313.2743 
-10 
A=28% 
B=10% 
QC=13% 
Docosenamide C22H44NO+ 
[M+H]+ 
14.895 338.3457 338.3423 
-10 
A=52% 
B=68% 
QC=17% 
PC (36:2) C44H85NO8P+ 
[M+H]+ 
19.91 786.6107 786.6013 
-12 
A=55% 
B=42% 
QC=30% 
PC (38:4) C46H85NO8P+ 
[M+H]+ 
19.82 810.6085 810.6013 
-9 
A=55% 
B=43% 
QC=9% 
PC (36:4) C44H81NO8P+ 
[M+H]+ 
18.587 782.5814 782.5700 
-14 
A=47% 
B=21% 
QC=13% 
PC (34:1) C42H83NO8P+ 
[M+H]+ 
19.455 760.5959 760.5856 
-13 
A=50% 
B=30% 
QC=24% 
PC (38:7) C46H79NO8P+ 
[M+H]+ 
18.581 804.5611 804.5543 
-8 
A=38% 
B=19% 
QC=16% 
PC (36:5) C44H79NO8P+ 
[M+H]+ 
18.702 780.5602 780.5543 
-7 
A=61% 
B=13% 
QC=20% 
LysoPC (16:0) C24H50NO7PNa+ 
[M+Na]
+ 
12.389 518.3252 518.3223 
-5 
A=53% 
B=14% 
 QC=7% 
Inosine C10H12N4O5Na+ 
[M+Na]
+ 
3.493 291.0721 291.0705 
-5 
A=65% 
B=30% 
QC=27% 
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d. UPLCMS-RP  -ve mode 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Met Name Mol Formula as 
Detected  
Retention time 
(min) 
m/z 
(found) 
m/z 
(theor) 
∆ppm CV%  
Uridine C9H11N2O6-  
[M-H]- 
 
1.9724 243.0605  243.0617 5 A=68% 
B=49% 
QC=40% 
Oxidized 
glutathione 
C20H31N6O12S2-  
[M-H]- 
2.4086 611.1427 611.1441 2 A=63% 
B=33% 
QC=54% 
Lyso PE C25H43NO7P-  
[M-H]- 
12.0835 500.2761 500.2777 3 A=49% 
B=35% 
QC=7% 
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e. UPLCMS-Organic  +ve mode 
 
Met Name Mol Formula as 
Detected  
Retention 
time 
(min) 
m/z 
(found) 
m/z 
(theor) 
∆ppm CV%  
TG (16:0/18:2/18:1) C55H104O6N+  
[M+NH4]+ 
15.495 874.7888 874.7864 
-3 
C=19% 
D=21% 
E=64% 
F= 40%, 
G=13% 
 QC=6% 
TG (18:2/18:1/18:1) C57H106O6N+  
[M+NH4]+ 
 
15.479 900.8043 900.8020 
-2 
C=15% 
D=22% 
E=75% 
F= 40% 
G=15% 
QC=7% 
TG (18:1/18:1/18:1) C57H108O6N+  
[M+NH4]+ 
15.779 902.8213 902.8177 
-4 
C=21% 
D=25% 
E=95% 
F= 43% 
G=16% 
QC=8% 
TG (18:2/18:2/16:0) C55H102O6N+  
[M+NH4]+ 
15.23 872.7736 872.7707 
-3 
C=21% 
D=32% 
E=72% 
F= 35% 
G=19% 
QC=8% 
PC (38:4) C46H85NO8P+ 
[M+H]+ 
7.938 810.6036 810.6013 
-3 
C=38% 
D=6% 
E=44% 
F= 22% 
G=5% 
QC=4% 
PC (36:2) C44H85NO8P+ 
[M+H]+ 
8.238 786.6028 786.6013 
-2 
C=31% 
D=16% 
E=30% 
F= 10% 
G=11% 
QC=9% 
PS (36:1) C42H81NO10P+ 
[M+H]+ 
8.21 790.5623 790.5598 
-3 
C=50% 
D=43% 
E=69% 
F= 28% 
G=26% 
QC=5% 
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PC (36:1) C44H87NO8P+ 
[M+H]+ 
10.287 788.6191 788.6169 
-3 
C=38% 
D=46% 
E=47% 
F= 29% 
G=24% 
QC=37% 
SM (d 18:1/24:1) C47H94N2O6P+ 
[M+H]+ 
12.750 813.6876 813.6850 
-3 
C=19% 
D=16% 
E=29% 
F= 11% 
G=12% 
QC=4% 
SM (d 18:1/16:0) C39H80N2O6P+ 
[M+H]+ 
5.58 703.5773 703.5754 
-3 
C=42% 
D=40% 
E=47% 
F= 25% 
G=21% 
QC=7% 
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f. UPLCMS-Organic  -ve mode  
 
 
 
 
 
 
                   
Met 
Name 
Mol Formula as 
Detected  
Retention 
time 
(min) 
m/z 
(found) 
m/z 
(theor) 
∆ppm CV%  
PC (32:0) C41H81NO10P- 
[M+FA-H]- 
7.15 778.5675 778.5598 
-9 
C=13% 
 D=12% 
 E=53% 
 F= 40% 
 G=4% 
 QC=35% 
PC (34:2) C43H81NO10P- 
[M+FA-H]- 
5.97 802.5606 802.5598 
-1 
C=14% 
D=12% 
E=41% 
 F= 30% 
 G=4% 
 QC=36% 
PE (38:4) C43H77NO8P- 
[M-H]- 
8.12 766.5397 766.5387 
-1 
C=18% 
 D=35% 
 E=21% 
 F= 20% 
G=3% 
 QC=38% 
PS (36:1) C42H79NO10P- 
[M-H]- 
7.539 788.5450 788.5442 
-1 
C=18% 
 D=26% 
 E=69% 
 F= 30% 
 G=22% 
 QC=35% 
PC (37:5) C46H81NO10P- 
[M+FA-H]- 
7.129 838.5623 838.5598 
-3 
C=71% 
D=28% 
 E=134% 
 F= 74% 
 G=27% 
QC=64% 
PI (38:4) C47H82O13P- 
[M-H]- 
5.66 885.5496 885.5493 
0 
C=9% 
D=8% 
 E=21% 
 F= 19% 
G=4% 
QC=35% 
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London Surgical Symposium, Imperial College London, 5
th
 November 2011. Oral. 
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9.5 PRIZES/ AWARDS/ GRANTS (RELATED TO WORK) 
 
Award/Prizes 
1. 1ST Prize for Best Oral Presentation at Annual meeting of European Venous Forum 
2012, Florence Italy.  
 
2. 2nd Prize Winner Best Oral Presentation at UK Venous Forum Royal Society of 
Medicine, April 2012 (Invited to present at Annual Meeting of American College of 
Phlebology 2012 at Miami Florida). 
 
3. Graham Dixon Charitable Prize for exceptional contribution to Cardiovascular 
Surgery for 2012, Award of £250 
 
Grants Awarded as Main Applicant  
1. European Venous Forum Research Grant  € 25,000 June 2013 
2. Graham Dixon Charitable Trust Research Grant £ 6,400 March 2012 
3. European Venous Forum PUMP Priming Grant    €5000  June 2011 
4. Graham Dixon Charitable Research Grant £4500 March 2011 
 
Travel Grant 
1. European Society of Vascular Surgery (ESVS) Congress Travel Grant € 1,000. 
August 2011  
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